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Invasive fungal disease (IFD) is difficult to diagnose. For clinical trials the 
European Organisation for Research in Treatment of Cancer (EORTC) and the 
Mycology Study Group (MSG) criteria are useful but there are few data on their 
value in clinical practice. The aims of this study were to:  
(1) investigate the incidence and risk factors of IFD;  
(2) assess the utility of galactomannan (GM), β-D glucan (BDG), the UK 
consensus fungal PCR, and lateral flow device (LFD) assays together 
with the safety and feasibility of biopsy;  
(3) assess the role of cytokines in the diagnosis and prognosis of IFD;  
(4) establish the prevalence of baseline CT abnormalities, and assess 
diagnostic CT features and spectrum of radiological signs. 
Methods 
Patients (N=203) were recruited prospectively and followed for a median 
(range) of 556 (12-730) days after chemotherapy or haematopoietic stem cell 
transplantation. Chest CT, Karnofsky score (KS), serum GM, and cytokine 
profiles were performed at baseline; during admission twice-weekly GM assays 
were performed on all patients.  BDG, serum and whole blood consensus 
PCR, and LFD assays were performed on a selection of samples from different 
IFD categories.  Neutropenic sepsis refractory to antimicrobials for ≥4 days 
triggered diagnostic CT and biopsy where feasible.  All patients were on 
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antifungal prophylaxis from admission. The revised EORTC/MSG criteria were 
used to diagnose IFD.   
Results 
The cumulative incidence of proven/probable IFD at 6, 12, and 24 months was 
16, 19, and 21%, respectively.  Using GM or BDG alone (plus host and clinical 
evidence) the apparent incidence of proven/probable IFD was 11 and 16% 
respectively.  The median time from index treatment to onset of IFD was 142, 
17, and 41 days for proven mould, proven candida and probable IFD, 
respectively (P < 0.001).  The 2-year overall survival (95% CI) were 45 (29-
61)% for proven/probable IFD vs. 87 (77-97)%  for no evidence of IFD (P < 
0.001).  Baseline CT abnormalities were found in 76 (38%) patients, 19 of 
which were EORTC signs. Risk factors for IFD on multivariate Cox regression 
were: EORTC CT signs (Hazard ration [HR] 4.3; 95% CI 1.9-9.8; P<0.001), IL-
2R >834 pg/ml (HR 2.3; 95% CI 1.1-5.1; P=0.037), MCP-1 >841 pg/ml (HR 
2.7; 95% CI 1.2-6.1; P=0.016), and KS <90 (HR 2.1; 95% CI 1.1-4.2; P=0.034) 
at baseline as well as monocytopenia >10 days (HR 2.6; 95% CI 1.3-5.4; 
P=0.009) and bacteraemia (HR 2.5; 95% CI 1.2-5.0; P=0.013). The sensitivity, 
specificity, PPV, and NPV for GM was 54, 71, 82, and 39%, respectively; 
coresponding values for BDG were 79, 55, 83, and 49%.  The proportion of 
cases identified by both tests was 38%. The sensitivity of biopsy was 35% and 
PCR and LFD were less sensitive but more specific than GM or BDG.  
Conclusions 
A multi-faceted approach is required to improve the diagnostic accuracy of 
IFD.  No single assay was able to detect all the cases but the combination of 
BDG and GM seem to offer the best biomarker combination.  Baseline chest 
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CT, KS, and cytokine profile as well as monocytopenia and bacteraemia are 
important risk factors. (ClinicalTrials.gov number NCT00816088).  
 4 
Table of contents 
Abstract ...................................................................................................................................... 1 
Table of contents ...................................................................................................................... 4 
List of Tables ............................................................................................................................. 9 
List of Figures ......................................................................................................................... 12 
List of abbreviations ............................................................................................................... 16 
Acknowledgements ................................................................................................................ 18 
Chapter 1 Introduction and Review of Literature ............................................................... 19 
1 Introduction and Review of Literature ......................................................................... 20 
1.1 Epidemiology of IA in haematological malignancies ............................................. 23 
1.1.1  Risk factors- environmental and acquired immune dysfunction ................ 23 
1.1.2 Genetic risk factors ............................................................................................ 28 
1.1.3 Incidence/prevalence of IA ................................................................................ 29 
1.1.2 Prognostic factors ............................................................................................... 32 
1.2 Pathogenesis: infection and the host immune response ..................................... 34 
1.2.1 TLR-PAMP system ............................................................................................. 36 
1.2.2 β-Glucan recognition .......................................................................................... 38 
1.2.3 Cytokine production in IA .................................................................................. 40 
1.2.4 Angioinvasion ...................................................................................................... 47 
1.3 Clinical features .......................................................................................................... 53 
1.4 Prevention & Prophylaxis .......................................................................................... 54 
1.4.1 Polyenes .............................................................................................................. 55 
1.4.2 Triazoles .............................................................................................................. 58 
1.4.3 Echinocandins ..................................................................................................... 65 
1.4.4 Secondary prophylaxis ...................................................................................... 65 
1.4.5 Guidelines ............................................................................................................ 66 
 5 
1.5 Treatment of IA ........................................................................................................... 69 
1.5.1 Empiric therapy ................................................................................................... 70 
1.5.2 Targeted therapy ................................................................................................ 72 
1.5.3 Salvage therapy .................................................................................................. 74 
1.6 Diagnosis ..................................................................................................................... 75 
1.6.1 Computed Tomography (CT) ................................................................................. 77 
1.6.2 Tissue diagnosis-biopsy .......................................................................................... 80 
1.6.3 Galactomannan ........................................................................................................ 82 
1.6.4 β-D-Glucan ................................................................................................................ 86 
1.6.5 Lateral Flow Device (LFD) ...................................................................................... 87 
1.6.6 PCR ............................................................................................................................ 88 
1.7 Study objectives ......................................................................................................... 90 
Chapter 2 Methods ........................................................................................................... 91 
2 Methods ........................................................................................................................... 92 
2.1 Study design ........................................................................................................... 92 
2.2 Study procedures ................................................................................................... 93 
2.3 Patients .................................................................................................................... 95 
2.4 Diagnosis of IA ........................................................................................................ 99 
2.5 Response to antifungal therapy ......................................................................... 102 
2.6 Laboratory methods ............................................................................................. 104 
2.6.1 Galactomannan (Platelia™ Aspergillus EIA, Bio-Rad) ........................... 104 
2.6.2 β-D-glucan (Fungitell® BG assay, Associates of Cape Cod) ................. 104 
2.6.3 Lateral Flow Device (LFD) .......................................................................... 105 
2.6.4 PCR (Consensus) ........................................................................................ 106 
2.6.5 Cytokine profiling (Luminex 30-plex panel, Invitrogen®) ....................... 106 
2.6.6 Genetic polymorphisms ............................................................................... 108 
2.7 Radiology methods .............................................................................................. 108 
 6 
2.8 Biopsy..................................................................................................................... 111 
2.9 Bronchoscopy ....................................................................................................... 114 
3.0 Database and Statistical analysis ...................................................................... 114 
Chapter 3 Results ........................................................................................................... 119 
3 Results ........................................................................................................................... 120 
3.1 Recruitment ................................................................................................................ 120 
3.2 Patient characteristics ......................................................................................... 120 
3.3 Incidence of IFD ................................................................................................... 126 
3.3.1 Incidence of IFD depends on the diagnostic tools used ......................... 147 
3.3.2 Treatment-specific incidences .................................................................... 149 
3.3.3 Timing of IFD ................................................................................................. 150 
3.3.4 Patients with more than one IFD episodes............................................... 152 
3.3.5 Concomitant bacterial and viral infections ................................................ 159 
3.4 Antifungal agents .................................................................................................. 161 
3.4.1 Prophylaxis .................................................................................................... 161 
3.4.2 Treatment ...................................................................................................... 162 
3.4.3 Antifungals at time of IFD diagnosis .......................................................... 163 
3.4.4 Prophylaxis-treament patterns among proven/probable IFDs ............... 164 
3.5 Galactomannan and β-D-glucan performance ................................................ 166 
3.5.1 Galactomannan ............................................................................................ 166 
3.5.2 Does persistent GM positivity predict poor prognosis ............................ 167 
3.5.5 β-D-glucan ..................................................................................................... 169 
3.5.6 Relationship between GM and BDG ......................................................... 169 
3.6 LFD ......................................................................................................................... 171 
3.7 PCR ........................................................................................................................ 174 
3.8 Bronchoscopy ....................................................................................................... 176 
3.9 Biopsy..................................................................................................................... 177 
 7 
3.9.1 Patient characteristics and clinical features ............................................. 177 
3.9.2 Histological findings ..................................................................................... 178 
3.9.3 Adverse events ............................................................................................. 181 
3.99 Diagnostic performance of different tests ......................................................... 182 
4.0 Risk factors associated with IFD, overall survival and prognosis ................. 183 
4.0.1 Risk factors for IFD ...................................................................................... 183 
4.0.2 Overall survival ............................................................................................. 185 
4.0.3 Causes of mortality ...................................................................................... 187 
4.0.4 Prognostic factors ............................................................................................... 189 
Chapter 4 Radiology Results ........................................................................................ 194 
4 Radiology results .......................................................................................................... 195 
4.1 Baseline scans ...................................................................................................... 195 
4.1.1 Do the results of the baseline scan influence the incidence of IPA?.... 197 
4.1.2 An unusual case of possible IPA ............................................................... 203 
4.2 Diagnostic scans .................................................................................................. 204 
4.2.1 Comparison of the CT signs between IPA and non-IPA patients ......... 206 
4.2.2 Location and distribution of lesions ........................................................... 207 
4.2.3 Inter-observer variation for the diagnostic scans..................................... 209 
4.2.4 Contrast enhancement ................................................................................ 211 
4.3 Follow-up scans .................................................................................................... 213 
Chapter 5 Cytokines Results .............................................................................................. 215 
5 Cytokines results .......................................................................................................... 216 
5.1 Baseline cytokines ..................................................................................................... 216 
Does the baseline cytokine concentration have any prognostic significance? ... 223 
5.2 Follow-up cytokines ................................................................................................... 225 
5.3 Genetic Polymorphisms in genes associated with cytokine biology ............ 231 
Chapter 6 Discussion ..................................................................................................... 240 
 8 
6 Discussion ..................................................................................................................... 241 
6.1  IFD incidence ............................................................................................................ 241 
6.2 Diagnostic tests .......................................................................................................... 247 
6.2.1 GM & BDG ........................................................................................................... 247 
6.2.2 PCR & LFD .......................................................................................................... 248 
6.2.3 Radiology ............................................................................................................. 250 
6.2.4 Biopsy................................................................................................................... 255 
6.2.5 Antifungals-prophylaxis, treatment and role of TDM ..................................... 258 
6.3 Cytokines .................................................................................................................... 260 
6.4 Risk factors ................................................................................................................. 263 
6.5 OS and Prognostic factors ....................................................................................... 267 
6.6 Case discussion ......................................................................................................... 269 
Chapter 7 Summary & Conclusions ............................................................................. 273 
7 Summary & Conclusions ................................................................................................. 274 
Chapter 8 Future Directions .......................................................................................... 278 
8 Future directions ........................................................................................................... 279 
9 References .................................................................................................................... 283 
Appendix 1 Publications from this Thesis ......................................................................... 322 
Appendix 2 Database variables (summary) ..................................................................... 324 
 9 
List of Tables 
Table 1: Risk factors for IA in haemato-oncology patients 
Table 2: Risk stratification of patients with haematological malignancies for IA 
Table 3: Cytokines of the innate immune system 
Table 4: Chemokines 
Table 5: Cytokines of the adaptive immune system 
Table 6: Cytokines of haematopoiesis and other growth factors 
Table 7: Properties of the Th1 and Th2 CD4 T helper cells 
Table 8: Triazole antifungal prophylaxis trials 
Table 9: Summary of the ECIL-3 and IDSA guidelines for prophylaxis against 
IA 
Table 10: Causes of false-positive galactomannan 
Table 11: Patient characteristics 
Table 12: KCH adult Haemato-Oncology Antifungal Guidelines 2007 
Table 13: Responses to antifungal therapy in patients with invasive mould 
disease  
Table 14: Scoring proforma used for scoring diagnostic scans 
Table 15: Demographics and clinical characteristics of the 3 patient groups 
Table 16: Laboratory characteristics of the 3 patient groups 
Table 17: Characteristics of the study cases according to the EORTC/MSG 
criteria  
Table 18: Comparison of the clinical characteristics between IA and non-IA 
patients 
Table 19: Proven IFD cases 
Table 20: Clinical and laboratory characteristics of concomitant bacterial 
infections  
Table 21: Antifungal agents used for prophylaxis according to KCH antifungal 
protocol   
Table 22: Antifungal treatments used according protocol or ITU admission 
 10 
Table 23: Pattern of prophylaxis-treatment among proven/probable IFD cases 
Table 24: Results of 973 sera tested for LFD and GM and a selection for BDG 
Table 25: BAL results 
Table 26: Characteristics of biopsy cases  
Table 27: Results of the biopsies and associated characteristics  
Table 28: Overall performance of the different diagnostic tests for detection of IA (or 
IFD where indicated) 
Table 29: Univariate Cox proportional hazards model for risk factors for IFD 
Table 30: Multivariate Cox proportional hazards model for risk factors for IFD 
Table 31: Causes of death 
Table 32: Univariate Cox proportional hazards model for prognostic factors 
Table 33: Multivariate Cox proportional hazards model for prognostic factors  
Table 34: Multivariate Cox proportional hazards model for prognostic factors 
for IFD patients 
Table 35: Baseline chest scan characteristics 
Table 36: Demographic and clinical characteristics of patients according to 
baseline pulmonary CT scan results 
Table 37: Diagnostic scan image findings  
Table 38: Comparison of the CT signs between proven/probable IPA and non-
IPA  
Table 39: Inter-observer agreement between the 2 radiologists in reporting CT 
scan 
Table 40: Contrast enhancement in Hounsfield units (HU) between IPA and not 
classified patients 
Table 41: Response rates among the IPA patients  
Table 42: Baseline cytokine profile comparing patients who developed IFD to 
those with no evidence of IFD 
Table 43: Baseline cytokine profile comparing patients who developed IA to 
those with no evidence of IA 
 11 
Table 44: Cox regression model on baseline cytokines for the development of 
IFD 
Table 45: Baseline cytokine levels as prognostic factors using univariate Cox 
regression 
Table 46: Association between gene polymorphisms and IFD in patients 
Table 47: Association between gene polymorphisms and IA in patients 
Table 48 Association between gene polymorphisms and IFD in donors of 
allogeneic HSCT 
Table 49 Association between cytokine gene polymorphisms and IA in donors 
of allogeneic HSCT 
 
 12 
List of Figures 
Figure 1: Model for immune response to fungal infection 
Figure 2: Model of Aspergillus fumigatus angioinvasion 
Figure 3: Histopathological appearances in angioinvasive aspergillosis 
Figure 4: Structure of Nystatin and Amphotericin B  
Figure 5: CT “halo” sign of angioinvasive aspergillosis in a neutropenic patient 
Figure 6: Air crescents and cavitation in angioinvasive aspergillosis.  
Figure 7: Mechanism of detection of (13)-β-D-Glucan  
Figure 8: Schematic presentation of the Aspergillosis study  
Figure 9: Outline of cases 
Figure 10: Recruitment  
Figure 11: CRP and fever 
Figure 12: Proven IFDs  
Figure 13: Antifungal experience of Case 2.  
Figure 14: CT brain of Case 2 
Figure 15: Coronal sections of the brain showing haemorrhagic foci 
Figure 16: Right frontal lobe at PM stained with H&E and Grocott   
Figure 17: Gross angioinvasion of the brain and occlusion of the cerebral artery  
Figure 18: Fungal meningitis showing hyphael and neutrophilic infiltration  
Figure 19: Post mortem findings on the heart 
Figure 20: Coagulative necrosis of lungs associated with numerous fungal 
hyphae 
Figure 21: Septic emboli in the pulmonary vessels   
Figure 22: Hepatic invasive fungal disease 
Figure 23: Intravascular fungal emboli with ischaemic renal cortical necrosis 
Figure 24: Duodenum showing infiltration by fungal hyphae  
 13 
Figure 25: CT chest showing a macronodule with ‘halo’ sign and air crescent 
sign 
Figure 26: Angioinvasive pulmonary aspergillosis 
Figure 27: The branching hyphae invading the heart due to Aspergillus 
fumigatus  
Figure 28: widespread violaceous skin lesions due to fusariosis 
Figure 29: Erythematous indurated skin lesions with central necrosis  
Figure 30: Blood cultures showing Fusarium spp with septate hyphae and 
conidia 
Figure 31: Study cases classified according to the revised EORTC/MSG 
criteria  
Figure 32: Incidencde of IFD varies with the diagnostic tools used 
Figure 33: Treatment-specific incidence of IFD.  
Figure 34: Interval between index treatment to EORTC/MSG classification   
Figure 35: Cumulative incidence of IFD by Kaplan-Meir estimate 
Figure 36: Patient 109. Baseline CT scan showing nodules and halo sign.   
Figure 37: Proportion of patients treated with antifungal agents for suspected 
IFD   
Figure 38: Antifungal drugs used within 2 weeks of EORTC/MSG classification 
Figure 39: The pattern of prophylaxis to treatment in proven/probable IFDs 
Figure 40: Serum GM testing on 3086 samples and proportion of positive 
results  
Figure 41: Quantification of GM antigenaemia by ELISA in 8 patients with 
persistent posive results   
Figure 42: Relationship between BDG and  
Figure 43: Relationship between LFD and GM in identifying IFD cases  
Figure 44: Relationship between LFD and BDG in identifying IFD cases  
Figure 45: Scatter plot of PCR on blood and serum samples.  
Figure 46: Overal survival analysis by Kaplan-Meier method  
 14 
Figure 47: Kaplan-Meier analysis of OS for patients with proven/probable IFD  
Figure 48: Survival estimates since EORTC classification 
Figure 49: Survival plots for patients with IFD v no evidence of IFD   
Figure 50: Survival plots of the whole cohort showing the effect of underlying 
diagnosis   
Figure 51: CT scan of JW 55y male with CML with normal neutrophil counts  
Figure 52: Figure 52: Outline of the baseline CT scan analysis 
Figure 53: Cummulative incidence of IFD and IPA according to baseline CT 
scan  
Figure 54: Cummulative incidence of IFD and IPA according to baseline CT  
(EORTC v non EORTC signs) 
Figure 55: Baseline CT scan of the chest (A) showing a nodule in the left lower 
lobe 
Figure 56: Distribution of nodules and Halo sign in the lungs among IPA 
patients.  
Figure 57: Distribution of cavities in IPA patients in different lobes of the lungs 
Figure 58: Distribution of GGO and consolidations in the lungs 
Figure 59: Bland-Altman plots for consolidation, GGO and micronodularity. 
Figure 60: Degree of contrast enhancement in Housell Units at different time 
points.  
Figure 61: Median (with IQR) cytokine concentrations IFD v no IFD 
Figure 62: Median (with IQR) cytokine concentrations IA v no IA 
Figure 63: Cummulative probability (incidence) of IFD by multivariate Cox 
regression  
Figure 64: Inflammatory cytokine panel at follow-up for IFD v no IFD  
Figure 65: Inflammatory cytokine II panel at follow-up for IFD v no IFD 
Figure 66: Th1/Th2 cytokine panel at follow-up for IFD v no IFD  
 15 
Figure 67: Chemokine panel at follow-up for IFD v no IFD  
Figure 68: Growth factor cytokine panel at follow-up for IFD v no IFD   
 16 
List of abbreviations       
AA aplastic anaemia 
ALL acute lymphoblastic leukaemia 
ALP alkaline phosphatase 
AML acute myeloid leukaemia  
AST aspartate transaminase 
BAL broncho-alveolar lavage 
BDG β-D glucan 
CLL chronic lymphocytic leukaemia  
CR complete remission 
CRP C-reactive protein 
CSA Cyclosporin A 
FA  Fanconi anaemia 
FBC full blood count 
FLAMSA fludarabine, Cytarabine, Amsacrine protocol 
GGO ground glass opacification  
GM galactomannan 
GMI galactomannan index 
Hb haemoglobin 
HL Hodgkin lymphoma  
IA invasive aspergillosis 
IFD invasive fungal disease 
IPA invasive pulmonary aspergillosis 
IST immunosuppressive therapy  
ITU intensive care unit 
KOH Potassium hydroxide 
 17 
KCl Potassium chloride 
LFD lateral flow device 
LFT liver function tests 
MDS myelodysplastic syndrome 
MMF Mycophenolate mofitil  
NHL non-Hodgkin lymphoma 
OS overall survival 
PR partial remission 
SNP single-nucleotide polymorphism 
PCR polymerase chain reaction 
TLR toll-like receptor 
U&E kidney functions tests 
WBC white blood count 





Supervisors Professor Ghulam J Mufti, KCL 
    Melvyn Smith, KCH 
Support/guidance Professor Antonio Pagliuca, KCH/KCL 
Radiology   Sujal Desai (KCH), Joanna Cleverley (Royal Free)  
Biopsy Mike Marrinan, Ranjit Deshpande, Donald Whitaker 
(KCH) 
Histology Sabine Pomplun (KCH), Prof. Andrew G Nicholson 
(Royal Brompton) 
EORTC classification Professor Chris C Kibbler (Royal Free) 
Laboratory work Lisa Berry (PCR & LFD), Virology staff (GM), 
Shahram Kordasti (Cytokines), Chris Thornton 
(LFD), Nik Lea & Eamaan Rufaie (SNP), KCL 
Tissue Bank (Nigel Westwood & Rajani Chellia) 
Bronchoscopy Surinder Birring, Jack Barker, Tracey Fleming 
(KCH) 
Data management  Hammad Sikondari (KCH), Bolaji Coker (KCL) 
Statistical advice  Abdel Douiri (KCL), Ross Harris (HPA) 
Educational grant  Pfizer/Gilead Sciences/Merck Sharp & Dohme 
Limited 
 
In addition, I am enormously grateful to all the patients who took part and all 
the nurses and junior doctors who helped with the study.  I thank my wife 
(Fatou) and our lovely children (Fatimah, Ahmad and Bilal) who put up with me 
during this challenging period! And finally, thanks and praises to the Almighty 













Chapter 1 Introduction and Review of 
Literature 
 20 
1 Introduction and Review of Literature 
Invasive aspergillosis (IA) is an important cause of morbidity and mortality in 
immunocompromised patients, particularly patients with malignant disorders 
undergoing high dose chemotherapy or haematopoietic stem cell 
transplantation (HSCT).1-3 It is usually caused by Aspergillus fumigatus: a 
ubiquitous filamentous fungus, or mould, found in soil and decomposing 
vegetation which can thrive independent of animal host. Aspergillus species 
cause a wide range diseases from ABPA to chronic, saprophytic and allergic 
conditions but  these are seldom life threatening unlike IA which is a leading  
cause of infection-related death in patients with acute leukaemia and those 
undergoing HSCT.4 Risk factors for IA include any immunosuppression; broad-
spectrum antibacterials; mucositis; quality of donor match; type of conditioning 
(eg total body irradiation, fludarabine); prolonged neutropenia; cytomegalovirus 
infection and graft-versus-host disease.5 IA is encountered less frequently in 
solid organ transplant patients but remains a significant cause of death in this 
group. As improvements in chemotherapy, supportive care, antimicrobial 
therapy and general management have improved the prognosis for many 
haematological malignancies, increasingly very compromised patients are 
surviving longer but succumbing to IA which (in neutropenia) has a high 
mortality.4,6   
 
However, there has been a significant decrease in mortality in patients with IA 
in the past two decades.7,8 This probably reflects the changing practice in 
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haematology with the use of reduced intensity HSCT and increasing use of 
peripheral blood stem cells,  both of which significantly reduces the duration of 
neutropenia, perhaps the main risk factor for IA.  The availability of a variety of 
more potent antifungal agents as well as better diagnostic tools such as 
modern computed tomography (CT), and detection of galactomannan, β-D-
glucan, and DNA by PCR allows earlier diagnosis and treatment.  At the same 
time clinical and epidemiological studies have identified risk categories.  
Furthermore antifungal prophylaxis is commonly used especially in the high 
risk categories such as allogeneic HSCT recipients and patients undergoing 
induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic 
syndrome (MDS). 
 
Although these technological advances in diagnostic tools have become 
available to clinicians IA is still notoriously difficult to diagnose in a timely 
fashion as there is no universally available ‘gold standard’. It is for this reason 
that the Invasive Fungal Infection Cooperative Group of the European 
Organisation for Research in Treatment of Cancer (EORTC) and the Mycology 
Study Group (MSG) formed a Consensus Committee in 1998 to develop 
standardised definitions for invasive fungal infections for clinical research and 
these were published in 2002 and revised in 2008.9,10  These definitions were 
developed for clinical research and have not yet been validated for use in 
routine clinical practice. However, the availability of these diagnostic tools has 
allowed clinicians to move away from the fever-driven empiric antifungal 
therapy to a diagnostic-driven approach which could potentially save money 
but also reduce the unnecessary toxic treatment side effects of antifungal 
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therapy.  However, it is unclear which of these paradigms is the superior option 
for the treatment of a persistently neutropenic patient.11  
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1.1 Epidemiology of IA in haematological malignancies 
Aspergillus spp are ubiquitous nonpigmented, regularly septate moulds 
commonly found in air, soil, water, dust, compost, rotting plants, other organic 
debris, building construction sites.3,12  Decomposing vegetable material is 
believed to be their primary ecological niche.13  The spores are acquired 
primarily by inhalation where they are trapped in the upper respiratory tract and 
only a small proportion reaches the airways in healthy immunocompetent 
individuals. They cause a variety of diseases including invasive aspergillosis, 
allergic bronchopulmonary aspergillosis, aspergilloma and allergic 
pneumonitis. There are over 200 species but only a few of these are 
pathogenic to humans such as A. fumigatus, A. flavus, A.niger, and A. terreus. 
Of these, A. fumigatus, first described by Johann Baptist Georg Wolfgang 
Fresenius in 186014, is the commonest cause of invasive aspergillosis 
accounting for ~90% of IA.2  A. terreus, though less common, is intrinsically 
resistant to amphotericin B and is associated with high mortality.15-17 
 
 
1.1.1  Risk factors- environmental and acquired immune dysfunction 
Two conditions are necessary for the development of invasive aspergillosis: 
simultaneous colonization and presence of risk factors.13 In most cases the 
colonization occurs outside hospital settings prior to admission into hospital 
especially among the elderly population.18,19 Environmental risk factors are 
important. Dry weather with high temperatures such as in summer and autumn 
are associated with higher incidence of IA.20,21 Farmers are a particular risk 
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group due to inhalation of mycotoxins, endotoxins, and other toxins which 
colonize their airways.22 Building reconstruction within hospitals may increase 
the risk of colonization and have been major causes of epidemic clusters in 
hospitalised patients.12,23 The role of high efficiency particulate air (HEPA) 
filters to reduce air contamination is important in reducing environmental 
exposure.24,25 Other possible sources of environmental contamination with 
spores include potted plants, flowers, carpets, and water distribution systems 
(as spores get released during showering).26,27  
 
The risk factors related to impaired host defences may be acquired in the 
majority of cases or genetic in some (Table 1).  Prolonged and profound 
neutropenia due to any cause is the most important risk factor for IA.28-33 This 
is not surprising given that neutrophils are the main effector cells involved in 
the phagocytosis and killing of Aspergillus spores.  Dysplastic neutrophils in 
MDS are less fungicidal than normal neutrophils.34  Lymphocytopenia and T-
cell dysfunction is also a risk factor following allogeneic HSCT.35,36   
Interestingly adoptive transfer of anti-aspergillus T- cells may be effective in 
treating IA in the haploindentical HSCT setting.37 
 
In allogeneic HSCT the quality of donor-recipient HLA match, the source of 
stem cells, type of conditioning regimen used, T-cell depletion, and CMV 
reactivation, and presence of acute or chronic graft versus host disease 
(GVHD) are associated with increased risk of IA.30,38 Recipients of cord blood 
transplantation are a particularly high risk group probably reflecting the naivety 
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of the immune cells in cord blood and also the slower immune recovery post-
transplant.39,40  In recipients of allogeneic stem cell transplantation a bimodal 
risk period is recognised. The early phase is characterised by neutropenia and 
damaged mucosal barrier which may be aggravated by acute GVHD during the 
first 100 days.41 The late phase is characterised by chronic GVHD, CMV 
reactivation, and treatment with steroids and other immunosuppressive 
agents.35,38,42-45 T-cell depletion reduces the incidence of GVHD but impairs 
reconstitution of cellular immunity and CMV reactivation.44   
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Table 1: Risk factors for IA in haemato-oncology patients (modified from8,46-49) 
Acquired  Genetic 
Prolonged neutropenia TLR polymorphisms 
HSCT 
    Older age at transplant 
    Underlying disease 
    Type of transplant 
       T-cell depleted or CD34-selected 
       Cord blood transplant 
       Unrelated or HLA-mismatched 
PBMC 
       CMV reactivation   
       GVHD 
Plasminogen SNP 
Mannose-binding lectin (MBL) 
IL-1 SNP 
IL-10 promoter gene polymorphism 
TNF-R2 promoter VNTR 
Immunosuppressive therapy: 
cyclosporine CSA), tacrolimus, 
mycophenolate mofitil (MMF), 
antithymocyte globulin (ATG)  
 
Corticosteroids   
Lymphocytopenia, monocytopenia 
T-cell dysfunction eg Alemtuzumab 









The dose and duration of corticosteroids used in the treatment of GVHD is 
important.38,46,50  Steroids have multitude of effects on the immune system 
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such as prevention of killing of phagocytosed  A. fumigatus51, blunting the 
alveolar macrophage production of proinflammatory cytokines such as IL-1a, 
TNF-α, and macrophage inhibitory factor 1α52, and Th-2 polarization53,54.  The 
new anti-neoplastic or immunosuppressive agents especially purine analogues 
(eg fludarabine) and antibodies targeted against immune cells such as anti 
CD52 (alemtuzumab), anti-thymocyte globulins (ATG), and anti-CD3 
antibodies, may produce transient neutropenia as well as prolonged 
lymphocytopenia and impairment of cell mediated immunity55,56. Similarly anti-
TNF therapy (eg infliximab and etanercept) for treatment of refractory GVHD or 
for non-haematological indications such as rheumatoid arthritis is associated 
with increased incidence of IA57.  IA acquired in the pre-transplant 
chemotherapy phase is an important risk factor as the risk of relapse during 
transplant in such patients is extremely high approaching 30%.45   
 
Iron overload, as assessed by marrow iron stores, has been recently identified 
as a risk factor for IA58 Transfusion-dependent MDS and AML patients are 
particularly at risk. Iron is an important element for a variety of biological 
pathways and in Aspergillus spp iron acquisition is essential for increased 
growth and virulence59 Interestingly the iron chelator deferoxamine is 
associated with increased iron uptake by certain moulds such as zygomycetes 
which use it as a siderophore to access previously unavailable iron and this 
uptake is associated with fungal growth.60  The newer iron chelators 
deferiprone and deferasirox do not act as siderophores for the fungus.61 
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1.1.2 Genetic risk factors  
The role of innate immune receptors such as the toll-like receptor (TLR) family 
in regulating both innate and adaptive immune responses to Aspergillus 
infection has attracted attention. Bochud et al have shown that single 
nucleotide polymorphisms (SNPs) in TLR2 and TLR4 (S4 haplotype) of HSCT 
donors rendered recipients more susceptible to IA by more than two fold.62  
The presence of TLR1 and TLR5 polymorphisms in recipients has also been 
shown to increase the risk of IA post- transplant.63  Other genetic risk factors 
include SNPs in the plasminogen gene64 and possibly mannose binding lectin 
(MBL) gene.65  Recent studies have also identified dectin-1 mutation as a 
novel risk factor for IA.66 
 
Cytokine gene polymorphisms are also associated with increased risk of IA. 
Interleukin 10 (IL-10) is an important regulatory cytokine that inhibits the 
inflammatory effector functions of macrophages and dendritic cells.  Seo et al67 
investigated 105 patients undergoing HSCT and examined three SNPs in the 
proximal region of the IL-10 promoter. They found that ACC haplotype, which 
is associated with decreased IL-10 production, was associated with a 9-fold 
decrease in the risk of developing IA. On the other hand increased IL-10 
production, as in the ATA haplotype, was associated with a higher incidence of 
IA. Other cytokine gene polymorphisms associated with increased risk of IA 
include variable number of tandem repeats (VNTRs) at position -322 of the 
TNFR2 gene68 and IL1 gene cluster polymorphisms.69 
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1.1.3 Incidence/prevalence of IA 
Taking the above risk factors into account it is possible to stratify patients into 
low, intermediate and high risk categories for IA (Table 2) 
 
Table 2: Risk stratification of patients with haematological malignancies for IA 
(modified from 49) 
Low risk Intermediate risk High risk 
Autologous HSCT Acute Lymphoblastic 
Leukaemia 
AML (particularly during 
induction 
chemotherapy) 
Hodgkin lymphoma Chronic Lymphocytic 
Leukaemia 
Allogeneic HSCT 









Non Hodgkin lymphoma  
Multiple myeloma   
 
After World War II there has been a steady rise in the incidence of invasive 
fungal infections in general and invasive aspergillosis in particular, primarily as 
a consequence of the use of more intensive chemotherapy for treatment, use 
of HSCT, and the better supportive care which makes it possible for 
increasingly immunosuppressive patients to survive longer than before.70  At 
the same time the widespread use of mould-active prophylactic antifungal 
agents has changed the epidemiology of invasive mould infections so that non-
fumigatus Aspergillus species such as zygomycetes, and fusarium have 
increased in relative terms.71,72 
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Pagano et al performed a multicentre retrospective cohort study in Italy 
(SEIFEM-2004 study) between 1999 and 2003 on 11,802 patients with 
haematological malignancies and they found IA incidence of 2.6%.73 The 
highest incidence was found in patients with AML (7.9%) particularly during the 
first induction chemotherapy when 43% of these cases were diagnosed.  The 
diagnosis of IA was probable in 60% and proven in 40% using the 2002 
EORTC/MSG criteria 9 and A. fumigatus was identified in 53% of proven 
cases. It is noteworthy that this study excluded patients with MDS, aplastic 
anaemia and those undergoing HSCT. The incidence of IA in patients with 
acute leukaemia and MDS is variable in different studies but it is around 5-
10%.74,75 This risk increases with multiple cycles of chemotherapy. The second 
Italian study (SEIFEM B-2004) focussed on HSCT patients. Amongst 3228 
patients 1249 were allogeneic and 1979 were autologous transplants.76  The 
incidence of IFI was 7.8% and 1.2% among allogeneic and autologous 
recipients respectively.  
 
A large retrospective US autopsy study was performed on 1017 patients who 
had chemotherapy or HSCT over a 15 year period between 1989 and 2003 in 
the M.D. Anderson Cancer Center by Chamilos et al.77  They found invasive 
fungal disease (IFD) in 31% of patients and 17% had IA. The majority (75%) of 
these cases were diagnosed post mortem. Patients with acute leukaemia and 
those undergoing HSCT had the highest prevalence of IA. 
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The incidence of IA in autologous HSCT is low and is estimated to be 0.3-
2%.45,76,78-80  Allogeneic HSCT is a higher risk procedure and the overall 
incidence is estimated to be 2.9-15%.31,45,50,80-85  The second at risk phase of 
IA post allograft poses a major challenge with cumulative incidences of up to 
15% at 12 months post- transplant.86  Pre-transplant, IA is another challenge 
due to the high of reactivation during the early or late phase post-transplant. 
The recurrence risk is associated with short duration (<1 month) of antifungal 
therapy before transplantation, persistence of radiological abnormalities and 
myeloablative conditioning, especially, total body irradiation-containing 
regimens.45 Martino et al evaluated 129 cases of proven or probable IA 
diagnosed prior to transplantation.87 They observed progression of IA in 27 
(17%) with cumulative incidence of 22% at 2 years post-transplant. This 
cumulative incidence was related to longer duration of neutropenia post 
allograft, advanced status of underlying disease, short duration of antifungal 
therapy (less than 6 weeks), myeloablative conditioning, CMV disease, donor 
source (bone marrow or cord blood), and presence of acute severe GVHD. 
 
Recently a network of 23 US transplant centres, the Transplant Associated 
Infections Surveillance Network (TRANSNET), prospectively enrolled 875 
HSCT recipients with proven and probable IFIs occurring between March 2001 
and March 2006.88 The median onset of IA was 99 days post HSCT and the 
12-month cumulative incidence of IA was 1.2% for autologous HSCT and for 
allogeneic HSCT it was 5.8%, 7.7%, and 8.1% for matched related donors, 
matched unrelated donors, and mismatched matched donors respectively. 
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However, there was a wide variation between the sites with incidences ranging 
from 3.1 to 20.6% for mismatched related donors. 
1.1.2 Prognostic factors 
The immune system and the underlying malignancy and its treatment are the 
primary factors that determine the outcome of patients with IA.49 In general the 
prognosis for patients with haematological malignancy who develop IA is poor. 
Lin et 7 carried out a large systematic review of literature and found that the 
overall case fatality rate was 58% in patients with malignancy but in those who 
had allogeneic HSCT or central nervous system involvement or disseminated 
IA it was approximately 90%. This has been confirmed by more recent studies 
showing mortality of 77-90% after allogeneic HSCT 8,76, 42% after 
chemotherapy 73, and 17% after autologous HSCT.76  The main adverse 
prognostic factors are summarised below 49: 
1. Neutropenia  
Prolonged neutropenia post allograft or chemotherapy is associated with poor 
outcome.46,89-91 This is usually due to progression or refractoriness of 
underlying disease. 
2. Progression of underlying disease 91 
3. Monocytopenia  
4. Disseminated disease especially with CNS involvement 
5. Renal and hepatic insufficiency 
6. GVHD and its treatment especially with high doses of steroids 
7. Persistently high serum galactomannan (GM) levels 
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In a recent study Koo et al evaluated 93 patients with proven and probable IA 
and showed that persistently high GM during antifungal therapy is associated 
with poor outcome.92 They concluded that GM at diagnosis and GM decay in 
the week following diagnosis are independent risk factors for mortality. In 
addition, the management strategy adopted may influence outcome. Treatment 
with voriconazole or lipid formulations of amphotericin B is associated with 
improved prognosis.8,46,90,91,93 It is also important to initiate effective antifungal 
therapy early in patients with IA as delay may worsen prognosis.49 
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1.2 Pathogenesis: infection and the host immune response 
Asexual reproduction is the primary form of reproduction by Aspergillus 
species and proceeds on specialised structures called conidiophores where 
the asexual spores (conidia) that easily form aerosols are produced.94  When 
inhaled, small conidia (2.0-3.5 µm in diameter), such as those of A. fumigatus 
may traverse the whole length of the respiratory airways down to the alveolar 
spaces whereas larger conidia of A. flavus and A.niger settle in the upper 
airways and paranasal sinuses. Effector cells of the innate immune system 
responds to eliminate the conidia: alveolar macrophages phagocytose and 
intracellularly destroy conidia by releasing NADPH oxidase-dependent reactive 
oxidant intermediates (ROI), neutrophils aggregate around the conidia and 
prevent their germination by releasing lactoferrin from their primary granules, 
and platelets release serotonin from their dense granules.51,95,96 The 
respiratory mucosa augments the immune response by secretion of 
antimicrobial peptides, such as surfactant proteins, lactoferrin, lysozyme and 
defensins.97,98  In effect the innate immune response to fungi has two 
objectives:  
1. pathogen destruction by phagocytosis or secretion of antimicrobial 
agents against undigestible fungal elements and  
2. instructive role to the adaptive immune system through pro-
inflammatory cytokines and chemokines, the induction of co-stimulatory 
activity by phagocytic cells and antigen uptake and presentation.36 
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The role of macrophages as the first line of defence was first described in a 
guinea pig model by Gernez-Rieux and colleagues.99 and later confirmed by 
Schaffner et al.100 Schaffner et al 100 gave an excellent description of 
macrophages as the first line of defence against spores and neutrophils as the 
second line of defence against hyphae and concluded:  
‘The host, thus, can call upon two independent phagocytic cell lines that form 
graded defence systems against aspergillus. These lines of defence function in 
the absence of a specific immune response, which seems superfluous in the 
control and elimination of this fungus’.  
In addition Schaffner et al identified the role of corticosteroids in invasive 
aspergillosis due to their inhibition of the conidiacidal activity of macrophages. 
 
In the immunocompromised patients the inhaled conidia germinate, a process 
that involves conidial swelling, to produce hyphae capable of tissue invasion.  
This is due to the fact that unlike conidia, hyphae are too large for macrophage 
engulfment and are targeted principally by Neutrophils.101 Activated neutrophils 
aggregate around hyphae and extracellularly secrete reactive oxygen species 
(ROI) and other antimicrobial peptides.102,103 Dying neutrophils also form 
neutrophil extracellular traps (NETs), composed of chromatin and DNA 
covered with granular fungicidal proteins.104 
 
The innate immune system relies on a limited repertoire of germ line-encoded 
receptors called pattern recognition receptors (PRR) on the surface of immune 
cells or in biological fluids to recognise pathogen-associated molecular 
patterns (PAMP), common molecular motifs shared by a large group of 
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microorganisms.105 The best characterised class of cellular PRR involved in 
the recognition of Aspergillus are Toll-like receptors (TLR) and lectin receptors 
(such as dectin-1). Soluble PRR include collectins (mannose-binding lectin 
[MBL], surfactant proteins, C1q) pentraxin (PTX) and ficolin.36 The primary  
structure of the Aspergillus cell wall is composed of a complex meshwork of β-
glucan, galactomannan and chitin  presenting potential targets for PRR 
binding.106  These result in the induction and propagation of inflammatory 
response to Aspergillus and indeed other fungi. For instance, binding of the 
soluble receptor long pentraxin-3 (PTX3) to conidial galactomannan mediates, 
through opsonization, conidial uptake by alveolar macrophages and dendritic 
cells, resulting in the production of protective T helper cell type 1 (Th1) 
cytokines.107 PTX3-null mice have increased susceptibility to IPA 107 and the 
administration of PTX3 protects against IA in a murine model of allogeneic 
bone marrow transplantation.108 
1.2.1 TLR-PAMP system 
TLRs are membrane signalling receptors that collectively recognise lipid, 
carbohydrate, peptide and nucleic-acid structures which are broadly expressed 
by a variety of microorganisms. However, Aspergillus-specific ligands for these 
PPRs are unknown. All TLRs, on binding PAMPs, stimulate a core of 
stereotypic responses but individual TLRs can induce specific responses which 
are either myeloid differentiation primary response gene 88 (MyD88)-
dependent 109 or independent.110 A major downstream effect of TLR signalling 
is the activation of nuclear factor-κB (NF-κB) which is an important 
transcription factor required for the expression of many genes related to innate 
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immunity and inflammation 111 (Figure 1). TLR2 and TLR4 mediate Aspergillus 
fumigatus recognition by macrophages.112,113 
 
        
 
Figure 1: Model for immune response to fungal infection. Fungi such as Aspergillus fumigatus 
(represented by ) are recognised by dendritic cells and other immune cells via their 
receptors such as TLR and Dectin-1 which triggers a cascade of intracellular reactions leading 
to activation of NF-κB, an important transcription factor that leads to transcription of key pro-






1.2.2 β-Glucan recognition 
β-glucans are naturally occurring polysaccharides that form a major constituent 
of the fungal cell wall and play an important role in antifungal immune 
responses. They are recognised by a PRR called dectin-1, which belongs to a 
family of calcium-dependent carbohydrate binding proteins expressed on the 
plasma membranes of macrophages, dendritic cells and other white blood 
cells.115-117  Dectin-1-β-glucan-binding starts a cascade of intracellular 
signalling leading to activation of NFκB. This in turn produces cytokines that 
help drive CD4+ T-lymphocytes towards a Th1 and Th-17 phenotype.36,118,119 
The latter is a signal transducer and activator of the transcription (STAT-3) 
dependent process.120  Th17 lymphocytes produce IL-17 and IL-22 which 
augments neutrophil production and recruitment, and production of 
antimicrobial proteins by epithelial cells respectively.120 Mutations of genes 
affecting this cascade have been shown to cause various fungal susceptibility 
syndromes such as Job’s (Hyper-IgE) Syndrome (STAT3 mutation), and 
recurrent mucocutaneous candidiasis (Dectin-1 and CARD-9).121,122 More 
recently the Dectin-1 polymorphisms (Y238X, rs6910526), which causes a 
change in amino acid 238 from tyrosine to an early stop codon leading to a 
truncated carbohydrate recognition domain (CRD) of dectin-1, has been shown 
to be an important risk factor for IA.66 Cunha and colleagues studied 205 adult 
patients with haematological malignancies who underwent T-deplete 
allogeneic HSCT and found that the presence of Dectin-1 Y238X 
polymorphism in either donors or recipients increased susceptibility to IA with 
the highest risk present in cases of simultaneous polymorphism in both donors 
and recipients.66     
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Dectin-1 activates the transcription of NFκB through the canonical and non-
canonical pathways, the only known PRR to do so.123 The NFkB family are key 
transcription factors and consist of five members which can homo- or hetero-
dimerise: p65, RelB, c-Rel, p50, and p52.124 The canonical pathway involves 
the phosphorylation of spleen tyrosine kinase (Syk) which induces an 
assembly of a protein scaffold consisting of caspase recruitment domain 9 
(CARD9), Bcl-10 and MALT1 which activates IkB Kinase (IKK) complex, 
leading to nuclear translocation of NFkB subunit p65 and c-Rel.125 The non-
canonical pathway is also Syk-dependent and results in the activation of NFκB 
subunit RelB and p52 which down regulates IL-12 transcription.123,124  Dectin-1 
also activates a Syk-independent pathway through the serine-threonine kinase, 
Raf-1 which represses the Syk-induced RelB activity but increases p65 
transcriptional activity to induce the Th1 and Th-17 phenotypes.118,123    
 
The innate immune system has the ability to distinguish between the resting 
and germinating conidia by a stage-specific β-glucan display.113,126 In the 
dormant conidia, β-glucan is shielded by an immunologically inert hydrophobic 
RodA protein covalently bound to the fungal cell wall.127  This immunological 
silencing of the resting fungal spores is consistent with previous observations 
that dectin-1 does not recognise resting conidia but instead recognises swollen 
and germinating conidia and is important in preventing excessive and 
potentially detrimental inflammatory host responses. TLR response to 
Aspergillus is also stage dependent: TLR2 is activated by both conidia and 
hyphae while TLR4 is only activated by conidia.128 This may be an important 
escape mechanism for germinating Aspergilli. Other immunomodulatory 
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mechanisms include the suppression of TLR2- and TLR4-induced IL-1β and 
IL-6 production by TLR2 internalisation with the conidia into phagosomes 
which results in a decrease in the surface receptor expression whereas 
hyphae selectively downregulate TLR4-mediated responses.129  It is suggested 
that TLR2 activation in the absence of TLR4 may skew host response to a Th-
2 type cytokine response which may impair effective host resistance to fungal 
infection.130,131   
1.2.3 Cytokine production in IA 
Cytokines are polypeptides secreted by cells of the innate and adaptive 
immune systems in response to fungal antigens that mediate and regulate 
effector functions of the immune cells. Typically their actions are brief and self-
limited with inhibitory feedback mechanisms to turn down their responses and 
their actions may be local or systemic. They initiate their actions by binding to 
receptors on target cells. They can be divided into 3 main functional 
categories132:  
1. mediators and regulators of innate immunity produced by mononuclear 
phagocytes in response to infectious agents that stimulate their PRR 
(Table 3 & 4)  
2. mediators and regulators of adaptive immunity  (Table 5) 
3. growth factors in particular haematopoiesis (Table 6)  
Chemokines (‘chemotactic cytokines’) stimulate and regulate leukocytes 
movement from blood to tissues. They consist of 8-12 kD poplypeptides 
containing two internal disulphide loops and are classified into 4 groups based 
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on the number and location of N-terminal cysteine residues.132 The CC 
(cysteine residues are adjacent) and CXC (cysteine residues are separated by 
one amino acid) families are the commonest and most important.  
 
Activation of PRRs induces the maturation of antigen presenting cells which 
facilitate the development of adaptive T helper (Th) cell-based immune 
response through the production of specific set of cytokines.36  These helper T 
cells have been traditionally divided into Th1 and Th2.133  Th1 cells are 
essential for defence against intracellular pathogens such as bacteria and 
fungi and produce large quantities of interferon-γ as their signature cytokine 
which activate macrophages and induce delayed hypersensitivity reactions 
(Table 7). Th2 cells function primarily to clear parasitic infections by mainly 
producing IL-4, inducing IgE production and recruiting eosinophils and mast 
cells to the site of infection.  More recently two further lineages have been 
described: Th17 and regulatory T cells (Treg).134,135  In the immunocompetent 
host the Th1 cytokine profile as well as the Th17 cytokines (IL-17A, IL-17F, IL-
22) provide robust antifungal responses at cellular as well as mucosal 
surfaces.120,136  An increase in Th1 cytokines versus Th2 cytokines has been 
shown to lead to improved outcomes in patients with IA.54  In mice rapid Th1 
differentiation of A. fumigatus-specific CD4+ cells occur during IPA in the 
lymph nodes draining the lungs and that these cells become fully differentiated 
IFN-γ producing CD4+ T cells upon arrival in the lungs.137 This process is TLR 
and MyD88-dependent in the lymph nodes but not in the lungs.137     
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Table 3:  Cytokines of the innate immune system (adapted from 132) 
Cytokine Main cell 
source 





Activated T cells, 






 Endothelial cells activation 
(inflammation & coagulation 
 Hypothalamus: fever  
 Liver: synthesis of acute phase proteins 
 Muscles/fat: catabolism 










 Endothelial cells activation 
(inflammation & coagulation 
 Hypothalamus: fever  







 T cells:Th1 differentiation 












 All cells: increased MHC class 1 
expression and inhibit viral replication 
 NK cells: activation 








 Macrophages & DCs: inhibition of 
effector functions (IL-12, TNF, IL-6, etc) 
and expression of costimulators and 





T cells, activated 
T cells 
Microbes,  
IL-1, TNF  
 Liver: acute phase proteins 






acids, LPS,  
 NK cells: proliferation (and perhaps 
differentiation & activation) 
 T cells: proliferation, survival of  







 NK cells & T cells: IFN-γ synthesis, Th1 
differentiation (synergy with IL-12) 
Chemokines See Table 2 
NK, natural killer; DC, dendritic cell; MHC, major histocompatibility complex; TLR, toll-like receptor; LPS, 
lipopolysccharide 
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Table 4: Chemokines (adapted from 132) 




CCL2 MCP-1 CCR2 mixed leukocyte 
recruitment 
CCL3 MIP-1α CCR1, CCR5 mixed leukocyte 
recruitment 
CCL4 MIP-1β CCR5 T cell, DC, 
monocyte and NK 
recruitment 
HIV coreceptor 




CCL11 Eotaxin CCR3 Eosinophil, 
basophil and Th2 
recruitment 
CXC chemokines 
CXCL8 IL-8 CXCR1, CXCR2 Neutrophil 
recruitment 
CXCL9 Mig CXCR3 Effector T cell 
recruitment 
CXCL10 IP-10 CXCR3, CXCR3B Effector T cell 
recruitment 





Table 5:   Cytokines of the adaptive immune system (adapted from 132) 
Cytokine Main cell 
source 




called T cell 
growth factor) 
T cells (mainly 
CD4+ T cells) 
Intracellular  
microbes 
T cells: proliferation & survival (induces anti apoptotic protein 
Bcl-2),  ↑cytokine synthesis; Treg development & survival 
NK cells: proliferation, ↑cytotoxicity 
B cells: proliferation, antibody synthesis (in vitro) 
Interleukin-4 (IL-
4) 





B cells: isotype switching to IgE & IgG4 
T cells: Th2 differentiation, proliferation, inhibition of Th1 & 
Th17 differentiation 
Macrophage: inhibition of IFN-γ-mediated activation 
Interleukin-5 (IL-
5) 





Eosinophils: activation, ↑production 
B cells: proliferation, IgA production (in vitro) 
Interleukin-13 
(IL-13) 
CD4+ T cells 
(Th2), NKT 
cells, mast cells 
Helminthic 
parasites 
B cells: IgE class switching 
Epithelial cells: ↑mucus production, inflammation 
Fibroblasts:  ↑collagen synthesis 





T cells (Th1, 






Macrophages: activation, ↑microbicidal activity           
B cells: isotype switching to opsonising and complement-
fixing IgG 
T cells: Th1 differentiation (via T-bet) 
Others: ↑expression of class I & II MHC molecules, ↑antigen 




Many cells Antigen 
stimulated T 
cells 
T cells: ↓proliferation and effector functions; Treg 
differentiation 
B cells: ↓proliferation; IgA production 
Macrophages: ↓activation; stimulation of angiogenic factors 
Fibroblasts: ↑collagen synthesis 
Interleukin-17 
(IL-17) 
T cells TGF-β + IL-6 
(+IL21 & IL-
1β) 
Endothelial cells: ↑chemokine production 
Macrophages: ↑chemokines & cytokine production 





cells, T cells 
Microbes,  
IL-1, TNF 
 B cells: plasma cell differentiation 




Table 6:  Cytokines of haematopoiesis and other growth factors (adapted from 132) 
Cytokine Main cell sources Principal cell target/cell 
population induced 
Stem cell factor (c-Kit ligand) BM stromal cells Pluripotent stem cells: all 
Interleukin-7 (IL-7) Fibroblasts, BM stromal 
cells 
Immature lymphoid cells: B & T 
lymphocytes 
Interleukin-3 (IL-3) T cells Immature progenitors: all 
Granulocyte-monocyte CSF 
(GM-CSF) 
T cells, macrophages, 
endothelial cells, 
fibroblasts 
Immature and committed 
progenitors, mature macrophages: 
granulocytes, macrophage activity 





Interleukin-6 (IL-6) Macrophages, 
endothelial cells, T cells 
Immature progenitors: all 
Epidermal growth factor 
(EGF) 
 Epidermal and epithelial cells 
Vascular endothelial growth 
factor (VEGF) 








Hepatocyte Growth factor 
(HGF) 
Mesenchymal cells Epithelial cells, endothelial cells, 
Immature and committed 





The role of Th17 in controlling IA is becoming clearer. IL-17 is important in the 
recruitment of neurophils, whereas, IL-22 induces epithelial production of the 
cationic antimicrobial peptides β-defensin 2 and 3.136  The controversy 
surrounding the role of Th17 is due to the fact that it encourages inflammatory 
tissue damage and on its own promotes, rather than controls, IA.138  In fact 
successful clearance of IA is dependent on robust Th1  response coupled with 
a weak Th17 response.94  This may be due to the fact that A. fumigatus 
possesses indoleamine 2,3-deoxygenase (IDO) which metabolises tryptophan 
into kynurenine, an immunoregulatory catabolite which inhibits Th17 and 
induces regulatory T cells.139  Polymorphisms of some cytokine genes have 
also been described which provide an additional layer of susceptibility to IA 
such as CXCL-10 140, IL-10 promoter 67,141, IL-1 69 and variable number of 
tandem repeats of TNF receptor type 2 promoter.68 These polymorphisms 
together with the Dectin-1 and TLR polymorphisms described above may 
become an important tool for risk stratification of patients undergoing HSCT or 
high dose chemotherapy. 
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Table 7: Properties of the Th1 and Th2 CD4 T helper cells (adapted from 132) 
 Th1 profile Th2 profile 
Cytokines produced 
   IFN-γ 
   IL-4, IL-5, IL-13 
   IL-10 











Cytokine receptor expression 
   IL-12R β chain 







Chemokine receptor expression 
   CCR4, CCR8, CXCR4 







Immune system promoted Cell mediated Humoral  
Main partner cell Macrophage  B cell 
 
 
1.2.4 Angioinvasion  
The majority of inhaled A.fumigatus conidia that reach the pulmonary alveoli 
are destroyed by type II pneumocytes, but about 3% of them survive within 
pneumocytes142.  The process of angioinvasive aspergillosis is thought to 
occur via the following steps 143: 
Within pulmonary alveoli 
1. Inhalation of airborne conidia 
2. Adherence of conidia to pulmonary epithelial cells 
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3. Endocytosis of conidia by epithelial cells primarily type II 
pneumocytes. Endocytosed live but not killed A. fumigatus conidia 
actively inhibit apoptosis, induced by TNF-α in type II pneumocytes.144  
4. Germination of conidia to form hyphae within the epithelial cells 
5. Growth of hyphae by apical extension and escape from the epithelial 
cells 
 
Within pulmonary vessels  
6. Hyphael penetration of abluminal surfaces on the endothelial cells of 
pulmonary vessels 
7. Endothelial cell damage by growing hyphae 
8. Haematogenous dissemination of hyphal fragments 
 
Within systemic blood vessels 
9. Adherence of hyphal fragments to the luminal endothelial cell surface 
10. Invasion of  luminal endothelial cells 
11. Endothelial cell damage 
12. Extravascular invasion 
These events are summarised in Figure 2. 
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Figure 2 Model of Aspergillus fumigatus angioinvasion according to Filler et al 
143
 
IA occurs via the following steps: infection is initiated by the inhalation of small numbers of 
airborne conidia (A), which adhere to pulmonary epithelial cells (B), and are rapidly 
endocytosed (C). Within the epithelial cells, the conidia germinate to form hyphae (D), which 
grow by apical extension and escape from the epithelial cells (E). Next, emergent hyphae 
penetrate the abluminal surface of endothelial cells (F) and induce endothelial cell damage 
(G). Hyphal fragments disseminate hematogenously (H) and adhere to the luminal endothelial 
cell surface (I) before invading these cells (J). Luminal invasion results in endothelial cell 
damage (K) and extravascular invasion of deep organs (L). 
 
Angioinvasion is a key feature of IA pathogenesis. As shown above there are 2 
types of angioinvasion: pulmonary and systemic. Pulmonary angioinvasion 
causes endothelial injury, release of proinflammatory cytokines, tissue factor 
expression and activation of coagulation cascade.145  Moreover A.fumigatus 
hyphae are potent inducers of platelet α-granules and lysosomal granules that 
leads to expression of membrane-bound (CD66 and CD62P) and soluble 
(RANTES, CD40L, DKK-1) inflammatory mediators.146  Consequently these 
processes lead to thrombosis and thus reduced tissue perfusion of the infected 
lung tissue leading to coagulative necrosis and effectively sequestering the 
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infected area.53 This is the hallmark of the histological and radiological 
appearance of IPA: a central zone of necrotic tissue  heavily infected by 
hyphae and a peripheral zone of haemorrhage with notable absence of 
inflammatory infiltrate into the affected area (Figure 3).147  The angioinvasion 
and subsequent coagulative necrosis prevents the recruitment of inflammatory 
cells to the site of infection.  Likewise, the vasculopathy and the sequestration 
of the affected area results in poor tissue perfusion and subtherapeutic 
antifungal drug concentrations at the infected area, despite treatment with a 
sensitive antifungal agents.148  The discrete nodule corresponds to the nodule 
surrounded by the ground-glass infiltrate (‘halo sign’) on computed tomography 
of the lungs.149  
   
Figure 3: Histopathological appearances in angioinvasive aspergillosis. Post-mortem lung specimen (left) with 
two target lesions caused by angioinvasive aspergillosis. The larger focus in the lower lobe shows a central 
zone of necrosis (asterisk) and a surrounding “halo” of haemorrhage (arrowheads). High power image (x20) 




Chamilos et al 77 found differences in the histopathological pattern of invasive 
pulmonary aspergillosis between neutropenic patients and non-neutropenic 
HSCT recipients with GVHD on immunosuppressive therapy.  In the latter 
group there was more lung inflammation and less aspergillus burden in 
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contrast to the neutropenic patients who had less inflammation, and high 
aspergillus burden accompanied by hyphal angioinvasion and extensive 
coagulative tissue necrosis.   
 
Systemic angioinvasion is less common but occurs in severely 
immunosuppressed and profoundly neutropenic patients.143 During systemic 
haematogenous angioinvasion the hyphae invade the luminal endothelium in 
contrast to abluminal invasion in pulmonary angioinvasion. In an in vitro model 
Kamai et al demonstrated important differences between luminal and 
abluminal angioinvasion.150 They found that luminal invasion was mediated by 
formation of endothelial pseudopods which engulfed the hyphae and that it 
caused greater endothelial cell damage but induced less expression of mRNA 
for E-selectin, TNF-α, IL-8, and tissue factor. The stronger proinflammatory 
and prothrombotic response to abluminal infection is probably designed to 
prevent haematogenous spread.  The actual receptors that mediate invasion of 
endothelial cells are yet to be identified. 
 
The formation of new blood vessels (angiogenesis) is a normal physiological 
response to inflammation and ischemia.151-153  The consequent tissue hypoxia, 
proinflammatory cytokines and reactive oxygen intermediates (ROI) are 
important pro-angiogenesis signals.94  The release of chemokines and 
cytokines (such as IL-8, TNF-α, HIF-1α) leads to the recruitment of neutrophils 
and macrophages to the lungs which release ROI such as hydrogen peroxide 
(H2O2) and others which upregulate NF-κB. The NF-κB induces the 
transcription of vascular endothelial growth factor (VEGF) and other pro-
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angiogenic factors.154-156  However, this normal physiological response is 
opposed by anti-angiogenic factors released by Aspergillus spp. 
 
Gliotoxin is one of the most important known anti-angiogenic factors. It is 
released by Aspergullus species as a secondary metabolite synthesised under 
transcriptional regulation of LaeA, a transcription factor that controls secondary 
metabolism.157  It downregulatates NF-κB directly and indirectly by reducing 
the concentration of H2O2.
158-160  Other antiangiogenic secondary metabolites 




1.3 Clinical features 
The ubiquitous nature of Aspergillus species means that all body cavities are 
target areas for colonization and invasion. The upper and lower respiratory 
tracts are the most frequent sites where inhalation of Aspergillus conidia is the 
route of infection. In immunocompetent hosts, alveolar macrophages and 
neutrophils phagocytose and destroy the spores before they cause disease.  In 
the immunocompromised host this primary defence is inadequate allowing the 
conidia to germinate into hyphae which then invade blood vessels leading to 
angioinvasive disease and haematogenous spread to other organs.163,164 
Unfortunately clinical features are non-specific by themselves however 
suggestive.  In the upper respiratory tract the patient may experience facial 
swelling, epistaxis, proptosis, and cranial nerve abnormalities due to either 
direct orbital involvement or from cavernous sinus involvement (rhinocerebral 
aspergillosis) as well as bone erosion or ischemia of the palate.32 
 
The lungs are commonest site of IA and patients commonly present with 
broad-spectrum antibiotic-resistant fever, which may be associated with cough, 
dyspnoea, pleuritic chest pain, or haemoptysis.  Immune reconstitution 
inflammatory syndrome (IRIS) may occur in patients during neutrophil recovery 
presenting with clinical respiratory and radiological deterioration but showing 
microbiological response as evidenced by the rapid normalization of serum 
galactomannan.165  Rapid recovery of neutrophils in patients with IPA may also 
be associated with pneumothorax or fatal haemoptysis.166-168 
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The second commonest site of IA is the central nervous system (CNS).79,86,169 
Patients presents with seizures, altered levels of consciousness with or without 
focal neurological signs. It is not possible on clinical or radiological grounds 
alone to distinguish cerebral aspergillosis from other causes of space 
occupying lesions such as toxoplasmosis, tuberculosis or even malignancy 
and biopsy is necessary to confirm the diagnosis. Cerebral aspergillosis may 
occur without pulmonary disease.13 Gastrointestinal tract involvement 
manifests with abdominal pain, haematemesis, or melaena.169  In disseminated 
disease skin lesions such as nodules which may be necrotic, crusted or 
echymotic with surrounding cellulitis or erythema may occur.2,169  Other sites of 
involvement include kidneys, liver, spleen, adrenal glands, bone, pleura, heart, 
stomach, and large vessels.13 Recipients of HSCT are more likely to develop 
disseminated disease.7 
 
1.4 Prevention & Prophylaxis 
The prevention of IA involves environmental infection control measures to 
reduce exposure to Aspergillus spp and other fungi as well as pharmacological 
prophylaxis during at risk periods.170 There are two ways to provide 
environmental control: laminar air flow and high-efficiency particulate air 
(HEPA) filtration. Laminar air flow involves air filtration, reverse isolation, gut 
decontamination and non-absorbable antimicrobials as prophylaxis during the 
treatment of haematological malignancy.171  It has been shown to be effective 
in reducing septicaemia and other types of infections in patients with 
leukaemia and aplastic anaemia undergoing HSCT.172,173 The most important 
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component of laminar air flow is filtered air. Filtration with HEPA during periods 
of neutropenia provides effective prophylaxis against mould infection.5,174,175 
Potted plants, plant material, marijuana, and tobacco smoking are important 
environmental sources of Aspergillus spores and should be avoided.171 
However, pre-exposure to Aspergillus spp. is probably universal and such 
strategies can realise only a limited reduction in IA incidence. The role of a 
‘neutropenic diet’, which excludes certain foods especially fresh vegetables 
and fruits, in preventing IA is unclear and currently there is no data on its 
efficacy but may have a role in the prevention of bacterial infections.176,177 
 
Antifungal prophylaxis offers some promise especially among high risk 
patients. It is important to differentiate between primary and secondary 
prophylaxis and the changing practice landscape over time.  Most of the data 
that exist in the efficacy of antifungal usage in this area relates to primary 
prevention and secondary prophylaxis will be dealt with separately. There are 




Nystatin was the first antifungal agent discovered in 1951.178  It was originally 
called Fungicidin and later Nystatin, New York State Department of Health, 
where its discoverers worked and was effective against oral mucosal 
candidiasis but was too toxic for systemic use.179  Amphotericin B 
deoxycholate was the first systemic agent discovered in 1956, isolated from 
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Streptomyces nodosus.180 It has striking structural similarity to nystatin (Figure 
4) and similar antifungal activities but is less toxic and can be administered 
intravenously. Polyenes exert their antifungal activity primarily by binding 
ergosterol, the principal sterol in the cell membrane of fungi. This leads to the 
formation of transmembrane pores which leads to efflux of protons and 
cations, depolarization of the cell membrane and ultimately cell death.181,182  
 
         
Figure 4: Structure of Nystatin (left) and Amphotericin B (right)  
 
 
Lipid formulations of amphotericin B (L-AmB) with less nephrotoxicity were 
developed in the late 1980s.  The evidence for the efficacy of Amphotericn B in 
preventing IA is conflicting.  The trials using conventional amphotericin B 
versus placebo used low dose regimens of 0.1mg/kg/day and four such trials 
were conducted in the late 1980s and early 1990s. Two of the studies showed 
a reduced incidence and mortality associated with IA among allogeneic HSCT 
patients receiving amphotericin B compared to placebo.183,184  However two 
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other studies showed no difference in IA incidence or survival benefit.185,186  
Four randomised trials were conducted using low dose L-AmB. The first two 
were safety studies involving allogeneic and autologous HSCT patients using 
1mg/kg/day and 2mg/kg 3 times weekly vs placebo respectively. Although 
safety was demonstrated in both, no difference was seen in the incidence of 
proven IFD or requirement for use of antifungal therapy.187,188  The third study 
was an open label randomised trial of 231 patients undergoing chemotherapy 
or autologous HSCT randomised to 50 mg Ambisome on alternate days or 
placebo.  This study demonstrated a significant reduction in the incidence of 
IA: 4% compared to 20%.189  The fouth study was non randomised study which 
compared amphotericin lipid complex (Abelcet) 2.5mg/kg 3 times weekly in 
AML and MDS patients undergoing induction chemotherapy with a historical 
control group that received Ambisome 3mg/kg 3 times weekly.  No difference 
was seen in the incidence of documented fungal infection between the two 
groups.190  Different dosing schedules were explored in two further studies. El-
Cheikh el at evaluated weekly Ambisome at 7.5mg/kg in patients with acute 
GVHD on high dose prednisolone after reduced intensity transplantation while 
Cordonnier et al used 10mg/kg in 29 patients with acute leukaemia undergoing 
chemotherapy or myeloablative transplantation.191,192  These doses were not 
well tolerated due to infusion-related toxicities and elevated serum creatinine. 
 
Aerosolised administration of Amphotericin B has been used as a prophylactic 
strategy. Conventional Amphotericin B was neither efficacious in preventing 
IFD nor well tolerated.193,194  Rijinders et al performed a randomised placebo-
controlled trial of aerosolised liposomal Amphotericin on two consecutive days 
 58 
per week in 271 patients with haematological malignancies with prolonged 
neutropenia.195  The primary end point was development of proven/probable 
IPA using the 2002 EORTC/MSG definitions.9 This strategy was both well 
tolerated and significantly reduced the incidence of IPA (14% among placebo v 
4% amphotericin group; OR 0.26, P=0.005). 
 
1.4.2 Triazoles  
The principal agents in use in current haematology practice are fluconazole, 
itraconazole, posaconazole, and voriconazole. Triazoles act principally by 
inhibiting CYP450-dependent enzyme lanosterol 14α-demethylase which is 
necessary for the conversion of lanosterol to ergosterol.171 Ergosterol is the 
predominant cell membrane sterol of most fungi. Table 8 summarises the 
evidence for the efficacy of triazoles as prophylactic agents in current 
haematological practice. The introduction of fluconazole in the late 1980s was 
a major advance. Not only did it significantly reduce IFD rate, mostly due to 
Candida spp,196 197,198 but it also had long-term survival benefit when given for 
75 days post-transplant.198,199  At the time of these trials the dose used for 
prophylaxis was 400mg/day as this was thought to have some anti-mould 
activity. In fact fluconazole has no anti-mould activity and lower doses 50-
200mg/day are also effective against candida.200,201  Predictably, the 
widespread use of fluconazole prophylaxis prevented candidiasis but did not 
reduce mould infection, especially IA.  
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Itraconazole has good in vitro anti-mould activity and this was borne out in 
clinical trials in the setting of chemotherapy or HSCT.202,203  However, 
itraconazole usage is hampered by two major issues- gastrointestinal side-
effects and serious drug interactions. It is available orally as a capsule or 
cyclodextrin suspension and the former requires an acidic environment for 
absorption and generally poorly absorbed. In the setting of allogeneic HSCT its 
most serious drug interaction is with cyclophosphamide, where it was found to 
cause high bilirubin and creatinine due to differential inhibition of cytochrome 
P450 isoenzymes resulting in higher cyclophosphamide toxic metabolites.204  
Vinca alkaloid-induced neurotoxicity is also an important drug interaction with 
itraconazole as well as fluconazole and voriconazole.205,206 
 
Posaconazole is the newest triazole prophylactic agent and is an analogue of 
itraconazole. Its efficacy has been shown in two large randomised trials in the 
context of patients with AML or MDS undergoing chemotherapy or patients 
with chronic GVHD post allograft.207,208  Cornely et al randomised 602 AML or 
MDS patients with prolonged neutropenia in a multicentre non blinded study to 
receive either posaconazole 200mg tds (n=304) or fluconazole 400mg/d (n= 
240), or itraconazole 200 mg bd (n= 58).207  The study patients received 
prophylaxis with each cycle of chemotherapy until neutrophil recovery and 
complete remission (CR), breakthrough IFD (according to the original 
EORTC/MSG definitions9) or up to 12 weeks. The primary end point was the 
incidence of probable or proven IFD which occurred in 7 patients (2%) in the 
posaconazole arm and 25 patients (8%) in the fluconazole/itraconazole arm.  
IA was less in the posaconazole arm at 1% vs. 7% in the 
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fluconazole/itraconazole arm (P<0.001). It is worth noting that the definition of 
IA in this study relied heavily on galactomannan positivity which was not 
necessarily accompanied by radiological features, cases which would be 
unclassified under the current EORTC/MSG definition.  Overall survival was 
significantly longer in the posaconazole arm.  
 
In the setting of HSCT, Posaconazole has also been evaluated.  There is 
limited data on its efficacy as primary prophylaxis as there is only one 
published study that evaluated this. Sanchez-Ortega et al compared 33 
patients within 100 days of allograft to 16 itraconazole historical controls and 
showed 0% and 12% incidence of probable/proven IFD in the posaconazole 
and itraconazole groups respectively.209 Overall survival and fungal free 
survival were also improved in the posaconazole group. The role of 
posaconazole prophylaxis in the context of extensive chronic GVHD was 
assessed by a double-blind randomised controlled trial of posaconazole 
compared to fluconazole in 600 patients by Ullmann et al.208  The incidence of 
IFD and IA was lower in the posaconazole arm (2.4% and 1.0% respectively) 
compared to the fluconazole arm (7.5% and 5.9%).  Overall survival was not 
significantly different between the two arms. 
 
Voriconazole has recently been evaluated as a prophylactic agent in two large 
multicentre randomised trials in the context of neutropenia post allograft.210,211  
Wingard et al randomised 600 allograft patients to voriconazole or 
fluconazole.210 The incidence of IFD, using the revised EORTC definitions,10 
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fungal-free survival, and overall survival were not significantly different 
between the two arms at 6 or 12 months post-transplant. The incidence of 
proven/probable IFD in this study was similar to the Ullmann et al study.208 The 
number needed to treat (NNT) with voriconazole to prevent one IFD was 26 212 
compared to 27 with posaconazole.213  A recently published multicentre 
European study, The IMPROVIT study randomised 503 allograft patients 
between voriconazole and itraconazole and found similar low rates of IFD in 
the both arms (1.3% voriconazole arm v 2.1% itraconazole arm) but 
voriconazole was better tolerated.211  Gergis et al retrospectively reviewed their 
experience with voriconazole in 97 patients compared to itraconazole (N= 36) 
and fluconazole (N= 36) who had GVHD on 1mg/kg/d of prednisolone.214  The 
incidence of IA in this study was 0% in the voriconazole group compared to 7% 
in the itraconazole/fluconazole group.   
 
Voriconazole has also been evaluated in patients undergoing chemotherapy. 
Vehreschild et al randomised 25 AML patients undergoing induction 
chemotherapy between voriconazole and placebo.215 The primary end-point for 
this study was the incidence of pulmonary infiltrates up to day 21 after start of 
chemotherapy. They found    no infiltrates in the voriconazole arm compared to 
33% in the placebo arm.  In addition four cases of hepatosplenic candidiasis 
were also found in the placebo arm. The trial was prematurely terminated upon 
publication of the Cornely el al 207 study as the authors felt it was unethical to 
continue in the light of improved survival with posaconazole. Finally Mattiuzzi 
et al compared efficacy and safety of voriconazole to itraconazole, both given 
intravenously in 123 AML or MDS patients undergoing induction or salvage 
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chemotherapy.216   The incidence of IFD was 0% in the voriconazole group 
compared to 4% in the itraconazole group (P= 0.17). There was significant 
toxicity in both arms. The cost implications and logistics of such an approach 
would be difficult to justify in clinical practice except where patients are unable 





Table 8: Triazole antifungal prophylaxis trials (Adapted from 179) 






RCT  DB 
single 
centre 
n = 356 
Autologous = allo
geneic HSCT. Up 
to engraftment 
Fluconazole 
400 mg/d vs. 
Placebo 
IFD 2·8% vs. 15·8% 














n = 300 
Allogeneic > autol
ogous HSCT Up 
to day 75 
Fluconazole 
400 mg/d vs. 
placebo 
IFD 7% vs. 18% Mortality 














n = 253 
Allogeneic (55%) 
and autologous 
(45%) Adult and 
paediatric patients 
Fluconazole 
400 mg vs. 
200 mg/d 
No difference in systemic 
IFD at day 50, 4% vs. 1% 
(P = 0·08) 
Low incidence of 
IFD both arms 
Menichetti 
217
  (1994) 
RCT 
multicentre 





150 mg/d vs. 
AmB 500 mg 
oral QID 
No difference in IFD 









n = 257 
Acute leukaemia 
anticipated 
ANC < 0·5 × 10
9
/l 
for ≥7 d 
Fluconazole 
400 mg/d vs. 
placebo 
No difference in IFD (4% 













400 mg/d vs. 
placebo 
Proven IFD17% vs. 3% 
(P < 0·001) No overall 
survival benefit 
Most useful in 
cytarabine/anthra















400 mg/d vs. 
placebo 








RCT  DB 
multicentre 
n = 140 
Allogeneic HSCT Itraconazole 
200 mg bd vs. 
fluconazole 
Proven IFD 9% vs. 25% 
(P = 0·01). IA 4% vs. 12% 
(ns) Trend towards fewer 
fungal deaths with 
itraconazole (9% vs. 18%, 
P = 0·13, ns) 









RCT DB  
single 
centre 
n = 299 
Allogeneic HSCT Itraconazole 




Invasive mould infection 
5% vs. 12% (P = 0·03) IFD 
7% vs. 15% (P = 0·03) 























2·5 mg/kg oral 
solution bd vs. 
fluconazole 
50 mg/d 
IFD one with itraconazole 
vs. six with fluconazole 
(P = 0·06) 
Note: most 
infections in the 
low dose 
fluconazole arm 












IFD itraconazole 6% vs. 








neutropenia >7 d 















2·5 mg/kg bd 
vs. placebo 
Proven and suspected IFD 
itraconazole (24%) vs. 
placebo (33%) (P = 0·35) 














2·5 mg/kg bd 
vs. AmB 
capsules 
500 mg QID 
No difference in proven 
IFD. Itraconazole (2·8%) 









n = 600 
Allogeneic HSCT 




200 mg tds vs. 
Fluconazole 
400 mg/d 
Proven/probable IFD 7% 
vs. 14% Mortality 
difference not significant 
Few patients with 
most severe form 
of GVHD (grade 













200 mg tds 
(n= 304)  vs. 
fluconazole 
400 mg/d 
(n = 240) or 
itraconazole 
200 mg bd 
(n = 58) 
Proven/probable IFD 2% 
vs. 8% (P = 0·0009). 
Mortality15% vs. 
22%P = 0·03 Serious 
adverse events possibly or 
probably related to 
treatment in 19 (6%) 
posaconazole group and 6 
(2%) in the fluconazole or 
itraconazole group 
(P = 0·01) 
Not powered to 
compare 
itraconazole. 











n = 600 
Allogeneic HSCT 
(HLA matched in 
at least 5/6 loci) 
Voriconazole 
200 mg bd vs. 
fluconazole 
400 mg daily 
Fungal-free survival at 
day 180 was not different 
at 75% and 78% IFD not 
significantly different 






tests twice weekly 









n = 503 
Allogeneic HSCT Voriconazole 
200 mg bd vs. 
itraconazole 
200 mg bd 
Proven/probable IFD 1.3% 
v 2.1%. OS similar. Vori 
better tolerated 
Quite low number 
of cases in both 
arms 
 
IFD, invasive fungal disease; HSCT, haematopoietic stem cell transplant; ANC, absolute neutrophil 
count; HLA, human leucocyte antigen; AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; 
ns, not significant; GVHD, graft versus host disease; IA, invasive aspergillosis; i.v., intravenous; AmB, 




The echinocandins are a novel class of antifungals that work by inhibiting β-
1,3-D-glucan synthase, the enzyme complex that catalyses the synthesis of β-
1,3-D-glucan, an integral component of the fungal cell wall that provides 
rigidity, antigenicity and fungal virulence.224 The uniqueness of the fungal cell 
wall and the specific action of the echinocandins may account for their safety 
and minimal drug interactions.  They are large molecules and are only 
available parenterally due to their poor oral bioavailability.225  Micafungin 
versus fluconazole has been studied for prophylaxis in allogeneic HSCT 
recipients in 2 randomised trials and Micafungin was found to be effective in 
invasive candida infection but without evidence of efficacy against IA.226,227  
Caspofungin has been shown to be as effective as itraconazole in patients 
undergoing chemotherapy.228 
 
1.4.4 Secondary prophylaxis  
Patients with previously documented evidence of IA who need further 
chemotherapy are given secondary prophylactic antifungal therapy during 
additional chemotherapy or transplantation to pre-empt relapse of IA.  These 
patients are at high risk of infection relapse without secondary prophylaxis.229  
This issue has been addressed in 2 small non-randomised studies. 
Vehreschild et al evaluated 75 cases from the Multinational Case Registry of 
Secondary Antifungal Prophylaxis who received caspofungin (N= 47) or 
itraconazole (N= 28).230  Patients treated with caspofungin were more likely to 
have uncontrolled underlying malignancy, incomplete response to previous 
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antifungal therapy and more likely to undergo allogeneic HSCT. Breakthrough 
IFD occurred in a third of the patients and overall survival was comparable 
between the groups. The second study was a prospective open label 
multicentre trial conducted by the European Group for Blood and Marrow 
Transplantation (EBMT) and evaluated the efficacy of voriconazole in 45 
allograft recipients who had previous proven or probable IFD.231 The 1-year 
cumulative incidence of IFD was 6.7%. Although 11 patients (24%) died within 
12 months of transplant, only one was due to systemic fungal infection. The 
results of this study are much better than historical controls and argue strongly 
in favour of secondary prophylaxis with voriconazole.  
 
1.4.5 Guidelines 
The above evidence and those derived from meta-analysis support the use of 
antifungal prophylaxis in high risk patients and is recommended by guidelines 
on both sides of the Atlantic.4,11,232  Table 9 summarises the updated European 
Conference on Infections in Leukaemia (ECIL-3) and the Infectious Disease 
Society of America (IDSA) consensus guidelines for antifungal prophylaxis in 
AI. The grading is based on the IDSA grading system.233  
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Table 9: Summary of the ECIL-3 and IDSA guidelines for prophylaxis against IA 
 ECIL-3 grading 
11




   Fluconazole 
   Itraconazole  
   Posaconazole 
   Aerosolised L-AmB & fluconazole po    













Allogeneic HSCT, neutropenic phase 
   Fluconazole 
   Itraconazole  
   Posaconazole 
   Voriconazole 
   Aerosolised L-AmB & fluconazole po       
   Micafungin 

















Allogeneic HSCT, GVHD phase 
   Fluconazole 
   Itraconazole  
   Posaconazole 












Despite the clinical trials discussed previously, the overall benefit, cost 
effectiveness and risks of primary prophylaxis remains a matter of 
debate.234,235  In addition, mould-active azoles can cause serious drug 
interactions through their inhibition of the hepatic cytochrome P450 enzyme 
system as well as cause serious side effects such as hepatic toxicity. 
Moreover, there remains a serious concern about the effectiveness of these 
agents due to poor absorption which may be an important issue in patients 
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with severe mucositis or diarrhoea as well as gastrointestinal intolerance.  
Because of this, therapeutic drug monitoring is recommended.4,11  The use of 
primary prophylaxis may also cause low Aspergillus antigenaemia leading to 
false negative serological tests such as  galactomannan.32  Local institutional 
fungal epidemiology and availability of timely diagnostic facilities are crucial. It 
is argued that for primary prophylaxis to be effective the background incidence 
need to be >5% since the number of patients needed to be treated to prevent 
one fungal infection would be >20, a figure suggested as the cost effective 
threshold.236 
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1.5 Treatment of IA 
Currently, three different classes of antifungal agents are licensed for the 
treatment of IA: polyenes, azoles and echinocandins. How these drugs are 
used varies considerably in different clinical practice but can be broadly 
categorised as: empirical, pre-emptive and targeted therapy. This is largely 
because currently there are no reliable diagnostic tools sufficiently sensitive 
and specific enough for the diagnosis of IA in routine clinical practice. Empirical 
treatment is the initiation of antifungal therapy among high risk patients at first 
suspicion of IA.237 In practice this usually means bacteria culture-negative 
neutropenic sepsis resistant to broad-spectrum antibiotics for 4-7 days but no 
specific radiological or laboratory evidence of IA. This fever-driven strategy 
was developed in the 1980s when there were no adequate diagnostic tools 
available.238 However, fever has a low positive predictive value for diagnosing 
invasive fungal infection239 and may miss cases in patients on high dose 
steroids or other immunosuppressive therapy (low negative predictive 
value).238  Clearly this approach will lead to the treatment of a large proportion 
of patients who have no IA. It has been the standard of care widely used and 
endorsed by guidelines, although it has never been compared to placebo or 
other treatment strategies.4,11,239-241  
 
The availability and the use of non-culture based methods of serological 
detection of cell components of Aspergillus such as galactomannan or β-D-
glucan as well as modern CT scanning techniques has given rise to the term 
‘pre-emptive’ therapy or the diagnostic-driven strategy.  It relies on sensitive 
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diagnostic tools such as galactomannan, β-D-glucan or PCR, as well as CT 
scanning in high-risk patients to guide therapy before full blown disease 
develops. This approach has been shown to reduce anti-fungal usage to about 
50% of the empirical approach 242 and has been recently shown to be non-
inferior to empirical therapy in a randomised trial.243  Targeted therapy is where 




1.5.1 Empiric therapy 
For many, Amphotericin B remains the gold standard for empiric therapy.  
However, it is a toxic antimicrobial with multiple infusion-related and other side-
effects, including renal impairment which may be augmented by other 
nephrotoxic drugs.6 Lipid preparations (liposomal amphotericin B [AmBisome], 
amphotericin B lipid complex [ABLC; Abelcet], ABCD [Amphocil or Amphotec], 
are less acutely toxic (and Ambisome may be marginally more effective) than 
amphotericin B, but are expensive and there remains evidence of less overt 
cumulative nephrotoxicity.244-248 The efficacy of liposomal amphotericn B was 
based on a multicentre double blind randomised trial involving 687 patients 
randomised to either conventional or liposomal amphotericin B.245 Liposomal 
amphotericin was as effective as conventional formulation for empiric therapy 
and was associated with fewer break-through infections, and less toxicity.  All 
the lipid preparations preferentially distribute to the reticulo-endothelial system 
with relative sparing of the kidneys.4 At the commonly prescribed dose of 
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3mg/kg/day AmBisome was as effective as 10mg/kg/day in the AmBiLoad trial 
but less nephrotoxic and had a trend towards better survival at 12 weeks.249  
 
Walsh et al conducted a multicentre double-blind randomised trial involving 
1095 patients who had persistent fever and neutropenia.250 Using composite 
end points caspofungin was found to be as effective as and better tolerated 
than liposomal amphotericin B. A similar finding was observed in children.251 
The efficacy of Micafungin was assessed in a prospective, non-comparative 
trial involving 277 neutropenic adults in 87 Japanese centres.252 Its efficacy 
was similar to previous empiric trials at 80.7% response rate. As a result of this 
trial, as well as another historical comparative study (Micafungin v 
caspofungin), 253  ECIL 3 accepted Micafungin as an empiric therapy.11 
 
Voriconazole was compared with liposomal amphotericin B in a multicentre 
randomised trial involving 837 patients.254 Using composite end point analysis 
to assess treatment efficacy, voriconazole failed the 10% non-inferiority cut off. 
Consequently it was not approved by the FDA for empiric therapy. Itraconazole 
is a possible alternative empiric agent if drug interactions are not an issue, but 
it has not been studied in allogeneic HSCT patients and blood levels should 




1.5.2 Targeted therapy 
This refers to treatment of probable and proven cases, but in some trials 
possible cases have been included.238  Voriconazole is recommended 
worldwide as the drug of choice for first line therapy for IA based on a 
prospective, randomised trial with amphotericin B as the comparator. The trial 
involved 277 patients with proven or probable IA randomised to voriconazole 
or conventional amphotericin B.  Patients treated with voriconazole had a 
significantly better response and survival rates (53% and 71% respectively) 
than the amphotericin B arm (32% and 58% respectively).47 However, about a 
third of the enrolled patients in this study had no microbiological confirmation of 
IA (therefore possible IA).257 Voriconazole is also considered the drug of 
choice for cerebral aspergillosis.258  Particular clinical scenarios however, 
favour the use of non-azole-based therapy:  
 prior exposure to mould active azoles  
 drug interactions and contraindications  
 moderate/severe hepatic and renal impairment  
 presence of mixed fungal infections including zygomycetes as it has no 
activity against this group (mucorales).238 
 
The AmBiLoad trial compared 3mg/Kg/d to 10mg/Kg/d for 14 days followed by 
3mg/kg/d in a double-blind trial involving 201 cases where the primary 
outcome was complete or partial response at the end of the study. The 
response rates were similar between the two arms (50% v 46%) although the 
higher dose was more toxic and was associated with a trend to higher mortality 
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rate.249 However, in this trial about 60% of the subjects were enrolled on the 
basis of suggestive radiological signs with no supporting mycological 
confirmation (possible disease).257  As a result, there remains uncertainly 
about the comparability of this study to the voriconazole trial even though the 
reported response rates were similar.47 Consequently, liposomal amphotericn 
B is considered an alternative drug of choice for first line therapy for IA.4,241 
Where there is mycological confirmation of A. terreus or where clinical 
suspicion is high, mould-active azoles should be used, as this organism is 
resistant to amphotericin B.259  
 
There is a paucity of data on the use of echinocandins as primary therapy of 
IA. Two prospective non-comparative phase II studies exist. Caspofungin was 
evaluated as first-line monotherapy of IA in 61 proven/probable patients with 
haematological malignancies, undergoing autologous transplantation. The rate 
of complete/partial response was 33% and 12 week-survival rate was 53%.260  
Another study enrolled 24 proven/probable allogeneic HSCT patients and the 
12 week response and survival rates were 33% and 50% respectively.261 
These studies are not directly comparable to previous studies as all patients in 
these caspofungin studies had mycologically documented disease and the 
majority had poor baseline characteristics (poor performance score, 
uncontrolled malignancy, and older age).  Nonetheless, caspofungin cannot be 
recommended as first line therapy but does provide an option for those unable 
to receive voriconazole or liposomal amphotericin B.11,238  Caspofungin is 
licensed for salvage therapy in patients with probable and proven IA refractory 
to or intolerant of other agents. 
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1.5.3 Salvage therapy 
Information on the number or proportion of patients failing first line therapy is 
scarce. Where possible tissue diagnosis should be obtained and drug levels 
monitored in such cases. Therapeutic options include switching to a different 
class of drugs to that used in the first line; liposomal amphotericin B, 
itraconazole, posaconazole and caspofungin are all approved for salvage 
therapy.4  Overall, up to 50% of those who failed first-line therapy can be 
salvaged.238  Because of their novel properties there is substantial interest in 
combining echinocandins with either triazoles or polyenes to exploit inhibition 
of both cell wall and cell membrane properties.32 Despite little supporting 
evidence, multiple antifungal regimens are increasingly used with augmented 
toxicity and substantially increased healthcare costs.262-264  A multi-centre 
randomised controlled trial is underway comparing voriconazole plus placebo 




There is good evidence that delayed diagnosis of IA is associated with poorer 
outcome.265,266  Very early therapy, when mould burden remains low and 
tissue necrosis minimal, offers the best chance of controlling infection. 
Although antifungals may prevent further loss of tissue and dissemination from 
the extending margins of an IA lesion, few antimicrobials penetrate into 
ischemic or necrotic tissue in adequate concentrations to exhibit an effect. IA 
usually presents as invasive pulmonary aspergillosis but infection may 
disseminate to brain, meninges, spleen, liver, skin and other sites. Aspergilli 
invade and block blood vessels producing infarction and extensive 
haemorrhagic necrosis. Neutrophils are the major defence and IA progresses 
particularly rapidly in neutropenic patients and those receiving 
corticosteroids.267  Despite what may evolve to be a dramatic necrotizing 
pneumonia with dissemination, aspergilli are rarely isolated from clinical 
material pre-mortem: blood cultures are almost invariably negative and sputum 
culture has poor sensitivity and specificity.265  The diagnostic yield of 
bronchoalveolar lavage in IPA is usually less than 25-30%. Culture is also 
slow. This, linked with a non-specific early presentation (typically pyrexia 
despite broad-spectrum antibacterials), delays diagnosis. A definitive diagnosis 
may be made by demonstrating invasion on histology, but this may be 
challenging in thrombocytopenic patients. In many centres a diagnosis of IA is 
usually inferred from characteristic changes on high definition CT scans. 
However, substantial tissue damage must have already occurred by the stage 
at which characteristic signs appear.265,267   Antibody tests are of no value in 
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the diagnosis of IA as the at-risk patient population is usually incapable of 
mounting responses.265 However, serological tests based on the detection of 
Aspergillus products are available and have been evaluated.267 
  
The Invasive Fungal Infection Cooperative Group of the European 
Organisation for Research in Treatment of Cancer (EORTC) and the Mycology 
Study Group (MSG) of the National Institute of Allergy and Infectious Diseases 
formed a Consensus Committee in 1998 to develop standardised definitions 
for invasive fungal infections for clinical research.  They proposed a consensus 
diagnostic criteria stratified into proven, probable, and possible invasive fungal 
infection based on clinical, host, and microbiological factors in 2002.9  These 
have since been revised but the basic classification into the 3 levels of 
certainty remains unchanged (Appendix).10  
 
The revised EORTC/MSG definition of proven aspergillosis requires 
histopathological proof and/or positive culture of a specimen from a normally 
sterile site. This is seldom possible in clinical practice as many of the patients 
who go on to have biopsy might have been on empirical treatment with 
antifungals for a few days before the biopsy. However, these would still be 
proven mould infections, if there is histological proof. The diagnosis of 
probable IA requires the presence of all 3 criteria: host factors 
(immunosuppressive state), clinical factors (radiological signs) and mycological 
evidence. The mycological evidence can either be direct; where there is 
cytological or culture evidence from sputum, broncho-alveolar lavage (BAL), 
bronchial brush, sinus aspirate samples, or it may be indirect; detection of 
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fungal antigen or cell wall constituents. Only galactomannan on serum, 
plasma, CSF and BAL and β-D-Glucan detected in serum are accepted as 
such evidence.  Possible IA is defined by the presence of host and clinical 
factors but no mycological evidence.  In practice proven and probable cases 
are combined into one category to define ‘invasive aspergillosis’.4  In the 
current revised definition patients with the appropriate host factors and 
mycological evidence who lack the clinical factor such as CT evidence of 
dense, well-defined lesions with or without a ‘halo’ sign, air crescent sign or 
cavity are not classified. In the old definition this was defined as possible IA.  
 
 
1.6.1 Computed Tomography (CT)  
The typical imaging signs of invasive pulmonary aspergillosis (IPA) have been 
established in studies which compared the relationship between 
histopathological features and corresponding appearances on CT.268-270   On 
macroscopic histological sections, there are foci of necrotising pneumonia with 
zones of haemorrhage and acute and granulomatous inflammation (Figure 
3).271 This corresponds radiologically, on axial CT scanning, to a focus of 
consolidation surrounded by a zone (the so-called ‘halo’) of ground-glass 
opacification (Figure 5).149,272  The halo sign is the first distinctive radiological 
feature of IPA. In previous studies, it has been suggested that the halo sign is 
specific for IPA.149  However, biopsy series have shown that a diagnosis other 
than IPA is made in around 50-60% of patients even when there is a high 
clinical and/or radiological pre-test probability of pulmonary aspergillus 
infection.268,270,273  Moreover, it is also clear that the halo sign is not sensitive 
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and, because the CT findings reflect the end-result of small vessel invasion 
and infarction, it seems likely that the halo sign occurs relatively late in the 
course of IPA.  
 
Figure 5: CT “halo” sign of angioinvasive aspergillosis in a neutropaenic patient. Axial image through the upper 
zones in a patient with MDS transformed to AML. CT through the upper zones demonstrates multiple rounded 
nodules; the dominant right upper nodule and the lesion in the left upper lobe (arrows) both have surrounding 
halo of ground-glass opacification.  
 
 
Whilst the typical CT findings have been established there remains uncertainty 
about the spectrum of CT findings in patients with IPA.  The problem is that 
biopsy confirmation is seldom available. Thus, the range and prevalence of CT 
features, other than the classical (i.e. foci of consolidation with halos of ground-
glass opacification) is unknown. Factors that might also influence the CT 
appearance of IPA (for instance, the use of concurrent/prophylactic antifungal 
chemotherapy, the severity of neutropenia, the underlying disease, etc) are 
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also unknown. During the first week following diagnosis, there is a tendency for 
the number and size of focal lesions to increase, irrespective of 
treatment.274,275  Greene et al found that the presence of a halo sign was 
associated not only with an improved response to antifungal drugs but also 
with improved survival at 12 weeks.149  
 
The second CT feature of IPA is the air crescent sign which, is a semilunar 
cavitatory lesion within a macronodule (Figure 6).276 This generally coincides 
with neutrophil recovery.149 There is an inverse relationship between the halo 
sign and the air crescent sign in the pattern of appearance from diagnosis.274  
Overt cavitation occurs later in the course of infection but its presence is less 
specific than either the halo or the air crescent signs.149 The EORTC/MSG 
recognizes well-circumscribed lesion(s) with or without a halo sign, air crescent 
sign and cavity as evidence compatible with IPA.10 
 
Another aspect of the CT diagnosis, which potentially warrants investigation, is 
the pattern of contrast enhancement.  The background to this is the knowledge 
that vascular lesions (specifically, malignant lung nodules) demonstrate greater 
enhancement following the injection of intravenous contrast.277 There is paucity 
of data among haemato-oncology patients and in particular how IPA may 
behave in such patients.  We hypothesise that, because foci of IPA represent 
regions of infarcted lung, the absence of enhancement following the injection 
of intravenous contrast might identify areas of IPA and that this might also be 
of value in the differentiation from other inflammatory or infective pathologies in 
which contrast enhancement would be the expected finding.  
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Figure 6: Air crescents and cavitation in angioinvasive aspergillosis.  
 
 
1.6.2 Tissue diagnosis-biopsy  
Imaging appearances of the chest or any other suspected area of IA are non-
specific.268,270,273 However, the potential difficulties associated with surgical 
biopsy in patients with poor performance status, co-morbidities and, not 
infrequently, impaired clotting remains a real challenge. As such there is a 
paucity of data in the literature about the diagnostic utility of biopsy in 
haemato-oncology clinical practice. The limited published data in this area are 
small retrospective studies.268,273,278,279  They suggest that the biopsy is safe 
and useful but the small size of these studies, often spanning many years, 
indicates that this diagnostic tool is underutilised in clinical practice and there 
may be significant selection bias.  The current techniques for obtaining tissue 
biopsy include bronchoalveolar lavage, transthoracic percutaneous needle 
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aspiration (often CT-guided), open biopsy, and video assisted thoracoscopic 
surgery (VATS). 
 
Less invasive techniques, such as VATS for surgical sampling of small 
intrapulmonary nodules hold promise but the issue of a false-negative biopsy 
results for nodules which are impalpable and/or not readily visible remains a 
crucial issue.280  Methods for assisting the pre-operative localisation of small 
lung nodules, including the image-guided placement of a hook-wire 281,282 or 
platinum microcoils 283 have been tested.  The easiest and safest appears to 
be the methylene blue technique of pre-operatively injecting methylene blue 
dye into the area under CT-guidance, which acts as a guide to the surgeon 
(surgical track) using a thin calibre needle. Data on the value of methylene 
blue ‘tattooing’ of small intrapulmonary nodules prior to the thoracoscopic 
resection are convincing and possibly presents a safe and accurate technique 
for localisation of pulmonary nodules.284-286  However, their utility in diagnosis 
of IPA in haemato-oncology patients is unknown. 
 
The typical histopathological features have been described and can be divided 
into two patterns.77,147  The first pattern, usually seen in neutropenic patients, 
consists of a discrete nodule with central and peripheral zones (Figure 3). The 
central zone is the area of coagulative necrosis, invading hyphae, and vascular 
thrombosis surrounded by peripheral zone of haemorrhage. There is notable 
absence of inflammatory infiltration.  The discrete nodule forms the basis of the 
halo sign. As patients begin to recover their neutrophils or in those with GVHD 
a different pattern emerges. This second pattern is described as fused lobular 
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consolidation, a broncho-pneumonic picture characterised by acute 
inflammatory exudates. It is thought that with neutrophil recovery the discrete 
nodule undergoes liquefaction necrosis leading to cavitation at the periphery of 
the persisting central zone of coagulative necrosis. This forms the basis of the 




The Aspergillus cell wall is complex meshwork of cross-linked polymers, 
mainly β glucans, chitin and galactomannan, which forms an interface between 
the fungus and its environment.106 Galactomannan (GM) is a polysaccharide 
component of mannoproteins in the outer cell wall.  GM belongs to a family of 
molecules called galactofurannose (Gal-f) antigens.287  These antigens contain 
galactofuranose residues that react with the rat IgM monoclonal antibody (EB-
A2) used in the enzyme immunoassay (EIA). The EB-A2 is directed against 
tetra (1→5)-β-D-galactofuranoside to both capture and detect Gal-f and has 
been applied widely for the diagnosis of IA in immunocompromised 
patients.288-291  The Gal-f residue is also present in fungal glycoproteins 
including phospholipase C and phytase.287,292  How these antigens are 
released by Aspergillus during infection and in what form they circulate in 
blood remains unclear.   
 
The approved indication for the test is in monitoring Aspergillus spp 
antigenaemia in high risk haemato-oncology patients. The results are 
expressed as an index relative to the mean optical (OD) density of the 
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threshold controls- ‘galactomannan index’ (GMI) (GMI= OD of sample/mean 
OD of the threshold control samples).289,291  The test was first commercially 
available in Europe in the mid-1990s when a GMI cut-off of ≥1.5 was 
considered positive and <1.0 as negative and indices of 1.0-1.5 as 
indeterminate.  However, in the United States a cut-off of 0.5 was considered 
positive as this was the accepted value by US Food and Drug Administration 
when the test was approved for diagnostic purposes in 2003.291,293  As a result 
different centres have adopted different GMI cut-offs to maximise sensitivity in 
their populations and undoubtedly this may account for some of the variation in 
the test performances.290,291,294,295   Different studies have validated the cut-off 
of 0.5 and this has been shown to have a better performance among high risk 
haematology patients and is currently the internationally accepted 
standard.267,290,291,296  
 
The performance of serum GM as a screening tool for high risk patients has 
been assessed in several studies which have demonstrated a specificity of 
greater than 85% consistently but varying sensitivities of between 29-100%.294  
In a meta-analysis by Pfeiffer et al on 27 studies from 1966 to 2005, the mean 
GM sensitivity was 71% (95% CI: 68-74%) and specificity was 89% (95% CI: 
88-90%) for proven cases but there was a significant heterogeneity among 
different patient groups.295  To increase the accuracy of the test it is suggested 
that it should be done twice weekly and that positive results should be 
retested.289  The sensitivity of the test is reduced in patients on mould-active 
primary prophylaxis due to reduced antigenaemia. Marr et al report a 
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sensitivity of 52% in patients receiving mould active antifungal prophylaxis 
compared 89% in those with no mould active agents.297  
 
One of the biggest draw backs of the test is false positivity. This is in part due 
to shared epitopes found on various products including foodstuffs, bacterial 
lipoglycans (eg Bifidobacterium spp.) and other fungi such as Penicillium spp. 
Table 10 lists the causes of false positive results. Piperacillin-tazobactam 
(Tazocin) and amoxicillin-clavulate or other β-lactam producing antibacterials 
are fermentation products of Penicillium spp and contamination with cell wall 
components of the Penicillium spp during production is the greatest problem in 
clinical practice and false positive results may occur up to 5 days after stopping 
antibiotic treatment.298 Intravenous fluids containing gluconate, such as 
Plasmalyte, have also been found to cause false positive results as gluconate 
is also produced by fermentation in mould cultures.299,300   
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Table 10: Causes of false-positive galactomannan test (modified from 289) 
 
False positivity caused by GM 
contamination 
Cross-reactivity caused by similar cell 
wall GM 
Antibiotics 
   Piperacillin-tazobactam (Tazocin) 
   Β-Lactam antibiotics eg amoxicillin- 
clavulanate 
Penicillum spp. including 
P. marneffei 
Plasmalyte (sodium gluconate) or any 
other intravenous fluid/nutrition containing 
sodium gluconate 
Histoplasma capsulatum 




Possibly Paecilomyces, Alternaria, 




Although the Platelia Aspergillus test is standardised for serum, testing for the 
presence of GM using other body fluids such as bronchoalvelolar lavage (BAL) 
and cerebro-spinal fluid (CSF) is very promising. GM detection in BAL appears 
to be more sensitive than serum in patients with IPA 289,301-303  and is accepted 
EORTC/MSG criteria for the diagnosis of probable IA 10. Similarly GM on CSF 
samples from patients with CNS aspergillosis may be useful and may result in 
earlier diagnosis.304-306  However, the use of GM testing on CSF is at best 
investigational and has not been validated in any large scale study. Urine has 
been studied, mainly in small retrospective or case studies, using 
heterogenous methods for the detection of the galactomananan antigen.307   
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1.6.4 β-D-Glucan  
β-1,3-D-Glucan (BG) constitutes a major carbohydrate fraction of cell wall 
(60%).  It is present in most fungi with the notable exception of Cryptococcus 
neoformans  and Zygomycetes 308 as well as some bacteria and plants.309 BG 
detection, therefore, represents a ‘pan-fungal’ diagnostic test.266,267,310 The BG 
testing is based on the ability of (13)-β-D-Glucan to activate the Limulus 
(amoebocyte of  the horseshoe crab) coagulation pathway.266 This Limulus 
reaction was first used to detect endotoxin which works via factor C, a protein 
serine zymogene (Figure 7). 
 
The Fungitell test (Associates of Cape Cod, Falmouth, MA), developed using 
amoebocyte lysate fractions of the American horseshoe crab, and was 
licensed by the FDA in 2004 following clinical validation by Odabasi et al.310  
There is limited experience of performance of BG testing in IA patients but 
there is a suggestion that it may be as good as or even better than GM in 
some cases.311,312  It is of course important to note that BG is not specific for IA 
and that candida and non-aspergillus mould infections, with the exception of 
zygomycosis and and cryptococcus may give positive results.309  In addition 
false positive results may be caused by surgical gauze, intravenous 
immunoglobulin or albumin preparations, cellulose membranes in 
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Figure 7: Mechanism of detection of (13)-β-D-Glucan by the use of horseshoe crab 
lysate. The enzymatic actions of endotoxin (in the box) are neutralised during the 
testing 
 
1.6.5 Lateral Flow Device (LFD) 
There is considerable interest in the search for newer, simpler and more 
reliable tests which can be used in clinical practice to accurately diagnose IA. 
The LFD is the latest attempt to fulfil these aspirations.  It is based on an 
immunochromatographic device (similar to the home pregnancy test kit in 
design) incorporating a mouse IgG monoclonal antibody, JF5 which binds to 
an extracellular glycoprotein epitope constitutively secreted by growing 
Aspergillus spp hyphal tips.313  The device has a release pad containing JF5 
conjugated to colloidal gold particles which serves as the detection agent, a 
Endotoxins 
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porous nitrocellulose membrane, and a test line consisting of a JF5 line and a 
control line (commercial rabbit anti-mouse Ig). Serum samples are added to 
the release pad and which pass along the porous membrane by capillary 
action and then binds the JF5 antibody if the antigen is present.  The bound 
antigen-antibody-gold complex appears as a red line and its intensity is 
proportional to the antigen concentration. The results are available in 10-15 
minutes.  Wiederhold et al have tested the performance of the LFD against GM 
and BG in a guinea pig IPA model and found the device positive earlier than 
GM or BG.314  However, there is limited experience on clinical samples. 
Further validation using clinical samples with associated clinical information 




Diagnosing IA by PCR in which Aspergillus-specific fungal genes, is likely to 
emerge as the most practical, sensitive and useful diagnostic approach.266,315-
319  Automated extraction methods are required to reduce contamination and 
make testing protocols feasible for routine diagnostic laboratories. Amplicon 
detection methods also vary; real-time detection maintains a low risk of 
contamination and reduces detection time. Various testing schedules, using 
different specimen types with single species and/or ‘pan-fungal’ PCRs, have 
been evaluated. These tests may be rapid (particularly with automated 
extraction), sensitive (capable of detecting 1-10fg/mL of DNA) and can be 
applied to various sample types. However, the lack of standardization makes 
PCR currently investigational.4,32  In particular, there is lack of consensus on 
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the optimum specimen type (ie whole blood versus plasma or serum) which 
impacts on the method for DNA extraction, as well as the sampling schedule 
(timing and frequency of sampling).  As such PCR has not yet been accepted 
as a diagnostic tool by the current EORTC/MSG.10.  
 
In an attempt to address the lack of standardised approach, a consensus 
protocol has been proposed comparing 2 primer sets (28S and 18S) on 3 
platforms on a panel of 8 negative and 8 spiked samples.320. It was found that 
the 2Asp primers (targeting 28S gene) had higher sensitivity, specificity, and 
positive predictive value than the 4Asp (targeting 18S gene) irrespective of the 
platform. This initial effort has provided the stimulus for greater international 
collaboration to develop a consensus protocol. 
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1.7 Study objectives 
1. To document the true ‘real world’ incidence and outcome of IFD in 
patients undergoing HSCT,  high dose chemotherapy, or 
immunosuppressive therapy with expected neutropenic period of 10 
days or more using all approved EORTC/MSG diagnostic tools;  
2. To establish clinical utility of current diagnostic tests; 
3. To assess the role of cytokines in the diagnosis and prognosis of IA; 
4. To establish the prevalence, spectrum, natural history and prognostic 
value of CT appearances in patients with invasive pulmonary 
aspergillosis; 











Chapter 2 Methods 
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2 Methods 
2.1 Study design 
This was a single centre prospective cohort study designed to evaluate the 
incidence and risk factors of IA in adult haemato-oncology patients undergoing 
HSCT or chemotherapy likely to render them neutropenic for 10 days or more. 
Figure 8 shows the schema of the study design.  
 
Figure 8: Study outline (not to scale).  Each study patient had baseline CT, sera and 
urine taken for GM (±BDG). Broncho-alveolar lavage (BAL) was offered to transplant 
patients only. Mycology surveillance tests was done twice weekly during study period 
while receiving one or more cycles of treatment (allogeneic or autologous 
transplantation, chemotherapy or immunosuppressive therapy) until full 
haematological recovery. Antibiotic (Abx)-resistant fever was investigated with 
diagnostic (Dx scan) and follow-up (FU) 1 and 2 10-14 days and 28 days respectively 
after abnormal Dx scan.  
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All transplant patients were followed up for at least four months from transplant 
if they had no post-transplant complications such as GVHD.  However, in the 
event of such complications they were followed up until this was completely 
resolved or they died or until the end of the study period. Similarly 
chemotherapy patients were followed up for at least four months after their last 
course of chemotherapy in the absence of any complications. Chemotherapy 
patients who then went onto transplant were followed up as per the transplant 
patients.  In the event of death, the cause of death was ascertained in the light 




2.2 Study procedures 
After admission into the study each patient had: 
 Clinical assessment (history, examination, weight, height, Karnofsky 
score) at admission and further evaluation (fever, presence of GVHD, 
respiratory symptoms) three times weekly during inpatient admission 
and during outpatient visits.  A full drug history was also taken, in 
particular antifungal drugs used: duration and reason for starting and 
stopping. 
 Blood tests (FBC, U&Es, liver function tests [LFT], Mg, CRP) at 
admission and three times a week during admission and outpatient 
visits. 
 Cytokine profile at baseline and fortnightly during inpatient admission. 
 94 
 Mycology (galactomannan, β-D-Glucan, PCR, lateral flow device [LFD]) 
at admission and twice weekly during inpatient admission and clinic 
visits.  
 Virology (allogeneic transplant patients only): CMV, EBV and 
adenovirus at admission and twice weekly during first three months and 
once a week thereafter. 
 Thoracic CT scanning 
All patients had a baseline non-contrast enhanced, low-dose scan. In 
addition, further scans were done: 
1. ‘Diagnostic’: contrast-enhanced thin section scans for patients who 
developed neutropenic sepsis unresponsive to second-line antibiotics 
(meropenem and vancomycin) for ≥48h with no positive microbiological 
cultures 
2. ‘Follow-up’: low dose non-contrast scans (x2) at two and four weeks 
post ‘diagnostic’ scan if the diagnostic scan had any abnormalities. This 
was to assess response to antifungal therapy. 
 Bronchoscopy 
This was optional for transplant patients (both allogeneic and 
autologous) before the initiation of the conditioning chemotherapy. The 
samples collected were sent for routine bacteriology, virology, and 
biochemistry tests as well as galactomannan, β-D-glucan, and PCR. 
Additional samples were sent for cytokine profiling (luminex).    
 Triazole trough levels weekly. The first levels were taken after at least a 
week of initiation of the azole. 
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 CXR weekly as part of routine clinical care 
 Lung biopsy.  Wherever possible neutropenic patients with sepsis and 
lung lesions had biopsies by video assisted thoracoscopic surgery 
(VATS) or open biopsy. Coagulation abnormalities were corrected 





Two hundred and three patients were recruited from King’s College Hospital 
into the study between December 2008 and May 2010. The inclusion criteria 
were: 
1. All adult (18 years and over) haemato-oncology patients admitted for 
transplant or chemotherapy likely to render them neutropenic 
(<0.5x109/L) for 10 days or more during treatment and  
2. Able to give informed consent.  
This includes the following patient groups: 
 Allogeneic HSCT 
 Autologous HSCT 
 MDS 
 AML 
 Aplastic anaemia 
 Salvage lymphoma chemotherapy such as CAIP, Hyper CVAD 
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The exclusion criteria were: 
1. Children under the age of 18y 
2. Refusal or inability to give informed consent 
 
The patient characteristics are shown in Table 11. Primary treatment refers to 







Table 11: Patient characteristics 
N= 203 characteristics 
Age (median, range) years 54 (19-73) 
M/F 123/80 
Undergoing diagnosis N (%) 
   AML 
   MDS 
   MDS/MPD 
   MPD 
   Aplastic anaemia 
   CML 
   ALL 
   NHL 
   Hodgkin lymphoma 
   Multiple myeloma 













Primary treatment N (%) 
   Allograft 
   Autograft 
   Chemotherapy alone 






Median follow-up (range) days 19 (12-834) 
*Others include CLL (1), plasma cell leukaemia (1), Blastic plasmacytoid dendritic cell 




All patients received antifungal prophylaxis according to the existing King’s 
protocol (Table 12).  The high risk group included patients undergoing 
allogeneic HSCT, AML induction/consolidation, salvage lymphoma 
chemotherapy, Alemtuzumab, purine analogues, and high dose steroids 
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therapy. Autologous HSCT and outpatient chemotherapy unlikely to cause 
prolonged neutropenia were considered low risk in this protocol. The study was 
approved by the King’s ethics committee and conducted in accordance with 
the Helsinki protocol (2008 revision). It was registered with the 
ClinicalTrials.gov (NCT00816088).  
 
Table 12: KCH Adult Haemato-Oncology Antifungal Guidelines 2007 
A. Prophylaxis 
 Primary  Secondary   
Low risk Fluconazole 200mg od po Voriconazole 200mg bd 
Posaconazole 200mg tds 
Ambisome 2mg/kg M/W/F 
Caspofungin 70→50mg od 
High risk Itraconazole suspension 200mg bd  
If having vinca alkaloids: 
Ambisome  2mg/kg M/W/F 
Caspofungin 70→50mg od 
B. Therapy 
Empiric   Ambisome 1→3mg/kg od 
 Casopfungin 70→50mg od 
Proven/probable  Ambisome 3mg/kg od 
 Voriconazole  
 Caspofungin 70→50mg od 
Salvage  Caspofungin 70→50mg od 
 Posaconazole 
 Flucytosine 
Combination  Combined haematology and microbiology consultant decision 
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2.4 Diagnosis of IA  
The diagnosis of IA was based on the current EORTC/MSG criteria.10  On the 
basis of these criteria IA may be proven, probable or possible: 
1. Proven invasive aspergillosis 
Recovery of a mould by culture from a sample obtained by a sterile procedure 
from a normally sterile and clinically or radiologically abnormal site consistent 
with an infectious disease process, excluding BAL, cranial sinus cavity, and 
urine 
OR 
Histopathologic, cytopathologic, or direct microscopic examination of a needle 
aspiration or biopsy specimen showing hyphal forms with evidence of 
associated tissue damage.  However, in the absence of a positive culture, 
proven IA cannot be made and such cases would be called proven mould 
infection. 
2. Probable invasive aspergillosis 
This was defined by at least one host factor + one clinical criterion + one 
mycological criterion  
3. Possible invasive aspergillosis 





1. Recent history of neutropenia (<0.5 x 109/L for >10 days) temporally related 
to the onset of fungal disease or ongoing neutropenia 
2. Receipt of an allogeneic stem cell transplant 
3. Prolonged use of corticosteroids (excluding patients with ABPA) at an 
average minimum dose of 0.3 mg/kg/day prednisone equivalent for >3 weeks 
4. Treatment with other recognized T-cell immune suppressants such as 
ciclosporin, TNF-α blockers, specific monoclonal antibodies alemtuzumab, 
nucleoside analogues during the past 90 days 
5. Inherited severe immunodeficiency (eg, chronic granulomatous disease, 
severe combined immunodeficiency). 
All study patients fulfilled one or more of these criteria. 
Clinical criteria 
Must be consistent with the mycological findings, if any, temporally related to 
current episode and other potential causes must have been eliminated.  
Lower respiratory tract fungal disease 
The presence of one of the following 3 signs on CT: 
 Dense, well-circumscribed lesion(s) with or without a halo sign 





Tracheobronchial ulceration, nodule, pseudo-membrane, plaque or eschar 
seen on bronchoscopic analysis. 
 
Sinonasal infection 
Imaging showing sinusitis, plus at least one of the following: 
 Acute localized pain (including pain radiating to the eye); 
 Nasal ulcer with black eschar; 




At least one of the following: 
 Focal lesions on imaging; 
 Meningeal enhancement on MRI or CT. 
 
Mycological criteria 
This may be direct or indirect. 
1. Direct demonstration of mould in sputum, BAL, bronchial brush, or 
sinus aspirate samples by the presence of fungal elements or recovery 
by culture of a mould. 
2. Indirect serological evidence by detection of antigen or cell wall 
constituents such as galactomannan antigen EIA in plasma, serum, 
BAL, CSF or β-D-Glucan detected in serum.  
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Patients who did not satisfy the above categorisation into proven, probable or 
possible were classified into: 
1. No evidence- no radiological or any other clinical abnormality, 
and no mycological evidence 
2. mycological evidence but no clinical abnormality 
3. abnormal radiology other than EORTC definition + mycological 
evidence 
4. abnormal radiology other than EORTC definition without 
mycological evidence 
scenarios 2-4 were  considered ‘not classified’. 
 
2.5 Response to antifungal therapy 
The EORTC/MSG consensus criteria were used to assess response at two 
and four weeks after initiation of antifungal therapy (Table 13).321  
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Success   
    Complete   
response 
Survival and resolution of all attributable symptoms and signs of disease; plus 
  Resolution of radiological lesion(s); persistence of only a scar or postoperative changes 
can be equated with a complete radiological response; plus 
  Documented clearance of infected sites that are accessible to repeated sampling (e.g., 
mould disease involving the palate, sinuses, or cutaneous lesions) 
  Partial 
response 
Survival and improvement of attributable symptoms and signs of disease; plus 
  At least 25% reduction in diameter of radiological lesion (s); plus 
  Documented clearance of infected sites that are accessible to repeated sampling (e.g., 
mould disease involving the palate, sinuses, or cutaneous lesions) 
  In cases of radiological stabilization (defined as a 0%–25% reduction in the diameter of 
the lesion), resolution of all attributable symptoms and signs of fungal disease can be 
equated with a partial response 
  In cases of radiological stabilization, biopsy of an infected site (e.g., lung biopsy) 
showing no evidence of hyphae and negative culture results can be equated with a 
partial response 
Failure   
     Stable        
response 
Survival and minor or no improvement in attributable symptoms and signs of disease; 
plus 
  Radiological stabilization (defined as a 0%–25% reduction in the diameter of the 
lesion); or 
  Persistent isolation of mould or histological presence of invasive hyphae in infected 
sites 
  Progression 
of disease 
Worsening clinical symptoms or signs of disease; plus 
  New sites of disease or radiological worsening of preexisting lesions; or 
  Persistent isolation of mould species from infected sites 
  Death Death during the pre-specified period of evaluation regardless of attribution 
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2.6 Laboratory methods 
2.6.1 Galactomannan (Platelia™ Aspergillus EIA, Bio-Rad) 
This test was routinely available at King’s and was performed according to the 
manufacturer’s instructions.   Briefly, 300µL of serum was added to 100µL of 
4% EDTA treatment solution, heated at 100 ºC for 3 min, and centrifuged at 
10,000 g for 10 min.  Fifty microlitres of the supernatant was added to 50 µL of 
conjugate (anti-GM monoclonal antibody EB-A2 labelled with peroxidise), and 
added to microtiter plates precoated with the anti-GM monoclonal antibody EB-
A2. Plates were incubated for 90 min at 37 ºC, washed, and incubated with 
200 µl of tetramethylbenzidine solution for an additional 30 min in the dark. 
Reactions were stopped with 100 µl of 1.5 M sulphuric acid, and optical 
densities read at 450 and 620 nm. Samples were run with positive, negative, 
and threshold controls supplied by the manufacturer. The optical density index 
was calculated as the optical density of the sample divided by the mean optical 
density of 2 threshold controls. 
   
2.6.2 β-D-glucan (Fungitell® BG assay, Associates of Cape Cod)  
The test was carried out according to the manufacturer’s instructions. In brief, 
5 μl of serum was transferred to the designated microplate wells and 20 μl of 
pretreatment reagent (an equal mixture of 0.25 M KOH and 1.2 M KCl) added 
and incubated for 10 min at 37 ºC. One hundred microlitres of Fungitell® 
reagent (eliminates Protein C which can also activates this pathway) was 
added to all wells containing controls and sera and shaken for 10 seconds. 
The plate was inserted into a microplate reader and read at 405/490 nm for 40 
minutes at 37 ºC using Vmean kinetic analysis every 10 seconds (Gen5 2.0, 
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BioTek). Samples were run in duplicates and the concentration of BDG was 
calculated using calibration curves. 
 
Sample selection 
Not all samples were processed due to cost and time considerations.  A 
selection of samples was taken to include (1) GM positive cases (n=131), (2) 
those with accepted CT signs but negative GM, i.e., possible IFD (n=41) (3) 
and negative controls (n=81) which were selected randomly from cases that 
had no evidence of IFD.    
 
2.6.3 Lateral Flow Device (LFD) 
The initial testing was based on the original work of Thornton 313 who supplied 
the LFD kits as part of our collaborative effort. The LFD did not contribute to 
the final EORTC status of study patients. A total of 988 serum samples from 52 
patients were tested which included all proven and probable cases as well as 
some controls (no evidence of IFD). Fifty microlitres of serum samples were 
mixed with 50 μl buffer (tissue culture medium with 10% sodium azide) and the 
mixture applied to the LFD devices and results were recorded as negative, 
weakly positive, or strongly positive depending the strength of the reaction on 
the test line. A further modification was later adopted in an attempt to increase 
the contrast between the background and reaction line. In that modification 50 
µl of serum was added to 100µl of PBS containing 4% (w/v) sodium EDTA and 
heated in a boiling water bath for three minutes and centrifuged for 5 minutes 
at 10,000 g. After this, 100 µl of the supernatant was added to the LFD and 
results recorded as above. 
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Sample selection 
Sequential serum samples from recruitment to end of study period were 
collected from 29 proven/probable IFD, 6 possible IFD, and 21 not classified 
patients.  All proven moulds were included except the cardiac case (case 7, 
Section 3.3) as no sera were available at the time of diagnosis. 
 
  
2.6.4 PCR (Consensus) 
The protocol was based on the work of White et al using bead beating 
extraction method on whole blood sample.320 The Asp 2 primers targeting the 
28S ribosomal DNA of Aspergillus spp and probes on the Rotorgene 6000 was 
used. The PCR results did not contribute the EORTC score. 
Sample selection 
Sequential whole blood (in EDTA) samples were tested from 52 patients with 
proven/probable IFD (16), possible IFD (4), not classified (24), and no 
evidence (8). Serum samples were tested from 16 patients with 
proven/probable IFD (10), not classified (3), and no evidence (3). Of these 16 
patients 13 also had blood PCR.  
 
2.6.5 Cytokine profiling (Luminex 30-plex panel, Invitrogen®)  
This was done at baseline and every two weeks during inpatient stay for all 
study patients.  The multiplex bead solid phase sandwich immunoassay 
method was used to measure 30 cytokines, chemokines and growth factors on 
the Luminex® 100TM machine on a 96 well plate capable of analyzing 80 
samples in each run. The 30-Plex assay included: G-CSF, GM-CSF, HGF, 
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INF-α, IFN-gamma ,IL-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, 
IL-12p40/p70, 1L-13, IL-15, ,IL-17, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, 
RANTES, TNF-α and VEGF. The assay standards were prepared according to 
the manufacturer’s instructions by combining 3 different premixed sets of 
protein standards reconstituted in 0.33 ml assay diluent. The standard curve 
was made by serially diluting reconstituted standards in 300 μL assay diluent 
to make 1:3, 1:9, 1:27, 1:81, 1:243, 1:729 dilutions and a blank.  After pre 
wetting the plate and drying using the vacuum manifold, 25 μL of the 30-Plex 
beads of defined spectral properties, conjugated to analyte specific antibodies, 
were added to the wells. The beads were soaked in 0.2 ml Working Solution 
for 15-30 seconds and then washed twice. Fifty microlitres of incubation buffer 
was added into each well. To the wells designated for the standard curve, 
100μL of the appropriate standard dilution was added. For the other wells 
designated for the samples, 50μL of Assay Diluent + 50 μL of sample were 
added and these were incubated for 2h at room temperature on an orbital 
shaker. During this incubation, analytes bind to the captured antibodies on the 
beads. 
 
The Biotinylated Detector antibody (100μl) was added to all the wells and 
incubated for one hour at room temperature to allow the antibodies to 
recognize their epitopes and bind to the appropriate immobilized analytes. The 
excess biotinylated detector antibodies were removed and streptavidin 
conjugated to the fluorescent protein (Streptavidin-RPE) added and incubated 
for 30 minutes. During this incubation the streptavidin-RPE binds to the 
bionylated detector antibodies associated with the immune complexes on the 
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beads to form a four-part solid phase sandwich.  After washing to remove the 
excess Streptavidin-RPE, the beads were analysed based on their spectral 
properties and the amount of associated fluorescence. 
 
2.6.6 Genetic polymorphisms 
Nine previously identified single-nucleotide polymorphisms (SNP) in TLR1 
(rs5743611, 239CG, T80R), TLR2 (rs5743708, AG, Q753R), TLR3 
(rs3775291, 234CT, L412F), TLR4.1 (rs4986791, 1363CT, T399I), TLR4.2 
(rs4986790, 1063AG, D299G), TLR6 (rs5743810, 745CT, P249S), 
CLEC7A [dectin-1]  (rs16910526, AC, Tyr238X), CARD9 (rs4077515, 
49499CT, N12S) , and INF-γ (rs2069705, GA, U/N) were analysed on 
samples from 189 patients (83 allogeneic HSCT recipients, 62 allogeneic 
donors, and 44 autologous HSCT recipients).   Genotyping was carried out as 
described previously.62,63,66,122,322-324 
 
2.7 Radiology methods 
All scans were performed with multi-slice, thin-section, continuous volume 
acquisition technique and reconstructed with 5 mm slice thickness using high-
spatial-frequency reconstruction computer algorithm. All scans were performed 
on the same scanner (Siemens Somatom Sensation 16).   At recruitment into 
the study, all patients were required to have non−contrast enhanced thoracic 
CT study unless a previous scan was performed within two weeks for clinical 
reasons.  Where a diagnostic scan was required due to failure to respond to 
second-line antibiotics, an initial low dose scan was performed (similar to 
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baseline scan) and if a focal lesion was found this was followed by contrast 
studies involving the affected area of the lungs. Patients with allergy to 
iodinated contrast or creatinine > 150µmmol/L were excluded. Intravenous 
iodinated contrast (70 ml Omnipaque™ at the rate of 4 ml/sec) was 
administered. One minute after the injection of contrast, the affected area of 
the lungs was scanned at 1 min, 2 min, 3 min, 5 min, and 10 min.  The degree 
of contrast-enhancement was measured in Hounsfield units (HU).  Three 
overlapping circular rings were placed on the nodule of interest and the HU 
recorded for each from pre-contrast and serially from 1 min to 10 min post 
contrast. The averages of these means were recorded. In addition, similar 
measurements were obtained from normal lungs for each phase of 
enhancement.  The degree of contrast enhancement was calculated by 




All the scans were reported by radiologists as part of the clinical services.  In 
addition, abnormal baseline scans and all diagnostic and follow-up scans were 
reported and scored in a semi quantitative manner by study radiologists. Two 
consultant chest radiologists with more than 10 years’ experience reviewed 
and scored the scans independently and where discrepancies existed, the final 
decisions were made by consensus. Two semi quantitative scoring systems 
were used for baseline/diagnostic scans and follow up scans. 
 
Diagnostic scans   
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Each lobe was scored for EORTC accepted clinical signs (nodules, mass, halo 
and cavity) as well as non-EORTC signs (ground glass opacity, micronodule, 
bronchiectasis, bronchial wall thickening, and tree-in-bud) using the current 
Fleischner Society definitions.325 Table 14 shows the layout of the proforma 
used for scoring. Each scan was independently scored by each radiologist and 
the average scores were compiled as the final score. If a particular score was 
more than 50% discordant, then the two radiologists agreed on a consensus 
score.  
 


























RUL            
LUL            
RML            
Lingul
a 
           
RLL            
LLL            
Nodules or mass: 0= none, 1= ≤ 3, 2= ≥ 3; halo or cavity: 0= absent, 1= present; 
GGO (ground glass opacification): % of the lungs affected, consolidation: % of lungs 
affected; micronodule: % of the lungs affected; BxExt (bronchiectasis extent): 0= 
none, 1= 1 broncho-pulmonary (BP) segment, 2= > 1 BP segment, 3= generalized; 
BxSev (bronchiectasis severity): 0= none, 0.5= trivial, 1= 100-200 % of pulmonary 
artery (PA); BxWT (bronchial wall thickening): 0= none, 0.5= trivial, 1< 50% PA, 2= 




A similar approach was used in scoring the follow-up scans at about two 
weeks (follow-up 1), four weeks (follow-up 2), or longer (follow-up other). The 
scores were based on the EORTC/MSG response criteria.321 Four possible 
outcomes were recorded: complete response (CR) [complete radiological 
resolution]; partial response (PR) [≥25% reduction in diameter of lesion(s); 
stable (0-25% reduction in diameter of lesion(s); progression (new lesions or 
worsening of pre-existing lesion(s). Each follow scan was scored individually 
by the two radiologists and the mean or consensus score (if the difference 
between the individual scores was >50%) was reached. 
 
2.8 Biopsy 
Lung biopsies were performed using the video-assisted thoracoscopic surgery 
(VATS) technique where possible. Open lung biopsy was reserved for cases 
where VATS was technically difficult or inappropriate. To increase the 
diagnostic accuracy of the biopsy, especially if the lesion was small, the 
procedure was preceded by CT-guided methylene blue ‘tattooing’ of the lesion 
as previously described.284 The decision to use methylene blue was a joint 
decision between the cardiothoracic surgeon, radiologist and haematologist. 
Briefly, the patients were placed on the CT table in a position that allowed the 
shortest access to the lesion and the target nodule was identified by 
preliminary scans.  Lignocaine (1%) was used for local anaesthesia. Using 
20G needles, 0.8-2.0 ml of sterile 1 % methylene blue dye (Martindale, UK) 
with equal volume of iodinated contrast was injected into the vicinity of the 
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target lesion and along the track as the needle was removed, including the 
visceral pleural surface and the overlying chest wall. The diameter of targeted 
nodules, perpendicular distance from the pleural surface and complications of 
the procedure were recorded. The patients were then transferred to the 
operating theatre and the illustrative CT scans were provided for the surgeon. 
The VATS procedure was performed under general anaesthetic. The surgeon 
visualized the track as well as the methylene blue on the pleural surface.  A 
wedge resection was performed and the specimens were sent for histology, 
microbiology and a separate fresh frozen sample for research (stored in the 
tissue bank at -80 ºC). 
 
Between March 2009 and February 2011 65 potential biopsies were identified, 
39 were performed and 38 were evaluable in 32 patients (one biopsy n=27; 
two biopsies n=4; three biopsies n=1) (Figure 9). There were 26 cases that 
were unfit for surgery due to poor clinical state of the patients (n=13), 
interference with chemotherapy/transplant schedule (9), and lack of 
theatre/surgical time (n=4). Slides were unavailable for review in one patient.  
 
The majority of evaluable biopsies (82%) were performed using VATS 
procedure under general anaesthesia.280  A wedge resection was performed 
and the specimens were sent for histology (fixed in formalin) and 
microbiological culture and sensitivity (not fixed in formalin).  Five of the proven 
biopsy samples were sent to the Mycology Reference Laboratory in Bristol for 
Panfungal PCR and nuclear ribosomal repeat region sequencing.326,327 
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Open lung biopsy was employed in one patient due to the anatomical position 
of the lesion and one of the VATS biopsies had to be converted to open biopsy 
due to intra-operative bleeding.  The four extrapulmonary biopsies were 
performed on the hard palate (2), mediastinal mass by mediastinoscopy (1), 
and heart (1). 
 
The biopsy results were reviewed by two histopathologists. A semi-quantitative 
reporting system was used: (1) primary and secondary histology patterns, (2) 
presence or absence of fibrosis, (3) infectious organisms seen or not, (4) 
presence or absence of any malignancy, (5) diagnosis, and (6) suggested 




1 excluded: slides unavailable






26 unfit for surgery
 





Transplant patients (both allogeneic and autologous) were offered baseline 
bronchoalveolar lavage before the initiation of the conditioning chemotherapy. 
The samples collected were sent for routine microbiology, virology, and 
biochemistry tests as well as galactomannan, β-D-glucan, and PCR. A uniform 
BAL protocol was used for all patients: 
 20ml bronchial wash with warm normal saline into bronchus 
intermedius followed by 
 150ml BAL into middle lobe in 50 ml aliquots 
 Samples to Microbiology for MC+S, PCR, BDG, GM. 
 Samples for cytokine profiling (Luminex) transported immediately 
on ice; centrifuged and the supernatant were stored at -800C and 
cell pellet re-suspended to analyse cellular components. 
 
3.0 Database and Statistical analysis 
All the patients recruited into the study had the following baseline details 
entered into our purpose-built database (IPAS): demographic details, reason 
for admission, past medical history including previous treatment details, 
disease status at admission, smoking and alcohol history, antifungal 
prophylaxis (type, dose, duration, reason for starting and stopping), antibiotics 
(type, dose, duration, reason for starting and stopping), CT scan results, 
bronchoscopy (where applicable), and clinical assessment (See CD for the full 
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database fields). Laboratory investigations included: FBC, U&Es, LFTs, Mg, 
CRP, galactomannan, β-D-glucan, PCR. Follow-up entry for the above tests 
was carried out on every patient as well as any changes in antifungal agents or 
antibiotics and the reason for such. Diagnostic and follow-up CT scan reports 
and biopsy results where available were also recorded. All patients were 
scored for evidence of IFD based on the EORTC criteria. 
 
At the end of the study data was extracted from the database into ACCESS 
and exported into statistical software such as SPSS version 19.0 or Stata® 
version 11.2 for further statistical analysis.  The incidence of IFD and IA was 
calculated for the whole cohort and for specific treatment categories, such as 
allogeneic HSCT, chemotherapy only, etc. Because each patient could have 
more than one treatment episode during the study, these incidences were 
based on treatment episodes rather than individual patients. Proven and 
probable IA were considered bone fide cases while possible IA was considered 
as a separate category.  Cumulative incidences of IA and IFD were calculated 
at 100 days, six months and one year post index treatment. The index 
treatment was defined as the immunosuppressive/myelosuppressive therapy 
that the patient received prior to developing fungal infection.  In case of no 
evidence of IFD the index treatment was the primary 
immunosuppressive/myelosuppressive therapy. The date of diagnosis was 
defined as the date in which the EORTC criteria were met and in the biopsy 
proven cases it was the day of the biopsy.  
Risk factor profiles 
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Risk factors for IFD and death were examined using the Cox regression 
model.328  Time to development of IA/IFD or death was used as the endpoint 
and censoring was the time of death or at the end of follow-up to obtain hazard 
ratios and 95% confidence intervals (CI). Independent variables tested in the 
univariate model included age, sex, performance status, ethnicity, occupation, 
smoking history, alcohol history, diagnosis, treatment received (chemotherapy, 
allogeneic HSCT, autologous HSCT, IST)  disease status at initiation of 
therapy, number of prior therapies received, antifungal prophylaxis and 
treatment, duration of cytopenia (neutropenia, lymphopenia, monocytopenia), 
baseline CT findings. All variables examined in the univariate model with P 
values <0.10 were entered in the multivariate model and eliminated in a 
forward stepwise (Likelihood ratio) fashion. Adjusted Hazard ratios and 95% CI 
were calculated. Statistical significance was defined by two-tailed P < 0.05.  
The Kaplan-Meir method was used to estimate the overall survival (OS).329    
Utility of diagnostic tests 
For the purpose of this study the EORTC/MSG definitions were considered as 
the ‘gold standard’ for diagnosing IA with tissue diagnosis being considered 
the reference diagnostic test.  Because of the difficulty of getting tissue 
diagnosis in the majority of patients the true disease status of the majority of 
patients remained unknown. To calculate the sensitivity, specificity and 
predictive values of the non-invasive tests used in this study using 2 x 2 tables, 
the following definitions were used: 
1. Proven and probable IA were considered true positives 
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2. Proven non-IA fungal infections and those with no evidence of IA were 
considered true negatives 
Cases of possible IA and those not classified under the current EORTC/MSG 
criteria were excluded. 
 
Cytokines 
The cytokine data was divided into baseline and follow-up 1 to 15 (sampling 
done at two weekly intervals during inpatient admission). Patients who were 
febrile at the time of initial samples or had already received chemotherapy 
were excluded. Stepwise logistic regression analysis was used for comparing 
the cytokine levels of those who eventually developed IA to those who did not.  
The mixed models 330 approach was used for assessing the diagnostic and 
prognostic value of repeated follow-up cytokine levels using binary outcome of 
proven/probable and no evidence of IA. The model was adjusted for clustering, 
age, sex, underlying diagnosis, treatment (allograft or autograft or 
chemotherapy), GVHD and bacterial or viral infection. 
 
Radiology 
The role of baseline CT scan (prior to starting immunosuppressive therapy) in 
predicting IPA was evaluated as above using the Cox proportional hazard 
model. The inter-observer agreement between the two radiologists in 
assessing diagnostic and follow-up scans was assessed by Cohen’s Kappa 
coefficient 331 for categorical variables and the Bland-Altman plots 332 for 
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continuous variables such as the percentage of the lungs affected by 
consolidation or ground glass opacification.  The value of contrast 
enhancement in the diagnosis of IPA was assessed by comparing the degree 
of enhancement in Hounsfield units between patients with proven/probable IPA 
and others with alternative diagnosis or not classified. Possible IPA was 














Chapter 3 Results 
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3 Results  
3.1 Recruitment 
Recruitment started in December 2008 after ethical and R&D approval in 
October 2008.  It started slowly partly to ensure all the recruitment process, 
sample collection, processing, testing and laboratory storage facilities were in 
place. By April 2009 recruitment peaked when 85% of all eligible patients were 
recruited (Figure 10).   
 
 
Figure 10: Recruitment  
 
 3.2 Patient characteristics 
During the study period 203 patients with haematological malignancies 
undergoing allogeneic HSCT (n=99), autologous HSCT (n=66) or 
chemotherapy/IST (N=38) were recruited into the study. Their demographics 
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and clinical characteristics are reported in Table 15 according to the underlying 
treatment received. The total number of neutropenic febrile episodes was 409 
with a median of 2 episodes/patient which was significantly more in the 
allogeneic HSCT and chemotherapy/IST patients compared to autologous 
HSCT patients (P<0.001). The median age was 54 years (range 19-73 years) 
and 123 (61%) were males. The ethnic origin was white (174; 86%), black (15; 
7%), Asian (9; 4%), Chinese (2; 1%), and others (3; 2%).  The median weight 
was 75 kg (range 47-134 kg).   In total 95 (47%) were smokers of which 25 
(12%) were current smokers while 149 consumed alcohol at a median of 5 
units/week (range 2-70 units/week). 
 
At admission into the study the median Karnofsky score was 90 (range 30-90) 
and median PAM score among the transplant candidates was 22.  The CMV 
status was sero-positive in 89 (44%), negative in 96 (47%), and unknown in 18 
(9%). The underlying malignancy was myeloid (n=111; 55%), lymphoid (46; 
23%), and multiple myeloma (46; 23%).  The disease status at admission was 
CR (56; 27%), partial remission (PR) [52; 26%], stable disease (42; 21%), 
progression/relapse (22; 11%), and new diagnosis (31; 15%). Prior to entering 
the study 172 (85%) received chemotherapy, IST or HSCT. In total 384 
treatments were administered from current diagnosis (new diagnosis or 
relapse) and during the study period: allografts 106 (1 allograft n=93, 2 
allografts n=5, 3 allografts n=1), chemotherapy (177), autografts (72), and IST 
(29).  Two hundred and sixty-three (68%) of the treatments were given during 
the study period: allografts (106), chemotherapy (77; 1 cycle n=20, 2 cycles 
n=10, 3 cycles n=4, 4 cycles n=2, 5 cycles n=1), autografts (67), IST (13).    
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Among the 106 allografts the donor source was from siblings (25; 24%), 
volunteer unrelated donors (73; 69%), cord blood (5; 5%), haplo-identical (2; 
2%).  One patient died before stem cell infusion. GVHD was seen in 37 (37%) 
patients, 28 (28%) of which were acute (grade I n=4, grade II n=15, grade III 
n=9) and 17 (17%) were chronic (limited n=10, and extensive n=7). The 
affected sites of the aGVHD were skin only (21), skin and gut (3), skin, gut and 
mouth (2), skin, gut and eyes (1) and gut only (1). The sites of cGVHD were 
skin (11), skin and gut (2), skin, mouth, gut (1), gut (2), and liver (1). The 
median time for the development of aGVHD was 62 days (range 19-104 days) 
and for cGVHD 159 days (range 117-224 days) from day of stem cell infusion. 
 
Of the 37 patients who developed GVHD 26 (70%) were treated with 
prednisolone at a starting dose of 1-2mg/kg/day and were treated for a median 
of 37 days (IQR 17-93 days). Additional immunosuppressive therapy was 
added in 3 of these patients: CSA (1), CSA, mycophenolate mofetil (MMF) and 
photopheresis (1), and infliximab (1).  Thirteen of the 14 ITU admissions died; 
12 in ITU and one after discharge. Their EORTC/MSG status was A. fumigatus 
(1), candida spp. (2), probable IFD (2), possible IFD (2), and not classified (7).  
Significant renal impairment (creatinine ≥ 240μmol/L) at the time of 
EORTC/MSG classification was seen in 4 patients while hepatic impairment 
was seen 35 patients.
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Table 15: Demographics and clinical characteristics of the 3 patient groups  








Age, mean (95% CI), y  48 (46-51) 58 (55-60) 48 (44-53) <0.001 
Male, n (%) 61 (62) 39 (59) 23 (61) 0.934 
Diagnosis, n (%) 
   MDS/AML 
   NHL 
   Myeloma 
   AA 
   ALL 
   HD 




























  Proven mould 
  Proven candida 
  Probable  
  Possible  
  Not classified 























Concomitant infections, n(%) 
   Bacteria 













Alive, n (%) 58 (59) 61 (92) 20 (53) <0.001 
Febrile episodes (total 409) 









Febrile episode duration, mean(95% 
CI), days 
28 (22-34) 12 (10-13) 22 (28-58) <0.001 
Receiving steroids, n (%) 48 (49) 4 (6) 13 (34) <0.001 
Steroid dose, mean (95% CI) 
   Total dose, mg 













ITU admission, n (%) 11 (11) 0 (0) 3 (8) 0.030 
*N=105 as 7 cases had 2 separate proven and probable IFD episodes and were counted twice and one patient was 
excluded as she had probable IPA at time of recruitment 
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The laboratory characteristics are shown in Table 16. Overall 93% of all 
patients developed neutropenia of <0.5 x109/l and 59.2% of patients had 
neutropenia greater than 10 days and this was not statistically significantly 
different between the 3 treatment groups (P=0.086). The mean CRP was 
significantly higher in the chemotherapy/IST group compared to the transplant 
patients (P<0.001; Figure 10). CRP correlated well with fever especially fever 
lasting ≥3 days (Figure 11). 
 
 
     
Figure 11: Error bar of CRP in the different treatment groups (left) and CRP 




Table 16: Laboratory characteristics of the 3 patient groups 
Characteristic Allogeneic  Autologous  Chemotherapy/IST  P value 
Serum GMI (N=3086) 
   Mean (95% CI) 













Serum BDG (N=253) 
   Mean (95% CI) 














Total positive/no. tested 
(%) 
   Weak positive 
   Moderate positive 





















FBC, mean (95% CI) 
   Haemoglobin (g/dl) 
   Neutrophils (x10
9
/l) 
   Platelets (x10
9
/) 
   Lymphocytes (x10
9
/l) 



























Leucopenia, N (%) 
   Neutropenia anytime 
   Neutropenia >10d 
   Lymphopenia anytime 
   Lymphopenia >10d 
   Monocytopenia anytime 





























Duration of cytopenia, 
Mean (95% CI), days 
   Neutropenia (N<0.5) 
   Lymphopenia (<0.3) 

















CRP, mean (95% CI) mg/l 53 (50-56) 43 (38-48) 82 (74-89) <0.001 
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3.3 Incidence of IFD 
During the study 45 proven and probable IFD cases were detected among 40 
patients. One of the probable cases was excluded as she had probable IPA 
prior to entering the study, leaving 44 evaluable cases (Table 15). Seven 
patients had 2 separate episodes of IFD and were counted twice leading to 
total 209 cases at risk of IFD.  The clinical characteristics of these cases and 
the other EORTC/MSG categories are shown in Table 17. Fourteen (32%) 
were proven and 30 (68%) were probable cases. Aspergillus fumigatus was 
seen in 2 cases and all the candidas were non-albican spp. (Figure 12).  The 
median age of the IFD cases was 52 years, similar to non-IFD cases and 52% 
were male.  Of the 44 IFD cases 29 received allogeneic transplantation (cord 
5, sibling 8, 16 unrelated), 3 received autologous transplantation, and 12 
received chemotherapy/IST.   
 
Figure 12: Proven IFDs  
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Table 17: Characteristics of the study cases according to the EORTC/MSG criteria  
 Proven Probable Possible Not classified No 
evidence 
Total  N 
(%) 
14 (7) 30 (14) 26 (12) 76 (37) 63 (30) 
Subgroup  Mould Candida - - Serology  Radiology - 
No.of 
cases (%) 
9 (4) 5 (3) 30 (14) 26 (12) 57 (27) 19 (10) 63 (30) 
Mean age, 
(y) 
52 52 50 48 51 54 51 
Male Sex, 
n (%) 




   
MDS/AML 
   NHL 
   Myeloma 
   AA  
   ALL 
   HL 


























































   Allo 
   Auto  
   Chemo               
































Excluding the non-Aspergillus-type cases the cumulative incidence of IA 
(proven and probable) was 37/209 (17.7%). IA cases were predominantly 
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myeloid, had more febrile neutropenic episodes and longer duration of 
neutropenia compared to non-IA cases (Table 18).  
 
Table 18: Comparison of the clinical characteristics between IA and no IA patients 
 IA (N=37) No IA (N=66) P value 
Age, mean, years  51.1 51.7 0.762 
Male, n (%) 20 (54) 38 (58) 0.730 
Diagnosis, n (%) 
   MDS/AML 
   NHL 
   Myeloma 
   AA 
   ALL 
   HD 


















No. of FNE/patient   3.2 1.2 <0.001 
FNE, mean, days 44.3 11.7 <0.001 
FBC, mean  
   Haemoglobin (g/dl) 
   Neutrophils (x10
9
/l) 
   Platelets (x10
9
/) 
   Lymphocytes (x10
9
/l) 





















Duration of cytopenia, Mean, days 
   Neutropenia (N<0.5) 
   Lymphopenia (<0.3) 













FNE: febrile neutropenic episode 
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Proven IFD 
The 14 proven IFD cases are shown in Table 19 and 4 patients were further 
discussed. 
Table 19: Proven IFD cases 













Mould IFD Neg 




Mould IFD Neg 




Mould IFD Neg 
4 72/F HL/AA Chemo  Nodules+halo Pos/ 
pos 
Mould IFD Neg 
5 54/M MDS Allo 
HSCT 
Nodules  Neg/ 
pos 
Mould IFD Neg 










NA Mould IFD Aspergillus 
fumigatus 




- Fusarium spp 
















HSCT Nodules   
Neg/ 
pos  
- Candida  
parapsilosis 
 




- Candida glabrata  


















- Candida Kefyr 
14 47/M NHL Allo 
HSCT 




*post mortem: disseminated mould. Tissue PCR failed to identify spp. NA; not available 
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Case 2- Disseminated invasive mould disease at post mortem 
This 61 year old female with AML M0 with complex cytogenetics received 
reduced intensity conditioning (RIC) matched unrelated donor (MUD) 
allogeneic HSCT in May 2009. She achieved CR post allograft with full donor 
engraftment. However, her post-transplant period was complicated by grade II 
acute and then extensive chronic GVHD resulting in prolonged systemic 
immunosuppressive therapy, recurrent CMV reactivations requiring antiviral 
therapies, prolonged cytopenias and recurrent neutropenic sepsis, and 
pulmonary embolism six post post-allograft. She was diagnosed with probable 
IPA (GM and BDG positive) four months post allograft. Lung biopsy was 
planned but she became acutely unwell on the morning of surgery and 
therefore biopsy was not performed. 
 
249 days post allograft she was admitted to her local hospital with diarrhoea, 
cough, progressive weight loss and deterioration in her renal and liver function 
tests. Two weeks after her admission she developed acute deterioration of her 
conscious level with Glasgow coma score (GCS) fluctuating between 7 and 10, 
bilateral ankle clonus, and upgoing planter on the right. She was then 
transferred to King’s. She was on Posaconazole, Gancyclovir, Enoxaparin 
treatment dose, Dapsone, Cetirizine, Levothyroxine, Mycophenolate, 
Ranitidine, Azithromycin, Prednisolone, and Ciclosporin. Her total antifungal 
experience during the study period is shown in Figure 13.  
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Figure 13: Antifungal experience of Case 2. She was on antifungals for a total of 248 
days of her 274 patient days at a cost of £29,711.60. 
 
Four days after admission in Kings she deteriorated further neurologically and 
became incontinent of urine and faeces, pupils became dilated and 
nonreactive bilaterally, and tone and reflexes were increased in all limbs. CT 
scan of her brain was performed and showed multiple bilateral low density 
lesions involving both grey and white matter (Figure 14). The differential 
diagnosis includes infection, neoplasia and multiple ischaemic lesions 
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Figure 14: CT brain showing  bilateral low density lesions in the right frontal lobe, 
predominantly involving white matter but extending to the insular, and anteriorly in the 
left temporal lobe, extending to the temporal operculum, the grey-white matter 
interface in the posterior right parietal lobe. No haemorrhage was 
identified.Unfortunately contrast could not be given due to the patient's poor renal 
function.  
 
The patient died within 24h of the CT brain and a hospital postmortem was 
carried out. This showed: 
1. Central nervous system 
Multiple haemorrhagic infarcts of varying sizes involving the white matter and 
cortex were found (Figure 15). Theses lesions were present in the frontal and 
parietal lobes, insular cortex, basal ganglia and cerebellum. 
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Figure 15: Coronal sections of the brain showing haemorrhagic foci (courtesy of the 
neuropathology department, KCH) 
 
Histology showed abundant fungal hyphae in the brain parenchyma and within 
blood vessels (Figure 16). The fungal hyphae appeared to be predominantly 
non-septated and branching predominantly at right angles. The fungi were 
infiltrating the walls of the blood vessels, and in places causing complete 
obstruction of vascular lumens (Figure 17). This affected both parenchymal 
and meningeal blood vessels; the latter was associated with neutrophilic 
infiltration of the meninges and fungal infiltration, consistent with fungal 
meningitis (Figure 18).  
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Figure 16: Right frontal lobe at PM stained with H&E (left) and Grocott (right) showing 





    
Figure 17: Gross angioinvasion of the brain (left) and occlusion of the cerebral artery 





Figure 18: Fungal meningitis showing hyphael and neutrophilic infiltration of the 





Two soft to firm lesions with red peripheral boundaries and yellow central 
areas were seen in the posterior left ventricular wall and the anterior lateral left 
ventricle. The appearances were suggestive of a recent myocardial infarct. 
This would explain the chest pain that the patient experienced on her last 






Figure 19: Post mortem findings on the heart. Top: low power view of the myocardium showing 
obstruction of the coronary arteries associated with foci of haemorrhagic changes, oedema, and 
neutrophilic infiltrate suggestive of acute myocardial infarction. Bottom: high power view of the coronary 
arteries stained with H&E (left) and grocott (right). Large luminal septic thrombi composed of fibrin and 
fungal hyphae are evident. (Courtesy of the neuropathology department, KCH) 
 
3. Lungs 
A triangular area of firm consistency was noted in the right upper lobe apex 
measuring 5cm in diameter with dark-red discoloration. This was associated 
with pulmonary emboli in the corresponding blood vessels and probably 
represented secondary organised infarcts. This was the likely cause of the PE 
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the patient was diagnosed with ante-mortem. Histology confirmed 
angioinvasive mould disease (Figures 20 & 21). Fungal cultures were negative. 
 
Figure 20: Coagulative necrosis of the lungs associated with numerous fungal hyphae 
(courtesy of the neuropathology department, KCH) 
 
 
Figure 21: Septic emboli in the pulmonary vessels associated with ischaemic and 






A mild degree of congestion and nutmeg appearance was noted. In addition, 
multiple pale/yellow irregular lesions were noted in parts of the liver. These 
were examined histologically and showed invasion by fungal hyphae (Figure 
22). 
 
Figure 22: Hepatic invasive fungal disease. Congested blood vessels are noted 
around central veins associated with haemosiderin laden macrophages. Numerous 
branching hyphae are seen within the vascular lumen with surrounding area of 









There were a few haemorrhagic lesions on the cortices of the left kidney. A 
mild degree of thinning of the cortices was noted but there was no evidence of 
mass lesions. Histological examination confirmed renal involvement by 
invasive fungal disease (Figure 23).  
Figure 23: Intravascular fungal emboli associated with ischaemic renal cortical 
necrosis (courtesy of the neuropathology department, KCH) 
 
6. Gastrointestinal tract 
The stomach contained blood-stained material and showed multiple dark-red 
mucosa lesions of about 2cm in diameter. Similar lesions were noted in the 
small and large intestine. Histological examination confirmed GI involvement 
with the disseminated fungal disease (Figure 24).   Fungal and bacterial 
cultures were all negative. Bone marrow examination showed hypocellularity 
but otherwise normal trilineage haemopoiesis with no evidence of relapse of 




Figure 24: Duodenum showing infiltration by fungal hyphae (courtesy of the 
neuropathology department, KCH).  
 
 
Case 4- Invasive pulmonary mould disease  
This was a 72 year old female who was diagnosed with Hodgkin lymphoma in 
2008 and treated with five courses of ChlVPP (chlorambucil, vinblastine, 
procarbazine and prednisolone) chemotherapy. This was followed by 
prolonged pancytopenia. She developed culture-negative neutropenic sepsis 
resistant to second line antibiotics. CT scan of the chest showed classic 
nodules with halo sign (Figure 25). Both GM and BDG were positive. Lung 
biopsy showed invasive mould disease (Figure 26) but fungal cultures were 



























 Figure 25: CT chest showing a macronodule with ‘halo’ sign (top) and air crescent 
sign (bottom)                                                                                                                                                               
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Figure 26: Angioinvasive pulmonary aspergillosis. The H&E shows extensive 
coagulative necrosis with angio invasion of the lung vasculature (A). The angio 




Case 7: Aspergillus endocarditis and angioinvasive cardiac disease  
This was a 59 year-old female with P53-deleted chronic lymphocytic leukaemia 
(CLL) heavily pre-treated with chemotherapy including alemtuzumab. She 
underwent RIC MUD allogeneic HSCT using 
fludarabine/melphalan/alemtuzumab (FMC) conditioning in May 2010. This 
was complicated by gastrointestinal GVHD, CMV and adenovirus reactivations, 
bacterial infections (Enterobacter cloacae on bronchoalveolar lavage, recurrent 
Pseudomonas aeroginosa chest infections) and cytopenia. She had prolonged 
inpatient admission in her local hospital where she developed new cardiac 
murmurs during her many neutropenic sepsis episodes. Echocardiogram 
showed a subaortic mass with outflow obstruction. She underwent removal of 
this mass 258 days post allograft and the histology and culture confirmed 
Aspergillus fumigatus sensitive to amphotericin B, voriconazole, caspofungin 
and itraconazole (Figure 27). Despite combination therapy with Caspofungin 
and voriconazole she progressed and died of her sepsis.  
    
Figure 27: The branching hyphae of from histological examination of the heart (left) 
which was cultured and identified as  Aspergillus fumigatus (right) 
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Case 8: Disseminated Fusariosis  
54 year old female with high risk MDS underwent RIC MUD allogeneic HSCT 
in September 2009 using fludarabine/busulphan/alemtuzumab (FBC) 
conditioning.  She had primary graft failure and underwent her second RIC 
allograft using an alternative donor and 
fludarbine/cyclophosphamide/alemtuxumb (FCC) conditioning in December 
2009. She developed neutropenic sepsis and widespread skin lesions which 
typically started as violaceous lesions (Figure 28) before progressing to 
erythematous indurated lesions (Figure 29). Fusarium spp with typical 








Figure 28: widespread violaceous skin lesions due to fusariosis. The lesions were 










Figure 29: Erythematous indurated skin lesions with central necrosis (with patient’s 
permission). These lesions were widespread but prominent on the upper limbs (top) 
and around the nose (bottom). 
       
 147 
  
Figure 30: Blood cultures showing Fusarium spp with septate hyphae and conidia 
3.3.1 Incidence of IFD depends on the diagnostic tools used 
Using all available diagnostic tools recommended by the revised EORTC/MSG 
criteria, the study cases were classified into proven, probable and possible 
IFDs. However, a significant proportion of cases could not be classified as 
such (Figure 31). Patients who had normal CT scans and negative GM and 
BDG were considered to have no evidence of IFD (N=63). The ‘not classified’ 
group included patients who had positive GM and/or BDG but no associated 
radiological features (N= 57) or had radiological abnormalities other than those 
recognised by this classification (N= 19) [see also Table 17]. One of the proven 
mould cases (case 5, Table 19) would have been classified as possible IFD by 
GM alone without histological proof.  
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Figure 31: Study cases classified according to the revised EORTC/MSG criteria  
 
The outcome of the EORTC/MSG classification is reliant on the diagnostic 
tools utilised. Using GM alone would have identified 22 probable IFDs while 
BDG alone would have identified 34 cases giving overall incidence of 11% and 
16% respectively (Figure 32). Blood cultures identified additional three cases 
of Candida parapsilosis, Candida guilliermondii, and Fusarium spp. that were 
GM and BDG negative. When all the tools were utilised the number of IFD 
cases increased to 44 with incidence of 21%. Therefore, using GM or BDG 





Figure 32: Incidencde of IFD varies with the diagnostic tools used 
 
 
3.3.2 Treatment-specific incidences 
During the course of the study the 202 evaluable patients received a total of 
384 treatments for their underlying haematological malignancies 
(chemotherapy 177, allograft 106, autograft 72, IST 29). The index treatment, 
identified as the treatment during which IFD occurred, was chemotherapy (21: 
induction 16, consolidation 4, aplasia post consolidation 1), allogeneic HSCT 
(17), IST (4: pre-IST aplasia 2, IST 2) and autologous HSCT (2). Therefore, the 
treatment-specific incidences were 17/106 (16%), 4/29 (14%), 21/177 (12%), 





Figure 33: Treatment-specific incidence of IFD.  
 
3.3.3 Timing of IFD 
The median time from index treatment to onset of IFD was 142, 17, and 41 
days for proven mould disease, candidiasis and probable IFD respectively 
(Figure 34). All the invasive candidiasis were detected among allogeneic 
HSCT patients and occurred significantly earlier than mould infection 
(P<0.001). The cumulative incidence of IFD at 3, 6, 12, and 24 months was 
16%, 19%, 21%, and 21 % respectively (Figure 35). The cumulative incidence 
of IA at 3, 6, 12, and 24 months was 14%, 16%, 17% and 18% respectively. 
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Figure 34: Interval between index treatment to EORTC/MSG classification by stem-
and-leaf plot. The boxes indicate the interquartile range and the numbers on the top of 






Figure 35: Cumulative incidence of IFD by Kaplan-Meir estimate 
 
 
3.3.4 Patients with more than one IFD episodes 
Seven patients contributed to more than one IFD episode: 
1) Patient 24 
A 59y old female with aplastic anaemia probably secondary to 
radiotherapy she received for breast cancer 3 years prior to the aplastic 
anaemia diagnosis. She was admitted for IST with CSA and ATG  and 
recruited into the study on 16/1/09. She received itraconazole as 
primary prophylaxis for a total of 215 days. She developed febrile 
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neutropenic episodes and was diagnosed with possible IPA in 
September 2009. She did not respond to IST and underwent a VUD 
allogeneic HSCT in March 2010 and grew candida parapsilosis from 
blood cultures 4 days post transplant. Her total  antifungal treatment 
included Ambisome for 38 days, voriconazole for 85 days, and 
caspofungin for 44 days. 
 
2) Patient 31 
A 54y old male with refractory AML and underwent VUD allogeniec 
HSCT using the FLAMSA protocol. His baseline CT scan showed 
nodules with halo sign. Within 48h of the CT scan he developed 
neutropenic fever and although GM was negative BDG was positive at 
523 pg/ml. He was treated with voriconazole for a total of 139 days. His 
follow-up CT scan at 4 weeks showed a complete radiological response. 
His post transplant period was complicated by grade 2 acute GVHD 
(cutaneous, gut and ocular) and received high dose of steroids for a 
total of 56 days. He also had CMV reactivations and was treated with 
ganciclovir for 21 days, valganciclovir for 16 days, and foscarnet for 2 
days. Six months after his admission to the study, whilst on 
voriconazole, he developed another febrile episode and a CT scan 
showed mutiple nodules with halo sign. GM was positive. He was 
treated with ambisome for 7 days and then posaconazole for 10 days. 
Lung biopsy was planned but he died on the morning of the planned 
procedure. A coroners post mortem was carried out and cause of death 
was recorded as ‘fungal pneumonia’ from macroscopic appearances of 
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his lung lesions. No histology samples were taken as this was a 
coroners PM.   
3) Patient 89 
A 55y old male with AML for which he underwent VUD allogeneic 
HSCT. He developed possible IPA and Candida guilliermondii 12 and 
17 days post allograft respectively. He received ambisome for 32 days 
and voriconazole for 12 days. He died from relapse 59 days after 
admission into the study. 
4) Patient 109 
A 28y old female with secondary MDS due to treatment of Burkitt 
lymphoma with chemotherapy and total body irradiation 9 years 
previously. She was admitted for standard cord blood allogeneic HSCT 
following inadequate response to 6 cycles of 5-azacytidine. She 
received posaconazole as primary prophylaxis for 25 days. Her baseline 
CT scan showed nodules in the lingula and left lower lobe (Figure 36). 
She was clinically well with no fever, or any other signs of sepsis. GM 
and BDG were negative. FBC showed Hb 8.9 g/dl, WBC 1.64 x109/L, 
neutrophils 0.26 x109/L, lymphocytes 1.33 x109/L, monocytes 0.02 
x109/L, and platelets 61 x109/L. CRP was <5mg/l. Three days after the 
baseline CT scan she had her first of five febrile episodes and was 
started on first line antibiotics. She failed to respond to second line 
antibiotics during her 3rd febrile episode and had a diagnostic scan. This 
showed nodules in the RUL, LUL, RML, LLL and a cavity in the LLL 
(Figure 36). GM and BDG taken 2 days prior to this febrile episode were 
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positive with GMI of 1.44 and BDG of 282 pg/l. She was treated with 
ambisome for 14 days before being changed to posaconazole. Lung 
biopsy using the VATS approach 10 days after the diagnostic scan 
showed invasive mould infection NOS.  She had 2 further febrile 
neutropenic episodes and grew candida kefyr during one of these. She 
died from EBV-driven post-transplant lymphoproliferative disorder 
(PTLD) classical Hodgkin lymphoma subtype 192 days after admission 
into the study. This presented as a febrile episode resistant to second-
line antibiotics while she was already on treatment dose of ambisome. 
The CT scan showed bilateral nodules in the RUL, LUL, lingula, RML, 
RLL, and LLL. Despite chemotherapy for her PTLD she deteriorated 








     
   
Figure 36: Patient 109. Baseline CT scan (A) showing a nodule with halo in the 
lingula. She was well and CRP was <5mg/l. No antifungal treatment was initiated. 
Diagnostic scan was performed 26 days after baseline scan without contrast (B) and 
with contrast (C) showing LLL nodules and both GM and BDG were positive. VATS 
biopsy confirmed invasive mould disease NOS. Second diagnostic scan (D) showing 
multiple nodules. Lung biopsy showed PTLD.  
 
5) Patient 127 
A 54y old male with MDS/MPD admitted for induction chemotherapy in 
August 2009. He had a total of 11 septic neutropenic episodes in 85 
days during 492 study days. He had total of 389 days of prophylaxis 
with itraconazole and 91 days of treatment with Caspofungin (20 days), 





neutropenic sepsis in September 2009 he did not respond to second-
line antibiotics and CT showed a nodule in his LLL. GM was negative 
(GMI 0.14) but BDG was positive at 137 pg/ml. He was therefore 
diagnosed with probable IFD. He had further febrile episodes in 
November 2009 when pulmonary CT showed RUL nodule and BDG 
was positive. He was treated with caspofungin and his follow up CT 
scan showed a complete radiological response. 
 
In October 2009 he was admitted for a matched sibling allogeneic 
HSCT with FLAMSA approach.  He relapsed post allograft and had to 
have re-induction chemotherapy followed by a second allograft in 
October 2010. During this period he had further neutropenic sepsis and 
CT scan showed a mass with halo sign in the LLL. GM remained 
negative but BDG was again positive. He then underwent a VATS 
biopsy which showed invasive mould disease. Fungal cultures were 
negative. He subsequently relapsed from his MDS/MPD and died. 
 
6) Patient 128 
A 43y old female with MDS/Fanconi anaemia and admitted for cord 
blood allogeneic HSCT and was recruited into the study in August 2009. 
She had a total of 8 febrile neutropenic episodes lasting for a total of 
145 days during her study period of 469 days. During this period she 
had 269 days of antifungal prophylaxis (itraconazole 31 days, 
ambisome 38 days, posaconazole 200 days) and 224 days of antifungal 
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treatment (ambisome 28 days, caspofungin 28 days, voriconazole 5 
days, and posaconazole 163 days). Her baseline CT prior to her 
transplant showed nodules and halo sign in the RUL and lingula, and a 
mass and cavity in the RUL. She was clinically well and underwent 
VATS biopsy which showed non-specific interstitial pneumonitis. In 
October 2009 she was diagnosed with probable IPA with nodules and 
halo sign associated with multiple positive GM and BDG results. VATS 
biopsy showed non-specific inflammatory changes probably due to 
inadequate samples obtained. In April 2010 during her 6th neutropenic 
sepsis episode, despite antibiotics and antifungal therapy, she 
continued to have fever. Bronchoscopy was performed and the BAL 
showed pneumocystis jiroveci on Grocott staining. 
 
7) Patient 164 
46y old man diagnosed with MDS/MPD who was admitted for induction 
chemotherapy in November 2009 followed by VUD allogeneic HSCT in 
January 2010. He experienced 2 febrile neutropenic episodes in 
December 2009 and November 2010. The CT scan in both cases 
showed bilateral nodules with halo signs. Both GM and BDG were 
negative throughout and he was therefore classified as having two 
possible IPA episodes. He was in complete radiological remission from 




3.3.5 Concomitant bacterial and viral infections 
Bacterial infections, where organisms were recovered from specimen cultures, 
were seen in 74 (36%) of this cohort. These organisms were Gram positive 
cocci (27; 36%), Gram negative rods (25; 34%), mixed (20; 27%) and non-
tuberculous mycobacterial spp (2; 3%). Concomitant bacterial infections, 
where organisms were recovered during the same febrile episode as the 
EORTC/MSG diagnosis, were seen in 18 (8.9%) of the study patients (Table 
20). Among the proven/probable IFD cases concomitant bacterial infections 
were seen in 8 (4.0%) patients. Two organisms were cultured during the febrile 
episode from 4 of these 8 concomitant infections. 
 
Viral infections/reactivations were seen in 24 of the 99 allograft patients (24%): 
CMV in 13, CMV/adenovirus in 2, CMV/EBV in 1, EBV in 5, adenovirus in 2, 
adenovirus/BK virus in 1. Viral reactivations detected by PCR were only 






Table 20: Clinical and laboratory characteristics of the 18 cases of concomitant 
bacterial infections 
EORTC class Diagnosis Treatment GM 
results 
BDG results Organisms 
Proven, n=3 
A. fumigatus (2), 





Chemo  (1), allo 
(2) 
 









maltophilia , VRE  
Probable, n=5 AA (1), AML 
(1), MDS (2), 
HD (1) 
Allo (2), auto (1), 
chemo (1), IST 
(1) 




Possible, n=1 AML  Allo  Neg  Neg  Micrococcus spp 
Not classified, n=8 Myeloma (3), 
AA (2), NHL 
(2), AML (1) 
Allo (3), auto (4), 
IST (1)  





staph aureus  
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3.4 Antifungal agents  
3.4.1 Prophylaxis 
Itraconazole and fluconazole were the most commonly used prophylactic 
agents for high and low risk patients respectively according to local antifungal 
guidelines 2007 (Table 21). However, there was a significant deviation from 
protocol for posanacozole, voriconazole and ambisome. Itraconazole was 
admistered intravenously in 15/215 (7%) of cases and in the rest as a 
solution/suspension. The median duration of antifungal prophylaxis was 87 
days (interquartile range 36-164 days). Eleven patients received no 
prophylaxis as they were receiving emperic antifungal treatment (9) or none (2) 
at the time of recruitment. The latter two patients were admitted for allogaft 
which were subsequenly cancelled. 
   





prophylaxis N (%) 
Unit protocol-secondary 
prophylaxis N (%) 
Not protocol N (%) 
Itraconazole 
N=215  
192 (89) 0 (0) 23 (11) 
Fluconazole  
N=59 
56 (95) 0 (0) 3 (5) 
Posaconazole 
N=68 
1 (2) 15 (22) 52 (76) 
Voriconazole  
N=23 
1 (4) 5 (22) 17 (74) 




3.4.2 Treatment  
Antifungal therapy was given to 101 (50%) patients during the course of the 
study for suspected IFD (Figure 37). The median duration of treatment was 32 
days (interquartile range 8-80 days; range 1-456 days). Patients who were 
treated for 2 weeks or more (33%) was similar to the combined incidence of 
proven/probable/possible IFD (70/209 33%) and also the Chamilos PM data.77  
 
 
Figure 37: Proportion of patients treated with antifungal agents for suspected IFD 
during the course of the study.    
 
 
In total 266 treatment episodes were adminstered using the drugs shown in 
Table 22 according the KCH antifungal guidance 2007 or ITU admission. 62 of 
the 101 (61%) Ambisome treatments were as first line agent compared to 




Table 22: Antifungal treatments used according protocol or ITU admission 
Antifungal agent Unit protocol ITU Other  
Posaconazole, N=50 37 (74) 1 (2) 12 (24) 
Voriconazole, N=41 33 (81) 1 (2) 7 (17) 
Ambisome, N=101 78 (77) 0 (0) 23 (23) 




3.4.3 Antifungals at time of IFD diagnosis 
Itraconazole was the most commonly used antifungal drug, used in 65% of 
patients, within 2 weeks of the EORTC/MSG classification (Figure 38).  Based 
on these the break-through proven/probable IFD was 5/23 (22%), 23/137 
(17%), and 3/24 (13%) for posaconazole, itraconazole, and fluconazole, 
respectively.  Ambisome, caspofungin, and voriconazole were used as empiric 
treatment.  Because itraconazole, posaconazole and fluconazole were used in 
different risk strata, these break-through rates are not directly comparable.    
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3.4.4 Prophylaxis-treament patterns among proven/probable IFDs 
Among proven/probable IFDs the commonest pattern of prophylaxis-treatment 
was the use of azole as primary or secondary prophylaxis followed by either 
Ambisome or caspofungin [azole-other] (Figure 39). Azole-other combination 
was used in 31 of the 44 (68%) proven/probable IFD cases (Table 23). Azole 
prophylaxis followed by azole treatment [azole-azole] was uncommon in this 




Figure 39: The pattern of prophylaxis to treatment among the 44 
proven/probable IFDs 
 
Table 23: Pattern of prophylaxis-treatment among proven/probable IFD cases 


































3.5 Galactomannan and β-D-glucan performance 
3.5.1 Galactomannan 
Using the programmed surveilance method described in Chapter 2, 3086 
serum samples were tested from the study patients. The median number of 
samples per patient was 11(range 1-90). The mean GMI was 0.22 (range 0.01-
8.3, IQR 0.09-0.22) and was significantly higher at 0.32 in the chemotherapy 
only group vs 0.20, 0.19 in the allograft and autograft groups respectively 
(P<0.001).  Using GMI cut off of ≥0.5, 169 (5%) samples were positive (Figure 
40). The chemotherapy-only group had a significantly higher proportion 
positive results at 9.6% vs 4.7% and 4.3% in the allograft and autograft groups 
respectively (P <0.001). 
 
 
Figure 40: Serum galactomannan testing on 3086 samples and proportion of 
positive results (GMI ≥0.5) 
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Among the 169 positive GM samples 62 (37%) were  from 22 proven/probable 
IFD cases representing 2% of the total samples tested and the rest were 
unclassified. In 10 of the 22 cases (45%) GM positivity preceeded CT signs.   
Eleven of these 62 GM positive samples were considered false positives as 
they were unrelated temporally to the IFD episode. Therefore, the false 
positive rate among the proven/probable cases was 18% (11/62).  The 
sensitivity, specificity, PPV, and NPV were 54% (49/91), 71% (27/38), 82% 
(49/60), and 39% (27/69), respectively. 
 
 
3.5.2 Does persistent GM positivity predict poor prognosis 
The 22 probable/proven cases identified as GM positive occurred in 21 
patients as one of them had 2 separate episodes (See section 3.3.3). Eight of 
these patients had ≥2 GM positive results (Figure 41).  Six of the patients 
remained persistently positive and all died with active IPA. Patient 1 relapsed 
from his AML as his IPA worsened.  Patient 3 was particularly intrigiung.  She 
was a 47 year old telephone operator diagnosed with lymphoblastic lymphoma 
and was admitted for induction chemotherapy on the UKALL 12 protocol.  She 
had 4 separate febrile neutropenic episodes for a total of 50 days and was 
treated with broad-spectrum antibiotics and received ambisome as primary 
prophylaxis as per protocol. Her GM was positive on 13 different occations, 4 
of which occurred 66, 64, 60, 11 days prior to the EORTC/MSG diagnosis with 
GMI of 0.75, 0.51, 0.97 and 0.75 respectively. CT scan carried out as a result 
of the second positive GM results (she was afebrile at the time) was 
completely normal. She was subsequently diagnosed with probable IPA and in 
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total received 83 days of antifungal therapy (ambisome 48 days, caspofungin 
26 days, posaconazole 9 days). Despite this her GMI continued to increase 
(Figure 41) in parallel with clinical deterioration. She subsequently died and 
had a coroners PM and cause of death was recorded as ‘bronchopneumonia’ 




Figure 41: Quantification of Galactomannan antigenaemia by ELISA in 8 patients with 
proven/probable IPA who had ≥2 GM positive readings. Patient 1 died from relapsed 
AML with active IPA, patient 2-6 died from IPA. Patients 7 & 8 cleared GM antigen 




A total of 253 samples from 179 patients were tested of which 152 were 
positive (>80pg/ml), 18 were indeterminate (60-79 pg/ml) and 83 were 
negative (<60 pg/ml). In this analysis, indeterminate results were considered 
negative and therefore 101 samples were negative. The mean BDG 
concentration was 147 pg/ml (95% CI 130-164) and this was significantly lower 
in the autograft patients at 90 (95% CI 63-117) vs allograft and chemotherapy 
groups at 139 (95% CI 120-159) and 198 (153-243) respectively (P<0.001; 
Table 16).  The proportion of samples with positive BDG results was 60% and 
this was not significantly different between the groups (P= 0.079).  The 
sensitivity, specificity, PPV, and NPV were 79% (66/84), 55% (17/31), 83% 




3.5.6 Relationship between GM and BDG 
Serology testing with GM and BDG was positive in 40 of the 44 
proven/probable cases. Two cases of candida and one fusarium were negative 
while no sample was available from the cardiac aspergillosis case at the time 
of diagnosis.  Both GM and BDG were positive in 15 of the 40 IFD cases 
(Figure 42). There was no significant differences between the GM and BDG 
positive proven/probable cases in terms of underlying haematological 




Figure 42: Relationship between BDG and GM positive results among 40 of 44 
proven/probable IFD serology-positive cases.  
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3.6 LFD 
A total of 973 sequential serum samples from 56 patients were tested with LFD 
(Table 24). There were 35 positive samples (3.6%; strongly positive 10, 
moderately positive 11, weak positive 14) from 7 patients (proven mould NOS 
1, probable IFD 4, and 2 false positives).  The 2 false positives were a possible 
IFD and proven A. fumigatus where the LFD positivity preceed the EORTC 
diagnosis by 170 and 38 days respectively. Therefore, using LFD as the sole 
mycological diagnsotic tool in this cohort the inicdence of IFD would be 8.9% 
(5/56). 
  
Table 24: Results of 973 sera tested with LFD and GM and a selection for BDG.  
 LFD, n (%) GM, n (%) BDG, n (%) 
Aspergillus fumigatus 0/5 (0) 3/5 (60) 2/2 (100) 
Moulds NOS 7/71 (10) 4/71 (6) 5/6 (83) 
Fusarium spp 0/4 (0) 0/4 (0) 0/1 (0) 
PCP 0/18 (0) 0/18 (0) - 
Candida spp 0/12 (0) 0/12 (0) 1/1 (100) 
Probable IFD 22/250 (9) 39/250 (16) 41/48 (85) 
Possible IFD 1/73 (1) 2/73 (3) 2/7 (29) 
Not classified 0/246 (0) 38/246 (15) 26/46 (57) 
No evidence 5/294 (2) 0/302 (0) 6/10 (60) 
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The modified LFD method with pre-treatment of sera was performed on 16 
samples from one of the patients with proven pulmonary A. fumigatus.  Only 
one sample was weakly positive 24 and 38 days prior to possible/probable and 
proven IFD, respectively.  These results were the same as the none pre-
treated ones and therefore no further pre-treatment tests were performed.    
 
The true performance of the tests is best assessed by the results of individual 
samples.  The true disease status was defined as proven aspergillosis, mould 
NOS and probable IFD. Patients with no evidence of IFD, candida, fusariosis, 
and PCP were considered true negatives. Possible IFD and not classified 
categories were excluded. Restricting the true disease status only to GM-
positive cases the sensitivity, specificity, PPV, and NPV of LFD was 4/46 (9%), 
311/316 (98%), 4/9 (44%), and 311/353 (88%) respectively.  
 
Relationship between LFD and GM and BDG 
Using LFD and GM as diagnostic tools identified 23 cases of proven/probable 
IFDs. Only 2 patients were identified by both tests and 3 were identified only by 
LFD (Figure 43).  A similar number of patients were identified by LFD and BDG 
but no additional cases were identified by LFD while five patients were 
identified by both tests (Figure 44).  
 173 
 
Figure 43: Relationship between positive LFD and GM in identifying IFD cases  
 




323 blood (in EDTA) samples from 52 patients were tested. Of these 19 (3%) 
samples were positive (Ct< 50) from 11 patients. The Ct of the positive 
samples ranged from 36-49 suggesting weak to moderate positivity.  The 11 
patients included those with A. fumigatus (1), mould NOS (1), probable IFD (1), 
possible IFD (1), not classified (2), no evidence (3) and 2 false positives. The 
false positives were a case of Candida glabrata and a probable IPA where 
PCR was positive 8 and 3 weeks respectively prior to the EORTC/MSG 
diagnosis.  Therefore, PCR truly identified 3/52 cases (5.8%). The sensitivity, 
specificity, PPV, and NPV were 15% (9/60), 97% (138/143), 75% (9/12), and 
73% (138/189), respectively for IFD.  The corresponding values for IA were 
14% (8/59), 97% (138/143), 62% (8/13), and 73% (138/189).  All the true 
positive PCR results were also GM positive.  
 
PCR was also carried out on 96 serum samples (proven A.fumigatus (6), 
proven mould NOS (10), probable (32), possible (2), not classified (24), no 
evidence (22)) from 16 patients. There were 21 (21.9%) positive samples from 
10 patients with A. fumigatus (4), mould NOS (6), probable IFD (7), possible 
(1), not classified (2), no evidence (1) . Two of the probable cases were likely 
to be false positive as they occurred 16 days after (while on antifungal therapy) 
and 4 weeks prior to the EORTC/MSG classification respectively.   The 
sensitivity, specificity, PPV, and NPV of serum PCR was 35% (17/48), 96% 
(21/22), 94% (17/18), and 40% 921/52), respectively.  There was little 
correlation between blood and serum PCR as only 5 of the 21 were positive by 
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both methods (Figure 45).  These samples were from 2 patients with proven A. 
fumigatus and mould NOS. 
 
 
Figure 45: Scatter plot of PCR on blood and serum samples. Only 5 samples 




Broncho-alveolar lavage (BAL) was performed on 9 patients. Three of these 
were pre-conditioning baseline procedures and 9 were diagnostic requests 
based on clinical indications (Table 25).  
Table 25: BAL results 





GM Virology Bacteriology Cytology 
1* MDS Allograft  Probable Baseline  Neg  - Neg  Neg  
2* MDS Allograft  Probable  Diagnostic  Neg  Neg  P. aeroginosa Neg  
3 Myeloma Autograft  NE Baseline  Neg  Neg  Neg  ND 
4† MDS Allograft  NE Baseline  Neg  Neg  Neg  Neg  
5† MDS Allograft  NE Diagnostic  Neg  Neg  Neg  ND 
6 MDS Chemo  NC Diagnostic  Neg  Neg  Neg  Neg  
7 MDS Chemo  NC Diagnostic Neg  Neg  Neg  Neg  
8 MDS Allograft  Probable Diagnostic  Neg  Neg  K.pneumoniae Neg  
9 ALL Chemo  Proven  Diagnostic  Neg  Neg  Neg  Neg  
10 AA Allograft  Possible Diagnostic Neg  Neg  Neg  Neg  
11§ MDS/FA Allograft Proven  Diagnostic  Neg  Neg  Neg  Pneumocystis 
jiroveci 
12§ MDS/FA Allograft Proven Diagnostic  - CMV Neg  Neg 
13§ MDS/FA Allograft  Proven  Diagnostic  - CMV CNS Neg  
* †§ represent the same group of patients 
Abreviations: CNS, coagulase negative staphylococci; not classified; NE, no evidence; NC, ND, not done. 
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3.9 Biopsy 
3.9.1 Patient characteristics and clinical features 
Table 26 shows the characteristics of the 38 cases biopsied. The main clinical 
features at the time of CT were fever (84%), abnormal baseline CT without 
fever (11%), and lack of adequate response to antifungal therapy (5%). Extra-
pulmonary presentation was seen in 4 cases: mass in the hard palate (2), 
mediastinal mass with pulmonary lesions (1) and cardiac mass with 
vegetations (1). The median neutrophil count was 1.5 x109/L (range 0.02- 7.35 
x109/L) and 17 (45%) cases had neutrophils <0.5 x 109/L at time of biopsy. The 
median duration of neutropenia prior to CT was 16 days (range 0- 233 days). 
The median pre-biopsy haemoglobin and platelet counts were 9.5 g/dl (range 
6.9- 13.1 g/dl) and 113 x109/L (range 45- 399 x109/L) respectively.  There were 
pre-operative transfusions in 30 (79%) cases. 
 
The primary pulmonary radiological features were: nodules in 32 cases (84%), 
nodules with halo sign in 19 cases (50%), nodules with cavity in 2 cases (5%), 
and consolidation in 5 cases (13%). 
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Table 26: Characteristics of biopsy cases  
Characteristics  Values 
Age, y, Median (range) 43 (21-73) 
 
Sex, M:F ratio 19:19 
Diagnosis, n (%) 
   Acute Myeloid Leukaemia 
   Myelodysplastic syndromes 
   Aplastic anaemia 
   Hodgkin lymphoma 
   Non-Hodgkin lymphoma 








Treatment received, n (%) 
   Allogeneic HSCT 
   Autologous HSCT 





Patients with more than one episode of biopsy were counted more than once.  
*others included ALL 2, multiple myeloma 1, CLL 1, common variable immunodeficiency syndrome 1.  
 
 
3.9.2 Histological findings 
The results of the biopsy were divided into groups A, B, and C (Table 27). The 
diagnosis of IFD was confirmed in 7 cases (18%) (Group A). A. fumigatus was 
recovered by culture from two of these cases. One of these was a 59 year-old 
woman with CLL who developed a sub-aortic valve and ventricular mass 
invading into the myocardium at day 258 post-matched unrelated donor 
transplant using alemtuzumab-based conditioning regimen on 
immunosuppressive therapy for chronic graft-versus host disease (see case 7 
section 3.3).   The second was a 67 year-old man with ALL undergoing 
induction chemotherapy and developed IPA. The other five cases in group A 
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were two cases of hard palate and three cases of culture-negative pulmonary 
mould IFD.  
 
An alternative diagnosis was obtained from 7 cases (18%) [Group B].  Two 
cases of these were Hodgkin lymphomas: an EBV-driven post-transplant 
lymphoproliferative disorder (PTLD) in a female post umbilical cord HSCT for 
secondary MDS and a relapsed nodular sclerosis Hodgkin lymphoma. The 
other five cases were chronic GVHD of the lungs (2), sclerosing haemangioma 
(1), multiple pulmonary embolism (1) and mediastinal tuberculous adenitis (1) 
due to Mycobacterium kansasii post umbilical cord HSCT.   
 
The remaining patients (24, 63%) were grouped under a miscellaneous 
category in group C.  These were all lung biopsies and methylene blue was 
used in 4 of these procedures to aid pre-operative localisation.  This group 
included cases where the predominant histological pattern was inflammatory 
changes but fungal hyphae were not seen (9), diffuse alveolar damage of 
uncertain aetiology (9), non-specific changes (3), and normal lung tissue (3).  
The mean (95% CI) interval between CT and biopsy was 16 days (11-21 
days). This was significantly longer in group B with 34 days compared to 15 
and 11 days for groups A and C respectively (P=0.001). The pre-biopsy 
radiological features and EORTC classification was similar between the groups 
(Table 2).  Overall, biopsy results were useful in 14 cases (37%) where the 
diagnosis was proven (group A) or an alternative diagnosis was made (group 
B). 
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Table 27: Results of the biopsies and associated characteristics  
Characteristics 
 
Group A: IFD   
N= 7 
Group B: alternative 
diagnosis                            
N= 7 
Group C: 
miscellaneous    
N= 24 
P value 
Histology, n A. fumigatus, 2 
 
Mould IFD, 5  
Chronic GVHD, 2 
Hodgkin lymphoma, 2 
Sclerosing haemangioma, 1 
PE, 1 








Site of biopsy Lungs (4) Palate 
(2) Heart (1) 
Lungs (6)    Mediastinum (1) Lungs  (24) 0.004 
Age (median), y 47 39 46 0.527 
Adequate sample, n (%) 7 (100) 7 (100) 8 (33) <0.001 


















CT to biopsy, Median 
interval, days 
15 34 11 0.001 
CT signs, n (%) 
   Nodules 
   Halo sign 

















Pre-biopsy, n (%) 
   Possible  
   Probable   















Median duration of AF 
prophylaxis, d 
86  23 82 0.337 
Median duration of AF 
treatment, d 
135 40 77 0.154 
Neutropenia, n (%) 3 (43) 4 (57) 10 (42) 0.166 
Median duration of 
neutropenia, d 
64 18 40 0.268 
The inflammatory changes included cases where IFD could not be excluded and included granulomas 
(5), bronchopneumonia (1), culture-negative acute pneumonia (1), respiratory bronchiolitis (1) and 
resolving infection (1). Diffuse alveolar damage cases involved non-specific lung injury which could be 
caused by drugs or non-specific infections and included organising pneumonia (6), non-specific interstitial 
pneumonitis (1), and non-specific lung injury (2).  
Abbreviations: AF, antifungal; GVHD, graft versus host disease; PE, pulmonary embolism. 
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Histology samples were considered adequate in 22 cases (58%) and this was 
significantly different between the groups. All cases in groups A and B but only 
8 cases (33%) in group C were considered adequate (P<0.001). The reasons 
for inadequate sample was not related to the biopsy method used (P= 0.369). 
 
3.9.3 Adverse events 
Biopsy was well tolerated. All pulmonary cases had pneumothorax but none 
required treatment and all had chest drains inserted in theatre. The drain was 
removed within 48 hours in 90% of cases.    Mild to moderate pleural effusion 
requiring no treatment was seen in 6 cases (16%).  Pain (mild/moderate) was 
seen in 7 cases (18%). There was no mortality or long term complications. One 
case of VATS was converted to open procedure due to haemorrhage in 




3.99 Diagnostic performance of different tests 
The clinical performance of the available diagnostic tools used in this study is 
shown in Table 28.  Because GM and BDG are used for the diagnosis of IFD, 
the clinical utility of these tests is measured against proven IFD and probable 
IFD using the alternative test.  BDG has better sensitivity than GM even for the 
diagnosis of IA.  Serum, compared to whole blood PCR has better sensitivity 
and PPV. 
 
Table 28: Overall performance of the different diagnostic tests for detection of IA (or 
IFD where indicated) 
 Sensitivity % (n)  Specificity % (n) PPV (% (n) NPV % (n) 
GM 54 (49/91) 71 (27/38) 82 (49/60) 39 (27/69) 
BDG 
   IFD 














   IFD 























LFD 9 (4/46) 98 (311/316) 44 (4/9) 88 (311/353) 




4.0 Risk factors associated with IFD, overall survival and 
prognosis 
4.0.1 Risk factors for IFD 
The Cox proportional Hazards method was used to assess potential risk 
factors for IFD. The factors assessed in the univariate model are shown in 
Table 29. A multivariate model using forward stepwise likelihood ratio was then 
created using variables with P ≥0.1 from the univariate model. The variables 
included in this model were Karnofsky score, index treatment, bacteraemia, 
neutrophil count, neutropenia ≥10days, monocytopenia ≥10days, baseline CT 
scan, hepatic dysfunction, itraconazole v others as first line prophylaxis, and 
ambisome v others as first line treatment. In addition the underlying 
haematological diagnosis was added to the model. The model significantly 
predicted IFD (omnibus χ2= 24.88, df = 4, p<0.001). The results are shown in 
Table 30. Karnofsky score <90, bacteraemia, monocytopenia>10 days, and 
baseline CT scan abnormalities were significant independent risk factors for 
IFD.  In addition, there was a trend for GVHD among allograft patients (HR 
2.45, 95% CI 0.97-6.24), p=0.059). Neither steroids nor the PAM score were 
significant in the univariate analysis for allograft patients (HR [95% CI] 1.07 
[0.94-1.17] and 0.79 [0.43-1.44] respectively). 
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Table 29: Univariate Cox proportional hazards model for risk factors for IFD 
Variable Hazard Ratio (95% CI) P 
Age  0.99 (0.97-1.02) 0.786 
Sex, male v female 1.26 (0.70-2.28) 0.446 
Race, white v others 1.12 (0.94-1.34) 0.203 
Weight  1.00 (0.99-1.02) 0.632 
Karnofsky score, <90 v ≥90 1.91 (1.04-3.51) 0.037 
CMV serostatus, neg v pos 0.61 (0.26-1.45) 0.266 
Diagnosis, MDS/AML v others 1.50 (0.81-2.78) 0.201 
Index treatment, Others v autographs 5.70 (1.37-23.69) 0.017 
Previous chemo/IST or HSCT, yes v no 1.30 (0.65-2.58) 0.454 
Bacteraemia anytime, yes v no 2.55 (1.36-4.78) 0.003 
Viral reactivation/infection, yes v no 1.30 (0.65-2.59) 0.460 
Neutrophil count  0.71 (0.53-0.95) 0.020 
Neutropenia >10d 2.30 (1.06-4.96) 0.034 
Monocytopenia >10d 3.34 (1.79-6.25)) <0.001 
Lymphopenia >10d 1.03 (0.47-2.22) 0.950 
Baseline CT, abnormal v normal 2.34 (1.17-4.68) 0.016 
Renal impairment, Creatinine >240μmol/l 0.87 (0.27-2.82) 0.817 
Hepatic dysfunction 0.44 (0.24-0.80) 0.008 
Itraconazole v others as first line prophylaxis 0.46 (0.24-0.86) 0.015 





Table 30: Multivariate Cox proportional hazards model for significant risk 
factors for IFD 
Variable Hazard Ratio (95% CI)  P  
Karnofsky score 2.11 (1.06-4.21) 0.034 
Bacteraemia  2.48 (1.22-5.03) 0.013 
Monocytopenia ≥10 days 2.64 (1.28-5.43) 0.009 
Baseline CT scan  2.52 (1.21-5.26) 0.014 
 
4.0.2 Overall survival 
The mean follow-up period in this study was 556 days (range 12-730; 95% CI 
519-593 days). The intense follow-up period where all study protocols were 
monitored was for a median of 194 days (range 12-647 days). The overall 
survival (OS) estimate at 3, 6, 12, and 24 months were 91%, 81%, 72% and 
68% respectively for the whole cohort. Excluding non-IA cases (i.e. IA cohort) 
the OS was 92%, 83%, 76%, and 70% at 3, 6, 12, and 24 months respectively. 
Figure 46 shows the KM estimates of OS for both the whole cohort and the IA 
cohort. Overall survival was significantly lower in patients with proven/probable 
IFD compared to those with no evidence of IFD while patients with possible 
IFD and not classified group had an intermediate survival outcome (Figure 47).  




Figure 46: Overal survival analysis by Kaplan-Meier method of the whole cohort (left) 





Figure 47: Kaplan-Meier analysis of overal survival for patients with proven/probable IFD vs 
others for the whole cohort (left) and for the IA cohort (right) . The 2-year survival estimates 
(95% CI) were 45 (29-61)%,  66 (56-76)%, and 87 (77-97)%,  for proven/probable, possible/not 
classified and no evidence of IFD respectively.The corresponding estimates for the IA cohort 
(N=195) were 52 (34-70)%, 66 (56-76)%, and 87 (79-95)% for proven/probable IA, possible 
IA/not classified, and no evidence respectively. 
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4.0.3 Causes of mortality 
There were 64 deaths in this cohort giving all-cause mortality rate of 32% at 
the end of the study period/follow-up. The causes of death are shown in Table 
31. Relapse or progression of underlying haematological malignancy was the 
commonest cause of death (59%) while IFD accounted for 20% of deaths.  
Among the 40 patients who developed proven/probable IFD during the study 
period 18 (45%) were alive and 22 (55%) died at a median 296 days (95% CI 
199-488) from the EORTC classification (Figure 48). The causes of death were 
relapse of haematological disease (6), IFD (13; proven A. fumigatus/mould 
NOS n=4, Fusarium spp. n=1, C. glabrata n=1, probable IA n=7)), GvHD (1), 
stroke (1) and PTLD (1). Therefore, the attributable mortality for IFD was 59% 
(13/22). However, 5 of the 38 deaths from relapse had active IFD at the time of 
death.  Therefore, it could be argued that the true attributable IFD mortality 
was 82% (18/22).  The median time between IFD diagnosis and death was 27 
days for patients who died of IFD and 120 days for those who died of other 
causes.  For patients from the IA cohort the median time between diagnosis 
and death was 25 days and 249 days for those who died from IA and those 
who died from other causes respectively.    
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Figure 48: Survival estimates from EORTC classification to death/censor for 
the whole cohort (left) and the IA cohort (right). The median survival was only 





Table 31: Causes of death 
 
*others included CNS toxoplasmosis post allograft (1), PTLD (1), accidental death (1), 
pulmonary haemorrhage (1) 
Cause of death,  N=64  N (%) 
Relapse/Progressive disease 38 (59.4) 
IFD  13 (20.3) 
MOF/sepsis other than IFD 5 (7.8) 
Stroke  2 (3.1) 
GVHD 2 (3.1) 
Others*  4 (6.3) 
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4.0.4 Prognostic factors  
 
Risk factors for death were analysed in a univariate Cox proportional Hazards 
model (Table 32). Factors with p ≤ 0.1 were then used to construct a 
multivariate model. A total of 202 cases were analysed and the model 
significantly predicted death (Omnibus χ2=77.25, df = 5, p<0.001). The 
underlying haematological diagnosis, bacteraemia anytime during the study 
period, ITU admission, hepatic dysfunction, and the index treatment received 
prior to the EORTC/MSG classification were the five independent prognostic 
factors that were significantly associated with death in the whole cohort (Table 
33). A second multivariate Cox proportional Hazards model (Omnibus χ2 = 
87.56, df = 4, p<0.001) was created for patients with proven/probable IFD 
compared to no evidence of IFD. For this model 103 patients were included as 
possible and not classified patients were excluded in order to fully assess the 
potential role of IFD as a risk factor for mortality (Table 34). The survival plots 
for the IFD v no IFD, ITU admission status, and renal failure are shown in 
Figure 49 and the other independent prognostic factors from the multivariate 
model of the whole cohort in Figure 50.  
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Table 32: Univariate Cox proportional hazards model for prognostic factors for 
(N=202) 
Variable Hazard Ratio (95% CI) P 
Age  1.00 (0.98-1.02) 0.962 
Sex, male v female 1.32 (0.79-2.21) 0.292 
Race, white v others 1.62 (0.46-5.73) 0.457 
Karnofsky score, <90 v ≥90 1.38 (0.81-2.36) 0.239 
Diagnosis, AML/MDS v others 3.47 (2.06-5.86) <0.001 
Index treatment, Others v autographs 6.97 (2.79-17.37) <0.001 
Proven/probable IFD 2.58 (1.54-4.31) <0.001 
GM pos ≥2 times 2.30 (1.25-4.26) 0.007 
Bacteraemia anytime, yes v no 2.48 (1.52-4.05) <0.001 
Viral reactivation/infection, yes v no 1.80 (0.98-3.31) 0.059 
ITU admission  5.99 (3.18-11.24) <0.001 
Neutropenia >10d 1.30 (0.78-2.16) 0.317 
Monocytopenia >10d 1.87 (1.14-3.06)) 0.013 
Lymphopenia >10d 1.65 (0.88-3.10) 0.117 
No. of febrile episodes 1.12 (1.01-1.24) 0.025 
Renal impairment Creatinine >240 2.91 (1.25-6.76) 0.013 
Hepatic dysfunction 3.34 (2.02-5.52) <0.001 
Itraconazole v others as first line prophylaxis 0.80 (0.46-1.40) 0.437 






Table 33: Multivariate Cox proportional hazards model for prognostic factors 
for the whole cohort 
Variable Hazard Ratio (95% CI)  P  
ITU admission 3.05 (1.58- 5.88) 0.001 
Index treatment, others v 
autografts  
2.83 (1.00- 8.01) 0.050 
Diagnosis MDS/AML v others 2.01 (1.13- 3.57) 0.018 
Bacteraemia  1.90 (1.16- 3.14) 0.011 




Table 34: Multivariate Cox proportional hazards model for prognostic factors 
for patients diagnosed with proven/probable IFD v no evidence of IFD*  
Variable Hazard Ratio (95% CI)  P  
ITU admission 3.11 (1.03- 9.43) 0.045 
Index treatment, others v 
autografts  
4.51 (0.97- 21.03) 0.055 
Proven/probable IFD 2.57 (1.03- 6.40) 0.042 
Renal dysfunction   21.74 (4.59- 100.00) 0.011 
 
*possible IFD and not classified cases were excluded from this analysis 
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Figure 49: Survival plots for patients with IFD v no evidence of IFD (left), ITU 
admission v no admission (right), and renal failure (bottom) using the multivariate Cox 
proportional Hazard Ratio (N=103). The model included diagnosis, bacteraemia, viral 
infection, ITU admission, steroid use, monocytopenia, lymphopenia, renal and hepatic 







Figure 50: Survival plots of the whole cohort showing the effect of underlying 
diagnosis (top left), positive blood cultures (top right), hepatic dysfunction (bottom 
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4 Radiology results 
4.1 Baseline scans 
202 of the 203 patients recruited into the study had baseline CT chest scans at 
the time of recruitment. One patient did not have the scan due to cancellation 
of planned allogeneic HSCT and was discharged early. The median time from 
recruitment to scanning was 0 days (range 0-10 days) and 192 (95%) of the 
scans occurred within 3 days of recruitment. Table 35 shows the baseline scan 
primary signs. 
Table 35: Baseline CT chest signs 
CT findings No. (%) patients, N=202 
Normal 126 (62.4) 
Nodules 16 (7.9) 
Halo sign 6 (3.0) 
Cavity  1 (0.5) 
Ground glass opacification 8 (4.0) 
Consolidation 16 (7.9) 
Bronchiectasis  4 (2.0) 
Micronodules  5 (2.5) 
Tree-in-bud 4 (2.0) 
Pleural abnormalities* 8 (4.0) 
Other abnormalities
†
 8 (4.0) 
 
*included pleural effusion (4), plaques (2), tag (1), thickening (1)   




Seven of the 23 (30%) patients with nodules had a febrile episode within 24 
hours of the scans and four of these seven patients subsequently fulfilled the 
criteria for probable IPA while 3 remained possible cases. One of these 
possible cases was rather unusual. He was a 55 year old man with CML and 
treated with imatinib and then dasatinib but with suboptimal response and was 
admitted for allogeneic HSCT. At admission his FBC were: Hb 10.6 g/dl, 
Neutrophils 7.16 x109/l and Platelets 346 x109/l. There were no previous CT 
scans performed at his local hospital and he had no neutropenic sepsis 
previous to admission. He was on itraconazole primary prophylaxis as per unit 
protocol. His baseline CT showed bilateral upper and lower lobe nodules with 
halo signs (Figure 51). Both GM and BDG were negative. Lung biopsy was 
planned but was not logistically possible during his conditioning chemotherapy.   
  
 
Figure 51: CT scan of JW 55y male with CML with normal neutrophil counts 
previously only treated with imatinib and dasatinib. He became febrile within 24-48h of 
starting conditioning chemotherapy.  Baseline CT (A) showed nodules with halo sign 
(arrow). He was treated with Ambisome for 1 day and then changed to caspofungin 
 A  B 
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for 16 days and then voriconazole for 52 days. Follow up CT after weeks (B) shows 
some partial resolution.  
 
4.1.1 Do the results of the baseline scan influence the incidence of IPA? 
126 patients who had normal baseline CT scans were compared to 72 patients 
with baseline abnormalities (Figure 52 & Table 36). Four patients who had 
baseline abnormalities (nodules) and became febrile within 24h of the scan 
were excluded from this analysis (See section 4.1.0). Of the 126 patients with 
normal scans 62 (49.2%) had no evidence of IFD, 37 (29.4%) were not 
classified, 10 (7.9%) were possible IFD, 15 (11.9%) were probable IFD, 1 
(0.8%) had A. fumigatus, and 1 (0.8%) had Candida guilliermondii.  Therefore, 
the incidence of proven/probable IFD and IA among patients with normal 
baseline scan was 13.5% and 12.7% respectively. Of the 72 patients with 
baseline abnormalities 19 (26.4%) had EORTC recognised signs and 53 
(73.6%) had non-EORTC signs. The EORTC signs were nodules (12), nodules 
with halo sign (6), and cavity (1).  The patients’ final classification was probable 
IFD (6), proven mould NOS (3), possible IFD (8), and alternative diagnosis on 
biopsy (2; Hodgkin lymphoma and Sclerosing haemangioma). Therefore, the 
cumulative incidence of proven/probable IFD in this group was 47.4%. The 
final EORTC/MSG classification of patients with non-EORTC signs were A 
fumigatus (1), proven mould NOS (1), Candida glabrata (1), Fusarium spp (1), 
probable IFD (7), possible IFD (5), and not classified (37).  The incidence of 
IFD and IPA in this group was therefore 20.8% and 17.0% respectively. 
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Table 36: Demographic and clinical characteristics of patients according to baseline 
pulmonary CT scan results 
 Normal CT  
N=126 
Abnormal CT  
N=72 
P-value 
Lesions none EORTC signs 19 (26.4%)* 
Non-EORTC signs 53 
(73.6%) 
- 
Age, mean (95% CI), years 51.3 (49.1-53.4) 51.4 (48.1-54.7) 0.940 
Males N (%) 
 
79 (62.7) 42 (58.3) 0.544 
Karnofsky score, mean 
(95% CI) 
87 (86-89) 85 (82-87) 0.177 
Pre-treatment, n (%) 
 
108 (85.7) 61 (84.7) 0.849 
Diagnosis 
   MDS 
   AML 
   NHL 
   Myeloma 
   Aplastic anaemia 
   ALL 
   Hodgkin lymphoma 





















   Allogeneic HSCT 
   Autologous HSCT 
   Chemotherapy 












Baseline mean (95% CI)  
   Neutrophil x10
9
/l 
   Lymphocytes x10
9
/l 















Leucopenia, n (%) 
   Neutropenia anytime 
   Neutropenia >10 d 
   Monocytopenia anytime 

















CRP, median (IQR) mg/l 
 
5 (<5-19) 15 (<5-60) NS 
Time to first febrile 
episode, median (IQR),d 
6 (0-9) 5 (2-18) NS 
Time to IPA, median 
(IQR),d 
37 (15-68) 31 (7-85) NS 
IPA N (%) 
 
16 (12.7) 18 (25.0) 0.002 
 
*EORTC signs included nodules (12), halo sign (6), cavity (1) while non-EORTC signs were 
consolidation (16), ground glass opacification (8), pleural diseases (8; effusion [4], plaques [2], thickening 
[1], tag [1]), bronchiectasis (4), micronodules (5), tree-in-bud (4) emphysema (3), sub-pleural reticulation 
(2), atelectasis (1), cysts (1), and PE (1) 
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The cumulative incidences of proven/probable IFD and IPA in patients with 
normal and abnormal baseline CT scans were compared by Cox proportional 
hazard model.  The model significantly predicted IFD (Omnibus χ2 = 8.56, df = 
1, p = 0.003) and IPA (Omnibus χ2 = 7.41, df = 1, p = 0.006). Patients with 
abnormal baseline scan had a significantly higher incidence of IFD and IPA 
(Figure 53). The significance remained when other confounders were adjusted 
for in a multivariate model (see Table 30 in section 3.9.1). A further sub-
analysis was performed to assess the impact of EORTC and non-EORTC 
signs compared to normal scans on the cumulative incidence of IFD (Omnibus 
χ2 = 14.09, df = 2, p = 0.001) and IPA (Omnibus χ2 = 15.50, df = 2, p < 0.001).  
Abnormal baseline scan with EORTC signs significantly predicted the 
incidence of both IFD and IPA while non-EORTC signs were statistically 
significant for predicting IPA (OR = 2.70, 95% CI 1.07-6.85) and a trend for IFD 
(OR = 2.21, 95% CI 0.91-5.35) (Figure 54).   
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Figure 53: Cummulative incidence of IFD (top) and IPA (bottom) according to baseline 
CT scan results.  
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Figure 54: Cummulative incidence of IFD (top) and IPA (bottom) according to baseline 
CT scan results.  
 
 203 
4.1.2 An unusual case of possible IPA 
42 year old retailer diagnosed with AML FAB M4 with FLT3 ITD in May 2009. 
She was treated with 3 cycles of chemotherapy (DA, FLAG Ida x2) before 
being admitted for a matched unrelated donor allogeneic HSCT using the 
FB4C conditioning. She was in CR and had normal lung function tests and had 
no known previous history of IPA. She was recruited to the study in February 
2010 and had baseline CT scan performed on the same day. This showed a 
nodule and consolidation in the left lower lobe (Figure 55). There was no 
supporting mycological evidence to upgrade to probable IPA. Her FBC was 
normal with Hb 11.1 g/dl, Neutrophils 2.55 x109/l and platelets of 153 x109/l. A 
VATS biopsy failed due to adherent pleura and CT guided biopsy was 
unsuccessful in obtaining adequate tissue.  As per unit protocol she was on 
itraconazole prophylaxis. She had 3 neutropenic febrile episodes lasting for a 
total of 22 days. During these febrile episodes she responded to antibiotics 
adequately and grew Micrococcus spp from blood cultures taken from her 
Hickman line. She remained on itraconazole prophylaxis for a total of 153 days 
and received no additional antifungal treatment.  A repeat scan 7 months later 
showed almost complete resolution of the opacity (Figure 55). 
 204 
  
Figure 55: Baseline CT scan of the chest (A) showing a nodule in the left lower lobe 





4.2 Diagnostic scans 
There were 151 diagnostic scans performed. Three were excluded: HRCT 1, 
incomplete lung exposure 2, leaving 148 evaluable scans among 108 patients 
(one scan n=84; 2 scans n=17; 3 scans n=3; 4 scans n=2; 5 scans n=1; 8 
scans n=1). The median age was 52 years (range 19-73 years) and 54 (58%) 
were male. The diagnosis were MDS/AML (87), NHL (17), multiple myeloma 
(13), aplastic anaemia (11), ALL (8), Hodgkin lymphoma (7), MPD (4), CLL (1). 
The treatment they were receiving at the time of scan were allogeneic HSCT 
(n=89, 60%), autologous HSCT (n=27, 18%), and chemotherapy/IST (n=22, 
22%). All the patients had neutropenic sepsis unresponsive to combination of 





The CT signs were defined based on the recommendations of the Fleischner 
Society definitions 325. IPA was diagnosed in 48 scans (proven n=7, probable 
n=41) and possible IPA was seen in 35 cases. Non-IPA cases included non-
Candida albicans spp (3), Fusarium spp (1), not classified (38) and no 
evidence (24). The CT findings are shown in Table 37.  Nodule/mass was the 
commonest type of lesion seen in patients with IPA, occurring in 46 (96%) 
cases.  
Table 37: Diagnostic scan image findings  
CT signs No. (%) of 
scans (N=148) 
No. (%) of 
proven/probable IPA                      
(N=48) 
No. (%) of 
proven/probable/possible  
IPA   (N=82) 
Nodule 77 (52) 44 (92) 75 (92) 
Mass 12 (8) 8 (17) 11 (13) 
Halo sign 41 (28) 21 (44) 39 (48) 
Cavity  15 (10) 8 (17) 15 (18) 
Ground glass 
opacity 
68 (46) 27 (56) 49 (60) 
Consolidation  70 (47) 25 (52) 48 (59) 
Micronodule  31 (21) 12 (25) 21 (26) 
Bronchiectasis  18 (12) 10 (21) 17 (21) 
Bronchiectasis 
severity 
19 (13) 9 (19) 17 (21) 
Bronchial wall 
thickening 
13 (9) 5 (10) 9 (11) 
Tree-in-bud 5 (3) 1 (2) 2 (2) 
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4.2.1 Comparison of the CT signs between IPA and non-IPA patients 
The CT findings seen in the diagnostic scans of patients are shown in Table 
38. The presence of a nodule was the most frequent feature and highest odds 
ratio at 308 (95% CI 53.9-1759.5) for the diagnosis of IPA. The sensitivity and 
specificity of a nodule in proven/probable IPA was 92% and 97% respectively 
while its positive and negative predictive values were 96% and 94% 
respectively. Among the proven mould IFD the sensitivity and specificity of 
nodule was 100%. The halo sign was observed in 44% of this cohort with IPA. 
Its sensitivity, specificity, PPV, and NPV for the diagnosis of proven/probable 
IPA were 44%, 97%, 91% and 70% respectively. Two patients who had the 
halo sign were found to have Hodgkin lymphoma on open lung biopsy and 
Acinetobacter baumannii pneumonia/septicaemia on post mortem 
examination. Pulmonary mass was observed in 17% of cases and its 
sensitivity, specificity, PPV and NPV were 17%, 98%, 89% and 62% 
respectively.  Cavitation was seen in 8 (17%) of proven/probable IPA. Its 
sensitivity, specificity, PPV, and NPV were 17%, 100%, 100% and 62% 
respectively. 
 
The other radiological features which are not EORTC/MSG-recognised criteria 
assessed in this cohort included ground glass opacities (GGO), consolidation, 
micronodules, bronchiectasis, bronchial wall thickening, and tree-in-bud signs. 
GGO, micronodules and bronchiectasis were found in a statistically 
significantly higher proportion of IPA patients compared to non-IPA cases 
(Table 38). GGO was present in 27 (56%) of IPA cases. All the GGO cases 
showed nodules (26) or mass with halo (1). Consolidation was present in 25 
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(52%) of proven/probable IPA cases which also showed nodules (23), mass 
with halo (1) and cavity (1). All the 12 scans with micronodules also showed 
nodules. Tree-in-bud infiltrations were rare in this cohort.     
Table 38: Comparison of the CT signs between proven/probable IPA and non-IPA 
cases 
CT signs No. (%) of cases 
with IPA (N=48) 
No. (%) of cases 
without IPA (N=66) 
P value 
Nodule 44 (91.7) 2 (3.0) <0.001 
Mass 8 (16.7) 1 (1.5) 0.003 
Halo sign 21 (43.8) 2 (3.0) <0.001 
Cavity  8 (16.7) 0 (0.0) 0.001 
Ground glass opacity 27 (56.2) 18 (27.3) 0.002 
Consolidation  25 (52.1) 23 (34.8) 0.066 
Micronodule  12 (25.0) 7 (10.6) 0.042 
Bronchiectasis  10 (20.8) 1 (1.5) 0.001 
Bronchiectasis 
severity 
9 (18.8) 2 (3.2) 0.007 
Bronchial wall 
thickening 
5 (10.4) 4 (6.1) 0.394 
Tree-in-bud 1 (2.1) 3 (4.5) 0.481 
 
4.2.2 Location and distribution of lesions 
a) EORTC signs 
The RUL and LLL were the commonest sites for nodules accounting for 47% of 
all nodules and the lingula had the lowest number (7% of nodules) (Figure 56). 
Of the 44 nodules among the proven/probable cases 33 (75%) had ≤3 nodules 
and 11 (25%) had >3 nodules. The distribution was bilateral in 21 (48%) cases 
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including all cases with >3 nodules.  All the masses were unilateral but 
involved more than 1 lobe in 2 cases. The distribution of the halo sign mirrored 
that of the nodules (Figure 56). Of the 21 IPA scans with a halo sign 11 (52%) 
were bilateral. Cavities were found predominantly in the RUL and LLL (90% of 
cavities) (Figure 57) and unilateral with only one bilateral case seen.  
                         
Figure 56: Distribution of nodules and Halo sign in the lungs among IPA patients.  
 
        Figure 57: Distribution of cavities in IPA patients in different lobes of the lungs 
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b) Non-EORTC/MSG signs 
The distribution of GGO was fairly uniform in the different lobes of the lungs 
(Figure 58) and bilateral in 17 (63%). Consolidation in IPA was bilateral in 14 
(54%) and showed a predilection for the lower lobes where 60% occurred 
(Figure 58). Micronodules were bilateral in 25% of cases. All the bronchiectasis 
involved one broncho-pulmonary segment with none generalised and only one 
was bilateral. All the bronchiectasis as well as bronchial wall thickenings was 
trivial in severity.  
    
Figure 58: Distribution of GGO and consolidations in the lungs 
 
 
4.2.3 Inter-observer variation for the diagnostic scans 
Each lobe of the lungs was independently assessed by two consultant 
radiologists for both the EORTC/MSG signs and other radiological features 
and their agreement is shown in Table 39. Overall there was a statistically 
significant agreement between the consultants but the degree of agreement 
was higher with the EORTC/MSG signs compared to non-EORTC signs. Four 
cases would have been misclassified using a single radiologist in this cohort: 
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nodules in the RUL, RLL, LLL and lingula. In addition a halo sign would be 
missed in the RLL. Two of these possible cases were upgraded to probable 
IPA with the additional mycological evidence. 
 
 
Table 39: Inter-observer agreement between the 2 radiologists in reporting CT scan of 
the chest  
Lesion/location Observed agreement (%) Kappa Coefficient P value 
Nodule 83 0.702 <0.001 
Mass  95 0.694 <0.001 
Halo sign 88 0.692 <0.001 
Cavity 97 0.796 <0.001 
Bronchiectasis 93 0.657 <0.001 
Bronchiectasis 
severity 
90 0.553 <0.001 
Bronchial wall 
thickening 
93 0.414 <0.001 
Tree-in-bud 97 0.489 <0.001 
 
 
The inter-observer variation for continuous signs (percentage of consolidation, 
ground glass opacification, and micronodularity) was assessed by the Bland-
Altman Plots in Figure 59. The degree of agreement between the 2 radiologists 





4.2.4 Contrast enhancement 
In order to assess the role of contrast enhancement in the diagnosis of IPA 27 
patients (17M, 10F; MDS/AML 17, other diagnosis 7; allograft 16, autograft 4, 
chemotherapy/IST 7) had diagnostic contrast studies. The final EORTC/MSG 
classifications were proven mould (3), probable IFD (12), possible IFD (1), and 
not classified (6). The lesions in the not classified patients were consolidation 
(5) and consolidation and micronodules (1).  The degree of enhancement over 
time was similar for both background lungs and the lesions of interests and 
demonstrates that the peak time of enhancement was 2-3 min from injection of 
contrast (Figure 60).   
Figure 59: Bland-Altman plots 
for consolidation, ground glass 
opacification and 
micronodularity. Rad1 and 
Rad2 refer to the radiologists 1 
and 2. The horizontal lines 
represent to the mean 
difference (middle) between 
the 2 radiologists and their 
95% confidence intervals as 
the limits of agreement 
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Figure 60: Degree of contrast enhancement in Housell Units at different time points. 
The enhancement pattern was similar for the lesions (left) and non affected 
background lungs (right)  
 
 
Patients with proven/probable IPA were compared with those not classified 
(Table 40). Possible IPA was excluded due to uncertainty associated with this 
diagnosis and the risk of misclassification. No statistically significant difference 
was found between the 2 groups.  
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27.2 21.7 0.519 
Median HU at 1 min 39.9 50.8 0.424 
Median HU at 2 min 57.4 45.8 1.000 
Median HU at 3 min 50.9 53.8 0.677 
Median HU at 5 min 52.7 59.4 0.519 
Median HU at 10 
min 
50.8 47.6 0.850 
 
 
4.3 Follow-up scans 
A total of 76 follow-up scans were performed: 34 and 42 at follow-up 1 and 2, 
respectively. These scans were performed 10-14 days (follow-up 1) and 28-30 
days (follow-up 2) post diagnostic scan to assess response to antifungal 
therapy. The EORTC/MSG response criteria were used to assess response. 
321 Among the 48 proven/probable IPA cases 29 scans were performed, 10 
could not be retrieved for scoring, 2 were post lung biopsy; the response rate 
among the 17 evaluable scans are shown in Table 41. The 19 scans that were 
not performed were due to early discharge (14), death (4) and patient refusal 




Table 41: Response rates among the IPA patients  
 Follow-up 1  Follow-up 2 
Complete response 1/17 2/13 
Partial response 7/17 8/13 
Stable disease 5/17 1/13 
Progression  4/17 2/13 
 
Successful response to therapy with complete or partial radiological response 
was achieved in 8 (47%) patients at 2 weeks compared to 10 (77%) at 4 
weeks. Four patients had no follow-up 2 scans due to death (2) and early 
discharge (2).  Among the 7 patients who achieved partial response (PR) at 2 
weeks 3 remained in PR at 4 weeks, 1 progressed and subsequently died, 1 
did not have a scan due to clinical instability, and 2 were discharged prior to 
follow-up 2 scan. One of the 2 patients who progressed at follow-up 2 died of 
IPA and the other achieved complete response on another scan done at 35 
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5 Cytokines results 
5.1 Baseline cytokines 
Baseline cytokine profiles were available for 172 (102 males, 70 females, median 
age 54, AML/MDS [69; 40%], aplastic anaemia [17; 10%], myeloma [43; 25%], 
NHL [29; 17%], others [14; 8%]) of the 203 patients. The other 31 patients had 
fever or chemotherapy administered before the cytokine samples were taken and 
were therefore excluded from this analysis.  The final EORTC/MSG classifications 
were: proven Aspergillus fumigatus (2) mould NOS (1), Fusarium spp. (1), 
Candida spp. (4), probable IFD (21), possible IFD (14), not classified (67), and no 
evidence of IFD (62). The incidence of IFD and IA in this cohort was therefore 
16.9% (29/172) and 14.4% (24/167) respectively. Proven/probable IFD and IA 
were considered true disease events while no evidence was considered as true 
negative. The possible and not classified cases were excluded from this analysis 
in order to avoid misclassification. The mean cytokine/chemokine concentrations 
of samples from patients with proven/probable IFD/IA were compared to those 
with no evidence of IFD using the Mann-Whitney method and the results are 
shown in Tables 38 and 39. 
 
Five cytokines were found to be significantly different between IFD and no IFD 
cases.  IL-15, IL-2R, MCP-1, and MIP-1α were significantly higher in IFD while IL-
4 was significantly lower in patients who developed IFD compared to no IFD 
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(Table 43 and Figure 61). Patients who developed IA had significantly higher 
HGF, MCP1, and RANTES compared to those with no IA (Table 43 and Figure 
62).    
 
Table 42: Baseline cytokine profile comparing patients who developed proven/probable 
IFD to those with no evidence of IFD 
Cytokine  IFD N= 29 no IFD N=62 Mann-Whitney 
p-value 
Median IQR Median IQR 
EGF 65.1    21.6-208.4 82.4 29.5-218.1 0.285 
EOTAXIN 74.7 31.0-150.0 63.4 37.8-100.6 0.740 
FGF 14.6 5.5-27.4 13.0 9.2-22.5 0.692 
GCSF 69.0 29.4-267.1 43.1 25.2-231.0 0.450 
GMCSF 20.4 20.3-24.1 20.4 19.7-24.1 0.696 
HGF 400.2 176.7-1346.1 179.2 67.9-829.8 0.071 
IFN-α 27.7 20.3-48.1 23.6 19.1-34.3 0.259 
IFN-γ 19.6 17.3-39.2 19.3 17.3-37.7 0.562 
IL-10 8.4 6.0-10.9 9.4 5.8-13.1 0.762 
IL-12 112.4 76.7-260.1 146.1 87.1-213.7 0.512 
IL-13 27.4 25.7-49.4 25.7 20.7-35.6 0.223 
IL-15 29.5 19.2-64.9 20.9 7.4-29.5 0.035 
IL-17 16.9 10.6-16.9 16.9 11.8-17.1 0.243 
IL-1β 16.9 9.8-19.2 14.1 9.8-16.9 0.303 
IL-1RA 362.7 167.4-696.2 266.3 192.2-640.2 0.851 
IL-2 6.7 4.8-13.7 6.4 5.0-9.9 0.746 
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IL-2R 616.7 322.3-1208.9 411.3 284.1-730.8 0.039 
IL-4 9.0 4.0-36.1 33.8 9.0-51.6 0.010 
IL-5 7.0 2.6-7.0 7.0 3.4-7.0 0.632 
IL-6 7.9 3.4-30.7 7.9 4.4-15.3 0.645 
IL-7 15.1 6.7-27.3 24.9 6.5-28.9 0.746 
IL-8 86.9 51.6-470.2 64.2 27.3-284.5 0.193 
IP-10 44.1 23.2-169.3 43.9 26.1-75.1 0.676 
MCP-1 785.8 353.2-1421.8 333.5 144.9-620.8 0.003 
MIG 85.9 43.2-168.5 85.9 52.4-182.2 0.925 
MIP-1α 37.2 25.2-125.0 28.6 20.2-48.1 0.049 
MIP-β 70.5 37.0-136.0 65.2 44.9-133.2 0.939 
RANTES 3609.6 600.7-7622.6 6510.0 4958.2-
8300.0 
0.074 
TNF-α 4.8 4.0-7.3 4.6 2.3-7.3 0.426 
VEGF 15.9 3.7-22.0 22.0 3.6-29.8 0.453 
 
Table 43: Baseline cytokine profile comparing patients who developed proven/probable 
IA to those with no evidence of IA 
Cytokine IA N=24 no IA N=62 Mann-
Whitney p-
value Median IQR Median IQR 
EGF 69.7 29.7-275.5 80.7 29.5-218.1 0.591 
EOTAXIN 72.8 33.1-166.3 64.9 37.8-100.6 0.701 
FGF 14.6 11.9-61.8 13.7 9.2-22.5 0.423 
GCSF 61.0 27.4-420.7 44.8 25.2-231.0 0.633 
GMCSF 20.4 20.3-24.1 20.4 19.7-24.1 0.985 
HGF 413.0 218.4-2045.8 179.7 67.9- 829.8 0.041 
IFN-α 24.2 20.3-48.1 24.2 19.1-34.3 0.343 
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IFN-γ 19.3 10.8-38.9 19.3 17.3-37.7 0.989 
IL-10 8.4 6.0-11.2 9.5 5.8-13.1 0.864 
IL-12 124.2 82.6-260.1 145.2 87.1-213.7 0.824 
IL-13 26.7 25.7-35.5 25.7 20.7-35.6 0.513 
IL-15 24.2 19.2-58.5 21.1 7.4-29.5 0.130 
IL-17 16.9 10.6-16.9 16.9 11.8-17.1 0.178 
IL-1β 16.9 9.8-16.9 14.4 9.8-16.9 0.385 
IL-1RA 433.0 199.5-779.0 266.3 192.2-640.2 0.494 
IL-2 5.9 4.8-13.7 6.7 5.0-9.9 0.850 
IL-2R 576.7 322.3-1104.5 412.0 284.1-730.8 0.091 
IL-4 10.8 4.7-50.1 32.4 9.0-51.6 0.068 
IL-5 7.0 2.6-7.0 7.0 3.4-7.0 0.993 
IL-6 7.4 3.4-17.6 7.9 4.4-15.3 0.376 
IL-7 25.2 8.4-27.3 24.8 6.5-28.9 0.959 
IL-8 85.1 41.9-331.6 64.8 27.3-284.5 0.327 
IP-10 43.3 23.2-149.4 43.7 26.1-75.1 0.926 
MCP-1 673.5 353.2-1242.1 334.4 144.9-620.8 0.013 
MIG 93.2 46.6-168.5 87.0 52.4-182.2 0.736 
MIP-1α 35.3 25.2-125.0 29.0 20.2-48.1 0.079 
MIP-β 70.5 41.2-136.0 66.7 44.9-133.2 0.882 
RANTES 3609.6 600.7-6510.0 6510.0 4958.2-8300.0 0.042 
TNF-α 4.0 2.8-7.3 4.6 2.3-7.3 0.801 






Figure 61: Median (with IQR) cytokine concentrations which were statistically significantly 
different by Mann-Whitney test between patients who developed IFD v no IFD 
 
 
Figure 62: Median (with IQR) cytokine concentrations which were statistically significantly 
different by Mann-Whitney test between patients who developed IA v no IA 
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The risk of IFD and IA were assessed in a univariate Cox proportional hazard 
model for baseline cytokines that were statistically significantly different between 
IFD/IA cases and those who had no evidence of IFD/IA.  A multivariate Forward 
Stepwise (Likelihood Ratio) model was then created and included IL15, IL-2R, IL-
4, MCP, MIP-1α, diagnosis, index treatment, bacteraemia, monocytopenia>10 
days, Karnofsky score, and baseline CT scan.  The final model significantly 
predicted the incidence of IFD (Omnibus χ2 = 42.32, d.f. = 3, p<0.001). The 
univariate model for HGF and IA (Omnibus χ2 = 2.08, p = 0.149) and RANTES 
and IA (Omnibus χ2 = 0.04, p = 0.949) did not fit well and were excluded from the 
final model. Therefore, no specific model was created for IA.   
 
The multivariate model showed that high MCP-1, IL-2R, and bacteraemia were 
independent risk factors for IFD (Table 44 and Figure 63).  The median MCP-1 
and IL-2R concentrations were 419.0 pg/ml (IQR 150.2-840.6 pg/ml) and 443.8 
pg/ml (IQR 297.0- 833.6 pg/ml) respectively. Among the 19 patients with MCP-1 
above IQR, 13 (68.4%) developed IFD compared to 16 of the 72 patients (22.2%) 
with IL-2R ≤ IQR (Pearson χ2 = 14.78, p<0.001). The Hazard or Odds ratio for IFD 
in patients with MCP-1 >IQR was 2.7 (95% CI 1.2-6.1).  Of the 24 patients with IL-
2R >IQR, 13 (54.2%) developed IFD compared to 16 of the 67 patients (23.9%) 
with serum concentrations ≤ IQR (Pearson χ2 = 7.47, p = 0.006).   The Hazard or 
Odds ratio for IFD in those with IL-2R >IQR was 2.3 (95% CI 1.1-5.1). Low IL-4 
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was a risk factor for IFD in the univariate model but this did not reach statistical 









Hazard Ratio      
(95% CI) 
P-value Hazard Ratio    
(95% CI) 
P-value  
MCP-1  4.6 (2.2-9.6) <0.001 2.7 (1.2-6.1) 0.016 
IL-2R 3.2 (1.5-6.7) 0.002 2.3 (1.1-5.1) 0.037 
IL-4  3.5 (1.7-7.3) 0.001 2.5 (0.9-7.2) 0.090 
MIP-1α 2.3 (1.1-4.8) 0.032 1.7 (0.7-4.2) 0.279 




Figure 63: Cummulative probability (incidence) of IFD by multivariate Cox 
regression model 1-survival plot according to baseline MCP-1  (left) and IL-2R 
(right) serum concentrations. 
 
 
Does the baseline cytokine concentration have any prognostic 
significance?  
Baseline cytokine serum levels were assessed as potential prognostic factors 
using the Cox regression model. A univariate model was created for each of the 
30 cytokines and the results are shown in Table 45. High IL-13 and IL-6 were 
associated with increased risk of death with risk/odds ratio of 1.8 (95% CI 1.0-3.4) 
and 2.4 (95% CI 1.3-4.3) respectively. 
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Table 45: Baseline cytokine levels as prognostic factors using univariate Cox regression 
model. In all cases cytokine levels within and below IQR were used as the indicator 
parameter   
Cytokine  Hazard Ratio (95% CI) p-value  
EGF 1.0 (0.5-2.0) 0.989 
EOTAXIN 1.0 (0.5-2.0) 0.924 
FGF 0.5 (0.2-1.2) 0.126 
GCSF 1.4 (0.7-2.6) 0.328 
GMCSF 1.3 (0.7-2.6) 0.392 
HGF 1.4 (0.6-2.8) 0.433 
IFN-α 0.7 (0.3-1.5) 0.316 
IFN-γ 1.3 (0.7-2.4) 0.466 
IL-10 0.9 (0.4-1.7) 0.679 
IL-12 1.0 (0.5-2.1) 0.913 
IL-13 1.8 (1.0-3.4) 0.048 
IL-15 1.6 (0.9-3.0) 0.125 
IL-17 1.1 (0.5-2.2) 0.849 
IL-1β 1.2 (0.6-2.3) 0.612 
IL-1RA 1.3 (0.6-2.3) 0.530 
IL-2 1.0 (0.5-2.0) 0.906 
IL-2R 1.7 (0.9-3.1) 0.108 
IL-4 0.7 (0.4-1.3) 0.256 
IL-5 0.7 (0.4-1.4) 0.323 
IL-6 2.4 (1.3-4.3) 0.004 
IL-7 1.5 (0.8-2.8) 0.211 
IL-8 1.1 (0.6-2.2) 0.714 
IP-10 1.1 (0.6-2.2) 0.741 
MCP-1 1.3 (0.7-2.5) 0.411 
MIG 1.3 (0.7-2.4) 0.458 
 225 
MIP-1α 1.1 (0.6-2.2) 0.713 
MIP-β 1.1 (0.6-2.2) 0.680 
RANTES 1.0 (0.4-2.9) 0.980 
TNF-α 0.9 (0.5-1.6) 0.745 
VEGF 1.1 (0.6-2.1) 0.792 
 
 
A multivariate model was created which included IL-6, IL-13, IL-2R,  ITU 
admission, hepatic dysfunction, bacteremia, underlying haematological diagnosis, 
and index haematological treatment (Omnibus χ2 = 61.64, d.f. = 8, p<0.001).  
Using the forward stepwise (Likelihood Ratio) method the final model predicted 
death accurately (Omnibus χ2 = 55.91, d.f. = 4, p<0.001). ITU admission, 
bacteremia, diagnosis, and index haematological treatment were independent 
prognostic factors. None of the cytokines were statistically significant factors.    
 
5.2 Follow-up cytokines  
 
A total of 412 serum follow-up samples from the 172 patients who had evaluable 
baseline serum concentrations were analysed. The median number of follow up 
cytokine samples per patient was 2 (range 2-15).  Each patient was followed up 
from no evidence of IFD through to final diagnosis every 2 weeks during inpatient 
admission. Each of these inpatient admission episodes represents an at-risk 
period for IFD as these coincide with chemotherapy, IST, transplantation or its 
complications.   Figure 64-67 shows the different cytokine panels at different time 
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points during the follow-up period.  Overall no significant differences could be 
detected between patients with IFD v no IFD. However, IL-2R overall was 
consistently higher in IFD patients and appeared to increase with longer follow up 
samples (Figure 66).  
 
 
Figure 64: Inflammatory cytokine panel at follow-up for IFD (maroon) v no IFD 
(dark blue)  
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Figure 65: Inflammatory cytokine II panel at follow-up for IFD (maroon) v no IFD 
(dark blue)  
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Figure 67: Chemokine panel at follow-up for IFD (maroon) v no IFD (dark blue)  
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Figure 68: Growth factor cytokine panel at follow-up for IFD (maroon) v no IFD 
(dark blue)  
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5.3 Genetic Polymorphisms in genes associated with cytokine biology  
A total of 127 patients (median age 53 [range 19-73] years, 76 [60%] male, 83 
allografts and 44 autografts, 111 [87%] white Europeans) were tested for 9 SNPs 
(SNP ID with amino acid change) in TLR1 (rs5743611, 239CG, T80R), TLR2 
(rs5743708, AG, Q753R), TLR3 (rs3775291, 234CT, L412F), TLR4.1 
(rs4986791, 1363CT, T399I), TLR4.2 (rs4986790, 1063AG, D299G), TLR6 
(rs5743810, 745CT, P249S), CLEC7A [dectin-1]  (rs16910526, AC, Tyr238X), 
CARD9 (rs4077515, 49499CT, N12S) , and INF-γ (rs2069705, GA, U/N). In 
addition, 62 (67%) donors of allogeneic HSCT were also tested for these SNPs.  
Among the 127 patients 25 were proven/probable IFD, 20 proven/probable IA, 15 
possible IFD, 48 not classified, and 39 had no evidence of IFD.  
 
The results are shown in Tables 46-49.  No statistically significant differences in 
any of the genetic polymorphisms were found between IFD or IA cases compared 
to those with no evidence of IFD or IA (Tables 46 and 47).  Among donors of 
allogeneic HSCT, no SNP was found in TLR 4.2 (rs4986790, AG D299G) 
among patients with IFD or IA compared to 4 (36.4%) cases of the those with no 
IFD or IA (Tables 48 and 49) and this difference was statistically significant. 
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Table 46 Association between gene polymorphisms and IFD in patients  
 IFD No IFD P value 
TLR1 N=63 
   Major allele (C/C) n=57 
   Minor allele (G/G) n=2 
   Major/Minor (C/G  n=4 

















   Major allele (G/G) n=50 
   Minor allele (A/A)n=0 
   Major/Minor G/A n=8 

















   Major allele (C/C) n=40 
   Minor allele (T/T) n=3 
   Major/Minor (C/T) n=20 

















   Major allele (C/C) n=54 
   Minor allele (T/T) n=0 
   Major/Minor (C/T) n=8 

















   Major allele (A/A) n=52 
   Minor allele (G/G) n=0 
   Major/Minor (A/G) n=8 

















   Major allele (G/G) n=29 
   Minor allele (A/A) n=6 
   Major/Minor (G/A) n=26 

















CLEC7A (dectin-1) n=61 
   Major allele (A/A) n=51 
   Minor allele (C/C) n=0 
   Major/Minor (A/C) n=10 

















   Major allele (C/C) n=15 
   Minor allele (T/T) n=13 
   Major/Minor (G/T) n=32 

















   Major allele (G/G) n=5 
   Minor allele (A/A) n=26 
   Major/Minor (G/A) n=33 


















Table 47 Association between gene polymorphisms and IA in patients   
 IA No IA P value 
TLR1 N=54 
   Major allele (C/C) n=46 
   Minor allele (G/G) n=0 
   Major/Minor (C/G  n=8 

















   Major allele (G/G) n=46 
   Minor allele (A/A)n=0 
   Major/Minor G/A n=8 

















   Major allele (C/C) n=37 
   Minor allele (T/T) n=3 
   Major/Minor (C/T) n=18 

















   Major allele (C/C) n=49 
   Minor allele (T/T) n=0 
   Major/Minor (C/T) n=8 

















   Major allele (A/A) n=49 
   Minor allele (G/G) n=0 
   Major/Minor (A/G) n=8 

















   Major allele (G/G) n=27 
   Minor allele (A/A) n=4 
   Major/Minor (G/A) n=25 

















CLEC7A (dectin-1) n=56 
   Major allele (A/A) n=46 
   Minor allele (C/C) n=0 
   Major/Minor (A/C) n=10 

















   Major allele (C/C) n=14 
   Minor allele (T/T) n=13 
   Major/Minor (G/T) n=29 

















   Major allele (G/G) n=4 
   Minor allele (A/A) n=23 
   Major/Minor (G/A) n=32 


















Table 48 Association between gene polymorphisms and IFD in donors of 
allogeneic HSCT 
 IFD No IFD P value 
TLR1 N=29 
   Major allele (C/C) n=25 
   Minor allele (G/G) n=0 
   Major/Minor (C/G  n=4 
   Any SNP (C/G or C/G) n= 4 
 















   Major allele (G/G) n=27 
   Minor allele (A/A)n=0 
   Major/Minor G/A n=1 

















   Major allele (C/C) n=14 
   Minor allele (T/T) n=1 
   Major/Minor (C/T) n=11 

















   Major allele (C/C) n=23 
   Minor allele (T/T) n=1 
   Major/Minor (C/T) n=4 

















   Major allele (A/A) n=20 
   Minor allele (G/G) n=1 
   Major/Minor (A/G) n=3 

















   Major allele (G/G) n=13 
   Minor allele (A/A) n=6 














   Any SNP (G/A or A/A) n=13    6 (40) 7 (63.6) 0.234 
CLEC7A (dectin-1)  n=31 
   Major allele (A/A) n=27 
   Minor allele (C/C) n=2 
   Major/Minor (A/C) n=2 

















   Major allele (C/C) n=12 
   Minor allele (T/T) n=3 
   Major/Minor (G/T) n=11 

















   Major allele (G/G) n=6 
   Minor allele (A/A) n=3 
   Major/Minor (G/A) n=16 


















Table 49 Association between cytokine gene polymorphisms and IA in donors of 
allogeneic HSCT 
 IA No IA P value 
TLR1 N=26 
   Major allele (C/C) n=22 
   Minor allele (G/G) n=0 
   Major/Minor (C/G  n=4 

















   Major allele (G/G) n=25 
   Minor allele (A/A)n=0 
   Major/Minor G/A n=1 

















   Major allele (C/C) n=13 
   Minor allele (T/T) n=1 
   Major/Minor (C/T) n=9 

















   Major allele (C/C) n=21 
   Minor allele (T/T) n=1 
   Major/Minor (C/T) n=4 

















   Major allele (A/A) n=18 
   Minor allele (G/G) n=1 
   Major/Minor (A/G) n=3 

















   Major allele (G/G) n=12 
   Minor allele (A/A) n=5 














   Any SNP (G/A or A/A) n=12    5 (38.5) 7 (63.6) 0.219 
CLEC7A (dectin-1) n=23 
   Major allele (A/A) n=19 
   Minor allele (C/C) n=2 
   Major/Minor (A/C) n=2 

















   Major allele (C/C) n=11 
   Minor allele (T/T) n=3 
   Major/Minor (G/T) n=10 

















   Major allele (G/G) n=5 
   Minor allele (A/A) n=3 
   Major/Minor (G/A) n=15 
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6 Discussion  
6.1  IFD incidence 
The true burden of IFD in haemato-oncology patients undergoing HSCT, intensive 
chemotherapy or IST is difficult to quantify partly due to imprecise diagnostic 
tools. In this prospective cohort study a high incidence of IFD was found among 
patients despite universal prophylaxis, a practice that has been previously shown 
to reduce the sensitivity of GM.297  Our results appear not to show this reduced 
sensitivity.  Moreover, the results show the importance of a multi-diagnostic 
approach in order to improve the diagnostic accuracy of IFD. CT scanning 
remains the centrepiece for the clinical diagnosis of IPA and the revised 
EORTC/MSG criteria10 rely on it as the sole objective clinical criterion for the 
diagnosis of IPA.  Baseline CT abnormalities, both EORTC and non-EORTC 
signs, were found in 38% of study patients and this was associated with increased 
risk of IFD.  Other important risk factors for IFD found in this study were baseline 
Karnofsky score <90, baseline cytokines MCP-1 >841 pg/ml and IL-2R >834 
pg/ml, monocytopenia >10 days, and bacteraemia.  Despite prompt antifungal 
therapy, proven/probable IFD was associated with higher mortality.  IFD was the 
second commonest cause of death accounting for 20%, with IFD-attributable 
mortality of 59%.   
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The EORTC/MSG criteria were designed for use in clinical trials but in this thesis I 
have demonstrated their applicability and usefulness in daily clinical practice.  
These criteria represent an important international consensus largely based on 
expert opinion to define a set of criteria on which clinical trials will be based.  
Although not designed or validated for routine clinical use, they are arguably the 
best diagnostic tools currently available in a very difficult area.  
 
The overall incidence rate of 21% and 18% for IFD and IA respectively in our 
cohort was higher than reported by most previous studies.88,89,210,211,333  However, 
our results are closer to post-mortem data by Chamilos et al who performed 1017 
autopsies over a 15-year period and found IFD incidence of 31%.77  The high 
incidence rate in this study may be due to several reasons.   
 
Firstly, this study was designed to examine the incidence of IFD and IA using the 
revised EORTC/MSG criteria in routine clinical setting to provide a ‘real world’ IFD 
incidence taking due cognizance of the sequential manner in which 
haematological malignancies and marrow failure syndromes are treated and thus 
provides an important insight into the patient journey from diagnosis or relapse, 
through cycles of chemotherapy, which may be followed by allogeneic HSCT and 
post-transplant complications.   Clinical trials such as Marks et al 211 or Wingard et 
al 210 typically concentrate on single treatment episodes such as allogeneic HSCT.  
Registry studies such as the Transplant-Associated Infection Surveillance 
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Network (TRANSNET) 88 are dependent on the completeness of the data 
collection from the participating centres.  Although the overall cumulative 
incidence of IFD in the TRANSNET study was low at 3.4% there was considerable 
variation between different institutions ranging from 0-21%.  The single centre 
nature of this study enabled close follow up of patients using all available tools.  
No patient was lost to follow-up.  We were able to recruit 85% of all eligible 
patients and by so doing able to provide an accurate risk assessment for this 
cohort.   
 
Secondly, long term follow-up is necessary to truly capture the at-risk period. The 
typical median follow-up period in clinical trials varies between three47,207 and six 
months 210,211.  While the majority of IFD and IA (76% and 78% respectively) in 
this cohort occurred within 3 months of their index haematological treatment 
(Figure 35) important differences exist between the subtypes of IFD (Figure 34).  
Invasive candidaemia occurred significantly earlier (median 17 days) than proven 
mould disease (median 142 days).  Notably all the Candida spp. were non-
Candida albicans, detected in allogeneic HSCT only, reflecting the changing 
epidemiology in the face of universal extended-spectrum primary prophylaxis with 
potential treatment implications.  The median time to mould IFD of 142 days 
underscores the importance of prolonged follow-up.  
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Thirdly the available diagnostic tools are crucial to the accuracy of IFD diagnosis.  
In this study, using GM or BDG alone would have underestimated the overall 
incidence of IFD by 10% and 5%, respectively.  Most clinical trials or registry 
studies only rely on GM as the diagnostic tool for probable IFD.210,211,334  These 
serodiagnostic tests such as GM, especially with the now widely used GMI cut-off 
of 0.5, and BDG have improved not only the sensitivity of IFD diagnosis but also 
provide earlier diagnosis.290,310  The approved indication for GM is in detecting 
Aspergillus antigenaemia while BDG also detects other fungal pathogens. 
However, BDG has been shown to be more sensitive than GM for diagnosing IA 
in line with our results.312  Unfortunately, it is also associated with high false 
positive rates.335  Moreover, there is less experience with BDG and in the UK few 
laboratories outside the reference laboratories offer this test routinely, not least 
due to cost considerations.  In this study only 38% of probable IFD were dually 
positive for GM and BDG (Figure 42).    
 
Finally, the gold standard, tissue diagnosis is rarely available in clinical trials and 
most studies.   Biopsy has an important role in the diagnosis of IFD.  For example, 
in this study one of the proven mould cases (morphological appearance of 
Aspergillus spp. by histology but culture negative) would have been misclassified 
as possible IFD by GM alone in the absence of the subsequent biopsy but was 
BDG positive. The 16 days interval between the CT scan and biopsy while on 
treatment dose of liposomal amphotericin B may explain the negative culture 
results in this case.  Species identification was only possible in 2 of the 7 moulds 
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(Table 19) which may be due to the delay in getting biopsy while patients are on 
antifungal therapy. However, molecular identification using PCR on biopsy 
specimens, although not currently an EORTC/MSG criteria, may facilitate species 
identification and likely to gain wider acceptance in the future.148,336  Arguably 
biopsy is more important in providing alternative diagnosis where CT scan and 
mycological tests suggest IFD. Two cases of probable and two possible IFD 
cases in this study were shown to have alternative diagnosis.   
 
Postmortem examination provides the final opportunity to secure tissue diagnosis.  
Certainly the gap between the incident rates of <10% reported in the clinical trials 
above and the post-mortem rates of 31% by Chamilos et al77 raises important 
questions about the accuracy of ante-mortem diagnosis.  Here in this thesis I have 
shown that this gap can be significantly bridged if all the diagnostic tools are 
utilized.  Post mortem (PM) examination was performed in only 5 (2.5%) patients 
reflecting the declining worldwide trend.337  Unfortunately two of these autopsies 
were performed according to UK corner’s PM rules 
(www.justice.gov.uk/whatwedo/coroners.htm), and no biopsies were taken. 
 
Autologous HSCT patients had a significantly lower incidence of IFD than 
allogeneic or chemotherapy patients similar to previous studies.72,76,88  However, 
no significant differences were found between allogeneic, chemotherapy and IST 
patients suggesting that these treatment modalities have similar levels of 
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immunosuppression and therefore risk of IFD.  However, the risk of IFD varied 
with cycles of chemotherapy.  Induction chemotherapy accounted for 76% of all 
chemotherapy-related IFD while consolidation and aplasia post consolidation 
accounted for 19% and 5%, respectively in keeping with previous observations.73 
 
Seven patients in this cohort had more than one IFD episode. Two of the patients 
had 2 episodes of probable IFD 6 months apart while the other had probable IFD 
and then proven mould NOS 13 months apart. In both of these cases the patients 
achieved radiological CR according to MSG/EORTC response criteria 321 after the 
first IFD.  Another patient had 2 possible IFD episodes 11 months apart after 
achieving CR.  The four remaining patients had possible, probable, and proven 
IFD followed by candidaemia and P. jirovecii in separate febrile neutropenic 
episodes.   
 
Bacteraemia was seen in 36% of patients and was concomitant with 
proven/probable IFD diagnosis in 9% of cases.  No difference in concomitant 
bacterial infections were found between allograft, autograft and chemotherapy 
patients (Table 15) in contrast to the findings of Bergeron et al who found this in 
48% of allogeneic HSCT recipients but only 5% in non-transplanted acute 
leukaemia patients.333  That study was a smaller study (N=55) and used a 
combination of original and revised EORTC/MSG criteria which makes 
comparisons with our study difficult.  In addition, bronchoscopy was only 
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performed in only 13 cases in our study and the concomitant infections refer to 
bacteraemia rather than presence of bacteria from BAL.  Arguably bacteraemia is 
a more significant pathology as blood is normally sterile in contrast to the 
respiratory tract.   
 
 
The low rate of bronchoscopy for diagnostic purposes was due to unavailability of 
this service in a timely fashion.  It was done only thrice a week with a waiting list 
making it difficult to fit patients in at a short notice. Positive bacteriological cultures 
from BAL were recovered from 3 patients (Table 25). Baseline pre-therapy 
bronchoscopy was not accepted by most patients.  In fact, the initial inclusion of 
this as part of the study for all transplant patients led to a significant reduction in 
recruitment.  Consequently a change of protocol was adopted for BAL to be 
optional.  
6.2 Diagnostic tests 
6.2.1 GM & BDG 
GM is an established diagnostic test for IFD.  However, the dynamics of GM 
release during infection remains unclear.287,294  It is therefore necessary to 
conduct regular surveillance monitoring during at-risk period to maximize the 
chance of early detection.  In this study 3086 tests were carried out. Surprisingly 
only 5% of these tests were positive and only 2% of these were true positives that 
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were temporally related to clinical signs of proven/probable IFD while the rest 
were unclassified.  The false positive rate among proven/probable IFD cases was 
18%.  Using proven IA and BDG-only positive probable IFD as true IFD, the 
sensitivity, specificity, PPV, and NPV were 54%, 71%, 82%, and 39%, 
respectively.  The wide variation in the performance of GM even in studies using 
GMI cut-off of 0.5 is well recognized.338  The lack of tissue diagnosis, the true gold 
standard, makes it difficult to define the disease state.  The low sensitivity in this 
study may reflect the inclusion of probable IFD with proven disease.  Proven 
disease in this study was small.  
 
The revised EORTC/MSG criteria recognizes positive GM results that bear 
temporal relationship with clinical and host factors but does not specify the 
minimum number of positive results in order to fulfill the diagnostic criteria for 
probable IFD.10  Eight of the 22 cases (36%) who had positive GM in this study 
had positive results more than once (Figure 41). Of these 8 cases 6 died due to 
IPA (5) or relapsed AML with active IPA (1). The two cases that survived became 
GM negative and achieved a complete radiological response suggesting that 
persistent GM positivity is associated with poor prognosis in as previously 
reported.92,296   
6.2.2 PCR & LFD 
Lack of standardization remains the main barrier to molecular diagnostic tests 
such as PCR.  The consensus PCR is an attempt to achieve international 
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standardization.317,339  It was performed on 323 EDTA samples from 52 patients 
with proven/probable IFD and a selection of possible and no evidence IFD cases.  
Using a Ct cut off of <50, 19 (3%) samples were positive. However, the Ct of 
these positive samples ranged from 36-49 suggesting weak-moderate positivity.  
Using the consensus PCR as mycological evidence it would have truly identified 3 
(6%) probable IFD.  All these 3 cases were also GM positive earlier or at the 
same time as PCR and therefore PCR offers no additional advantage over GM.  
Serum PCR appears to have better sensitivity and PPV, the key diagnostic 
variables in this cohort, than the EDTA whole blood method (Table 28).    
 
The immunochromatographic LFD is a new serodiagnostic tool for IA not yet 
validated for use in clinical practice.  973 samples from patients with full EORTC 
classification spectrum from proven to no evidence of IA were tested (Table 24). 
The sensitivity of this test is poor (9%) for detecting proven mould and GM-
positive probable IA (Table 25).  This may be partly due to the narrow antigen-
specificity, derived from the hyphael tip of growing Aspergillus spp.313, of this test.  
However, it was negative in all 5 sera from proven A. fumigatus patients. It is also 
worth noting that the LFD is a qualitative test.  Of the 35 positive samples 10 were 
strongly positive (from 2 patients with proven mould NOS, and probable IA), 11 
were moderately positive (from 3 patients: 1 mould NOS and 2 probable IFD), and 
14 were weak positive (6 patients with proven mould, probable, and possible IFD). 
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The narrow specificity of the LFD may be a disadvantage in clinical practice where 
the primary focus is in identifying pathogenic moulds.  The actual species may 
only be relevant where differing antifungal sensitivities of the different organisms 
may be an issue.  This requires identification by mycological cultures and 
susceptibility testing.336   Only 9% of cases were identified by both GM and LFD 
(Figure 43).  This was rather surprising given LFD specificity for Aspergillus spp.  
On the contrary there was a better relationship between BDG, a panfungal assay, 
and LFD (Figure 44). In fact, all the patients identified by LFD as true probable 
IFD were also detected by BDG suggesting that LFD has no additional diagnostic 
advantage over BDG.   
6.2.3 Radiology 
CT scanning remains the centrepiece for the clinical diagnosis of IPA and the 
revised EORTC/MSG criteria rely on it as the sole objective clinical criterion for 
the diagnosis of IPA.10  Baseline CT abnormalities of EORTC and non-EORTC 
signs were found in 38% of patients.  These abnormalities were associated with 
increased risk of IPA in patients with EORTC signs. Baseline CT scanning was 
performed pre-therapy with no signs of sepsis, vividly illustrated by two case 
histories in Figures 51 and 55. Patients with baseline abnormalities were similar in 
demographic and clinical characteristics to those with normal scans.  CRP and 
neutrophil counts did not differ not only between these 2 groups but also between 
those with EORTC and non-EORTC signs. No significant differences were found 
between patients who developed proven/probable IFD compared to those who did 
not in patient with EORTC signs in the distribution, morphology and location of 
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signs.  The demonstration of baseline abnormalities in non- neutropenic patients 
with no signs of sepsis is intriguing and to our knowledge not previously described 
in a prospective study among adult haematology patients.   A retrospective study 
in children found abnormal chest CT scan in 44% of children prior to undergoing 
HSCT.340 
 
Fever-driven management strategies, such as ours, depend on failure to respond 
to broad-spectrum antibacterial therapy for ≥96h to diagnose IA. Fever is not 
currently recognised either as a host or clinical factor in the current revised 
definitions.10  However, it remains the centrepiece for empiric therapy, widely 
endorsed by international guidelines for treatment of IA.4,11  Patients who are 
otherwise well with no fever and abnormal CT findings present clinical challenge 
for the treating physician.  Positive GM or BDG before the onset of fever is well 
recognized242,341 but abnormal CT preceding other clinical signs of infection and 
mycological evidence of IA is not.  
 
In a retrospective study Nucci et al described a group of patients with non-EORTC 
signs who on subsequent scanning exhibited the typical EORTC signs after a 
more prolonged neutropenic phase.342  They suggested that the non-EORTC 
signs may be an earlier clinical manifestation of IPA before the onset of 
neutropenia. In this thesis I found no significant differences in baseline neutrophil, 
lymphocyte, or monocyte counts suggesting that this did not influence the 
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prevalence or the nature of the lesions in this study (Table 36).  Moreover, time to 
first febrile episode and IA was not statistically significantly different. 
 
IFD is a disease of the immunocompromised, often due to underlying 
haematological malignancy, and its often complex treatment regimens and many 
risk factors have been described.49 Abnormal baseline CT scan adds to this list 
reflecting the significance of damaged lungs in the pathogenesis of IPA.  Indeed 
the respiratory tract is in constant contact with Aspergillus conidia, saprophytic 
organisms which are able to exploit the immunocompromised environment 
proffered by the failure of the immune system.343  Neutrophils and macrophages 
in concert with intact respiratory mucosa provide the primary effector cells against 
invasive disease.51,95,97  It is likely that pre-existing lung abnormalities may provide 
the type of ecological milieu conducive to fungal proliferation.   
 
Nodules are by far the commonest type of lesions seen in the diagnostic scans in 
this study in keeping with previous observations in acute angioinvasive IPA.149,344  
The halo sign was seen in about 44% of IPA patients.  Nearly 50% of lesions were 
bilateral reflecting the multifocal nature of IPA.  All but one of the patients with 
baseline EORTC-signs at time of diagnosis of IPA had the diagnostic lesions in 
the same lobe, while three quarters occurred in a different lobe of the same lung 
suggesting angiogenic spread from the original focus.  In contrast diagnostic 
lesions in patients with non-EORTC signs were predominantly (78%) contralateral 
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but significant proportion (44%) occurred within one lung.  Eight of these 9 lesions 
were nodules reflecting the general trend.  The relatively fewer cavities/air 
crescent signs in this prospective study are in keeping with early scanning policy 
and consistent with previous studies.149,344 
 
Despite the good clinical performance of CT scan lesions, especially EORTC-
signs performed early in the process to correctly identify IPA cases, CT remains 
observer-dependent and non-specific.47,345  It is therefore imperative that imaging 
is used in conjunction with other tests such as GM, BDG and biopsy whenever 
possible.  The agreement between the 2 radiologists was good (Kappa >0.69) for 
EORTC signs but less so for non-EORTC ones.  It is worth noting that the 
observers in this study were experienced radiologists with expertise in IPA. Even 
so 4 (8%) of the diagnostic scans with EORTC signs would have been 
misclassified using a single chest radiologist.  
 
The hallmark of angioinvasive aspergillosis is coagulative necrosis with 
surrounding area of haemaorrhage due to thrombosis of the affected vessels and 
effective sequestration of the infected area.53,143,145 The hypothesis for contrast 
studies was that this process is relatively avascular and therefore should have no 
or reduced enhancement in contrast to malignant lung nodules where 
angiogenesis is a key pathogenic mechanism.277  Twenty-seven patients were 
studied and the peak enhancement post contrast injection for both the 
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background lung and the lesions of interest was at 2-3 min.  No significant 
differences were found between patients with proven/probable IPA and those with 
consolidation (Table 40).  This was disappointing but may be due to two main 
reasons. 
 
The first reason is that the number of cases was small which makes meaningful 
comparison difficult.  Secondly, the comparator arm to proven/probable IFD was 
consolidation which may not be appropriate as IPA may present with 
consolidation.149,346,347  Moreover, 4 of the 6 patients with consolidation were also 
GM-positive, which is considered by some authors as probable IFD.333,342   This is 
a fundamental point as, unlike lung tumours which may be benign or malignant, 
there is no clear cut comparator arm in lung infection except biopsy proven 
alternative sources of sepsis with no evidence of IPA.  Nonetheless, IPA nodules 
enhance with contrast.  This would suggest that there is no decrease in blood flow 
to the area of interest even with thrombosis of some of the vessels. Perhaps a 
compensatory hyperaemia which occurs as normal inflammatory response is 
responsible for this enhancement. 
 
Systematic CT scanning is not without its own drawbacks. The average number of 
scans/patient in this study was 2 but a typical febrile patient may have 4 or more. 
This undoubtedly involves more radiation and there are growing concerns about 
the risk of future secondary malignancies.348  Equally the importance of CT 
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scanning in the diagnosis of IPA is not in doubt. In this study steps were taken to 
reduce radiation exposure by using low-dose scanning techniques which would 
not compromise diagnostic accuracy.349 
 
Practical difficulties remain in assessing response to antifungal therapy in routine 
clinical practice and studies thereof such as this. Of the 48 diagnostic scans only 
17 (35%) and 13 (27%) patients had follow-up 1 and 2 respectively.  Early 
discharge after engraftment and resolution of fever contributed to 29% of failure to 
objectively assess response to antifungal therapy.  Radiological CR was rare in 
this cohort; achieved only in 1 of 17 follow-up 1 and 2 of 13 follow-up 2 scans. 
Progression of radiological lesions was seen in 4 patients at follow-up 1: 2 
deteriorated further and died of IPA, while the other 2 achieved CR and PR, 
analogous to the previously reported worsening of radiological lesions around 2 
weeks in the face of clinical improvement.344 
6.2.4 Biopsy 
CT scanning is a crucial diagnostic tool for detection of IFD. However, CT lacks 
specificity even for the highly suggestive nodule with halo sign.350,351 The 
specificity is improved by serodiagnostic tests such as GM and BDG but obtaining 
tissue diagnosis is the gold-standard for the diagnosis of IFD.  Previous studies on 
tissue diagnosis were largely retrospective and small.  Kim et al performed a 
retrospective analysis on 32 cases with haematological malignancies with CT 
features suggestive of IFD on whom they performed open lung biopsies.268  They 
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found 17 cases of histologically proven IFD among their study population (53%). 
Complication rates in this study were said to be minimal with no mortality.  Nosari 
et al used the percutaneous CT-guided approach in a retrospective study 
involving 17 cases in 5 years and found Aspergillus spp. in 8 and mucorales in 4 
cases. 278  
 
In this study 38 biopsies involving 60% of eligible patients were performed.  In the 
40% of cases where biopsy was not carried out, this was mainly due to 
interference with chemotherapy/transplant schedules or lack of theatre time when 
needed.  Physician reluctance to biopsy neutropenic and thrombocytopenic 
patients also played a part. Biopsy results were useful in 14 cases (37%) where 
the diagnosis was proven (group A) or an alternative diagnosis was made (Group 
B). The quality or adequacy of the samples obtained from the biopsy was the key 
factor that determined the usefulness of the results. In groups A and B all samples 
were adequate compared to 33% in group C (P<0.001). The inadequate biopsies 
were all lung biopsies obtained by VATS (14), CT-guided (1) and transbronchial 
(1) approaches. The VATS approach is minimally invasive but accurate 
localisation of the lesion may be an important limitation which may give false 
negative or inconclusive results.  Methylene blue tattooing did not improve this, 
although the number of cases where this was performed was small.  
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Tissue biopsies are not only important in the diagnosis of IFD but also for 
treatment based on the correct species identification and susceptibility testing.336  
The number of cases with proven diagnosis in this study was surprisingly low 
given the highly selective nature of susceptible patients with clinical features 
compatible with IFD who had GM and BDG surveillance performed twice weekly.  
The sensitivity of biopsy was low at 35% in accordance with previous studies.352  
Only two of the seven proven cases were culture positive.   Earlier biopsy may 
improve culture positivity.  Molecular detection techniques such as PCR are not 
currently utilised in species identification in the revised EORTC/MSG criteria but 
they are likely to be used in the future.327,336  Four of the five proven IFD biopsies 
in this study were positive by PCR and in two of these species identification was 
possible by nuclear ribosomal repeat sequencing suggesting a complementary 
role with culture. 
 
It can be argued that biopsy is more important in providing alternative diagnosis 
where CT scan and mycological tests suggest IFD. Two cases of probable and 
two possible IFD cases in this study were shown to have alternative diagnosis.  
The 15 days median interval between probable/possible IFD and proven cases in 
this study reflects challenges such as physician reluctance to biopsy neutropenic, 
thrombocytopenic patients, and timely availability of theatre slots.  Species 
identification was only possible in 2 of the 7 moulds which may be due to the 
delay in getting biopsy while patients are on antifungal therapy.   
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The adverse events from biopsy were reassuringly low. This is an overriding 
concern for patients and physicians looking after them. Surgical techniques such 
as VATS are safe and where available should be used as part of the diagnostic 
armamentarium. The biggest challenge facing such techniques is whether 
adequate samples can be obtained. 
6.2.5 Antifungals-prophylaxis, treatment and role of TDM 
Universal prophylaxis initiated at admission was the local policy and the agent of 
choice was based on the perceived risk of neutropenic sepsis. There was 
considerable alteration thereafter based on the number and frequency of 
neutropenic sepsis and response to antimicrobial therapy. It therefore, becomes 
very difficult to assign a particular agent to break-through IFD. The agent that a 
particular patient was receiving within 2 weeks of EORTC classification may be a 
useful surrogate marker for this. Based on these the break-through 
proven/probable IFD was 22%, 17%, and 13% for posaconazole, itraconazole, 
and fluconazole, respectively.  As these antifungal prophylactic drugs were used 
in different risk strata, these rates are not directly comparable.  It is also worth 
noting that about 75% of posaconazole and voriconazole were not given 
according to protocol (Table 21). 
 
Antifungal therapy was received by 50% of study patients during the course of the 
study. Although this may seem excessive in a cohort with proven/probable IFD 
 259 
incidence of 21%, a closer look at patients who had therapy for two weeks or 
more revealed a figure of 33% which bears close resemblance to the autopsy 
data.77 Moreover, the combined incidence of proven, probable, and possible IFD 
was 34%.  Possible IFD with antibacterial-refractory neutropenic sepsis is usually 
treated in the same way as proven/probable IFD in clinical practice. 
 
As azoles form the core of antifungal prophylaxis in our cohort, empiric therapy is 
usually with polyene (liposomal amphotericin B) or echinocandins (caspofungin) in 
accordance with ECIL-3 guidelines on antifungals.11  Azole prophylaxis followed 
by azole treatment was rare in this cohort (9%).   
 
The role of therapeutic drug monitoring (TDM) was assessed by a parallel study 
firstly to develop this capacity locally and secondly to use this service to guide 
clinical care.353 For itraconazole, a target serum itraconazole concentration of 0.5 
mg/L is recommended for effective prophylaxis.354,355  A large inter-patient 
variability in the measured serum itraconazole and hydroxyitraconazole 
concentrations (0.02-5.31 mg/L and 0.02-4.42 mg/L for itraconazole and 
hydroxyitraconazole, respectively) was found.  Moreover, 70 of the 163 samples 
(43%) had serum concentrations below 0.5 mg/l.356 
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Perhaps TDM is more important for posaconazole as its pharmacokinetics is 
affected by fatty food intake and proton pump inhibitors, which are commonly 
prescribed in haematology patients undergoing chemotherapy or HSCT.355  Of the 
57 samples from patients prescribed posaconazole, 30 (53 %) had pre-dose 
serum concentrations below the threshold concentration of 0.5 mg/L suggested by 
Andes et al.355  and 43 (75 %) had concentrations below the FDA-recommended 
minimum concentration of 0.7 mg/L 
(http://www.fda.gov/cder/foi/nda/2006/022003s000_NoxafilTOC.htm).356  This is in 
keeping with previous observations,357,358 highlighting the difficulty in achieving 
serum concentrations considered appropriate for antifungal activity in most 
patients.  This is quite worrying and may partly account for the high incidence of 
IFD in this cohort.  Subsequently attempts have been made to ensure adequate 
concomitant fatty food intake for patients on posaconazole.  
6.3 Cytokines 
Predicting IFD prior to chemotherapy or HSCT can allow a more stratified 
antifungal prophylaxis and treatment.  Baseline serum cytokine measurement, 
made possible by the availability of bead technology, provides useful measure of 
immune function.  Four serum cytokines, MCP-1, MIP-1α, IL-15, and IL-2R were 
found to be significantly higher, while IL-4 was significantly lower in patients who 
developed proven/probable IFD compared to those with no evidence of IFD.  A 
smaller IA cohort showed higher HGF, MCP-1 and RANTES in proven/probable 
IA compared to no IA.   
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Cytokines and chemokines, produced by an array of immune cells, form an 
important component of host defenses against infection by various pathogens.  
Typically their actions are brief and self-limited with inhibitory feedback 
mechanisms to turn down their responses.132  The presence of significant 
differences between those who develop IFD and those who remain disease free 
during the course of significant, often prolonged, immunosuppressive therapy 
would suggest that these baseline cytokines signify an important immune 
dysregulation or that they might be a marker for occult infection.  The respiratory 
tract is in constant contact with Aspergillus conidia, which exploit the 
immunocompromised environment proffered by the failure of the immune 
system.343  Neutrophils and macrophages in concert with intact respiratory 
mucosa provide the primary effector cells against invasive disease.51,95,97  MCP-1 
(CCL2), MIP-1α (CCL3), and RANTES (CCL5) are important chemotactic 
molecules for neutrophils, monocytes, and dendritic cells.132,359,360  If these are 
markers of occult infection then they represent pretty early biomarkers preceding 
fever, CRP or indeed IL-6 rise. 
 
IL-4 is a Th2 cytokine and high levels are associated with adverse outcomes in 
murine models of IFD.361  The lower levels in proven/probable IFD may be a 
marker of ongoing Th1 inflammatory reaction.  IL-15 and IL-2 are important 
immunoregulartory molecules of the innate immune system and share two of the 
components of their receptor molecules, IL-2Rβ, IL-2Rγ.132,361  High levels at 
baseline is likely to be a marker for occult infection. 
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It is important to note that 31 patients were excluded from this baseline analysis 
who either had fever or their chemotherapy given prior to sample collection.  In 
doing so major causes of inflammatory were avoided. Care was taken to transport 
the samples on ice and ensure sera were separated immediately and frozen at -
800C until ready for analysis.   
 
Follow-up cytokine assays were performed on 412 samples with a median of 2 
samples per patient collected on a fortnightly basis.  No significant differences 
were found between patients with proven/probable and no evidence of IFD.  
Could it be that a more frequent sampling is required to clearly see a pattern of 
cytokines that differentiate between IFD v no evidence of IFD?  It may also reflect 
the fact that cytokines are mainly an innate immune response and less of an 
adaptive immune system and as such lack specificity for fungal infection at a time 
when patients are having a massive inflammatory challenge from chemotherapy, 
donor cell infusion, as well as fever from non-IFD cases.   
 
Chai et al investigated 119 patients with IA from the Global Comparative 
Aspergillosis Study47 and found high baseline IL-8 and persistently elevated IL-6 
and CRP as poor prognostic factors.362  Important differences exist between that 
study and the current one.  Firstly the Global Comparative Aspergillosis Study 
was a clinical trial comparing voriconazole v amphotericin B and the case 
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definitions for proven and probable IA were based on earlier EORTC/MSG 2002 
definitions9. Secondly there was no comparator arm in that trial as the study entry 
criteria was proven/probable IA.  It is therefore difficult to assign the cytokine 
dynamics to IA.  Thirdly the baseline values in that study refer to IA prior to 
initiation of antifungal therapy which is contrast to true baseline values in the 
current study where the patients showed no clinical signs of sepsis or 
chemotherapy. Finally, the persistently high CRP and IL-6 after initiation of 
antifungal therapy obviously mean that the affected patients are not responding to 
therapy. It is interesting that there was no mention of fever in the Chai et al study, 
a well-known clinical indicator of sepsis which correlates with CRP.  In this thesis 
duration of fever was found to correlate with magnitude of CRP (Figure 11).  
Persistent fever despite antifungals or antibacterial for that matter is an indication 
to alter therapy especially if this was the case for a week or more as in the Chai et 
al study362.  This is especially relevant in a disease which is difficult to diagnose 
and the majority of patients were probable cases some of which would be 
unclassified on the revised EORTC/MSG definitions. 
6.4 Risk factors 
This cohort was selected on basis of traditional risk factors38,49,174 especially 
prolonged neutropenia.  Severe neutropenia <0.5x109/L was seen in 93% of 
patients and 59% had severe neutropenia for 10 days or more.  It is therefore, not 
surprising that no significant association was found between neutropenia and IFD 
on multivariate analysis.  Abnormal baseline CT scan, prolonged monocytopenia, 
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bacteraemia, poor performance status and high serum MCP-1 and IL-2R are 
independent risk factors described here.   
 
Abnormal baseline CT reflects the significance of deranged pulmonary milieu in 
the pathogenesis of IPA.   Other baseline independent risk factors include high 
MCP-1, high IL-2R, and Karnofsky score of less than 90 reflecting the importance 
of pre-therapy clinical status as risk factors for IFD. High MCP-1 and IL-2R are 
likely to reflect occult infection.  Because no normal ranges exist for the normal 
population for these cytokines, the interquartile ranges were used instead.  High 
levels refer to levels higher than 419 pg/ml and 841 pg/ml for MCP-1 and IL-2R, 
respectively. 
 
Karnofsky score was first described by Karnofsky and Buchenal in 1949 as a tool 
to assess a patient’s ability to survive chemotherapy.363  Since then it is has been 
widely used to assess risk of death in cancer patients with fungaemia364, risk 
factor for bacteraemia365,366, and prognosis in BMT367,368. It is a semi-quantitative 
measure of patients’ clinical state but remains somewhat subjective as are most 
clinical assessments.  A more specific performance score for allograft patients, 
PAM score, was not found to be a significant risk factor IFD in this study. 
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Prolonged severe monocytopenia, especially in concert with neutropenia renders 
the affected patients bereft of the necessary phagocytic function required to 
combat inhaled spores and thus prevent invasive disease. Monocytopenia has 
been noted in previous studies as a risk factor for IFD.35    
 
It is not infrequent for bacterial infection to coexist with IFD.81,333  The association 
is not surprising given the underlying immune paresis.  It is vitally important to 
demonstrate this as it requires dual antibacterial and antifungal therapy.  To my 
knowledge bacteraemia has not been previously demonstrated as an independent 
risk factor for IFD. The infection does not have to be concomitant and the 
organisms may be Gram negative or positive.  It is likely that bacteraemia anytime 
during the at-risk period is a surrogate marker for the degree of 
immunodeficiency.  Alternatively there be could a more fundamental biological 
interaction between bacteraemia and the immune system which facilitates IFD. 
 
Previous studies have found GVHD and steroids as risk factors for IFD.30,35,38,40,50  
In contrast to earlier studies there was only a trend in the multivariate model for 
GVHD as a risk factor (HR 2.45; 95% CI 0.97-6.24; P=0.059) in this study.   This 
is likely to be due to smaller sample size in this study (N=99 allogeneic HSCT) but 
more importantly GVHD was seen in 37% of allografts but only 9% had grade III-
IV acute GVHD and 7% had extensive GVHD.  This is much lower than the case 
in the above studies and reflects the differences in transplantation practices.  
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Reduced intensity conditioning with T-depletion, using anti-thymocyte globulin 
(ATG) or alemtuzumab were used in our allograft protocols.  Alemtuzumab is 
associated with profound and prolonged immune suppression.30  On the other 
hand Alemtuzumab or ATG significantly reduces the risk of severe form of GVHD, 
an important risk factor for IFD.49  Consequently steroids were only sued in 26% 
of transplant patients and therefore not surprising that it was not found to be a 
significant independent risk factor. 
 
Genetic polymorphisms involving genes of the innate immune system are 
important risk factors for IFD and there is a growing list of these candidate 
genes.62,66,69,121,122,324  The selection of 9 genes to examine for this susceptibility 
was based on these studies. No statistically significant associations were found 
between these previously described SNPs and susceptibility to IFD in our cohort.  
The reason for this is likely to be due to sample size and the small number of IFD 
cases in the cohort. 
 
The number of IFD cases in our cohort was quite small (25 proven/probable 
cases) which makes the detection of these associations statistically challenging.   
The cases examined were based on the allogeneic and autologous HSCT 
patients whose DNA samples were collected for chimerism studies in the 
allogeneic HSCT programme in our institution.  Our study was not initially set up 
to examine this relationship and DNA samples were not stored for this purpose. 
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Similarly the donor samples were provided from the chimerism studies and were 
not available or sufficient in all cases.   
 
6.5 OS and Prognostic factors 
In this cohort 64 patients died at a median follow-up of 18.5 months (95% CI 17.3-
19.8). Relapse of the primary haematological malignancy was the commonest 
cause of death followed by IFD which accounted for 20% of all deaths.  However, 
assigning a cause of death may not be straight forward as there may be 
competing causes such as relapse and IFD.  No general consensus guidelines 
exist but for myeloablative allogeneic HSCT patients an American Society for 
Blood and Marrow Transplantation (ASBMT) has agreed on a scheme that helps 
consistency of reporting.369  Although this is followed here it must be recognized 
that there is an inherent bias towards relapse and GVHD at the expense of 
infection; sepsis is only accepted as cause of death in the absence of relapse and 
active GVHD.  
 
Among the 40 IFD patients in the study 22 (55%) died at a median of 25 days 
from IFD diagnosis; 13 died due to IFD in remission of hematological malignancy 
and no GVHD and therefore attributable mortality of 59% consistent with previous 
studies.46,90,91  However, 5 of the 6 relapse cases had active IFD and therefore the 
true attributable mortality rate in this cohort was 82% (18/22).  The adverse 
outcome for IFD cases was not due to late diagnosis or delayed initiation of 
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therapy as antifungals were commenced with clinical suspicion of IFD while 
investigations were carried out; a hybrid empiric and pre-emptive or diagnostic-
driven approach242.  Although the outcome for IFD patients has been improving 
steadily in the last 30 years8 this study has high-lighted the fact that for patients 
with proven/probable IFD using the current revised EORTC/MSG criteria the 
prognosis remains poor. This is likely due to advance disease in this category 
exemplified by the fact that all the proven mould cases in this cohort died, 
although one died from PTLD rather than IPA.  It is also worth noting that the 
changes in the diagnostic criteria for IFD over time make it difficult to compare 
older studies to more recent ones such as this one.  
 
Interestingly patients with possible IFD or not classified had intermediate outcome 
which may reflect the heterogeneous nature of this group. The challenge is to 
separate out true IFD cases from those with other non-IFD pathologies or false 
positive mycological test using better diagnostic tools. In practice this is a large 
group compared to proven/probable IFD.370  Possible IFD and those unclassified 
on the basis of non-EORTC radiological signs with no alternative diagnosis are in 
practice treated as proven/probable IFD with antifungals and some recent studies 
consider these as bone fide IFD.333,342  The intermediate outcome of these cases 
suggests that they may represent an earlier form of IFD. If so what then 
determines progression to full blown proven/probable disease?  In this cohort it 
was certainly not due to delayed institution of antifungal therapy. 
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In the multivariate model the independent factors associated with mortality for the 
whole cohort were ITU admission, having allogeneic HSCT/chemotherapy/IST v 
autologous HSCT, AML/MDS v other diagnosis, bacteraemia, and hepatic 
dysfunction.  These are collaborated from previous studies.46,90,93  Excluding the 
possible and unclassified cases ITU admission, allogeneic 
HSCT/chemotherapy/IST v autograft, proven/probable IFD, and renal impairment 
with creatinine >240 were significant independent factors.  Persistently positive 
GM results were only significant in the univariate model in line with Koo et al92 but 
not in the multivariate analysis probably due to small numbers. 
 
6.6 Case discussion 
Case 2: This 61 year old lady had allogeneic HSCT from unrelated donor with 
DQB1 mismatch for poor risk AML and had several important post-transplant 
complications. Her baseline CT showed tree-in-bud appearances in the RLL and 
was clinically well (afebrile, CRP <5 mg/L, Karnofsky score 90, PAM score 29, Hb 
12.1, Neutrophils 6, platelets 391, marrow was in CR). However, within 24 hours 
of starting conditioning chemotherapy she became febrile and was started on 
broad-spectrum antibiotics. This was initially thought to be due to ‘campath fever’ 
commonly seen following administration of first dose of alemtuxumab and may be 
related to cytokine storm or acute phase reaction from the drug.371  Her 
temperature settled with antibiotics and culture results were negative.  
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Her diagnostic scan was done 22 days after admission into study and it showed 
GGO.  A subsequent non-study clinical scan a week later showed that the RUL 
GGO had progressed to consolidation. GM and BDG remained negative.  Second 
diagnostic scan 3 months after the first diagnostic scan was reported as: 
‘There are new tiny (<2mm) focal opacities in the right upper lobe…..Findings are 
non-specific but not typical for established angioinvasive aspergillosis’  
Subsequent review by study radiologists confirms nodules in RML.  GM and BDG 
were positive during 7 days prior to CT scan.  This highlights the importance of 
chest radiologist review. 
 
Her antifungal management (Figure 13) deserves some comments. She was on 
antifungals for a total of 272 days of her 296 study days costing £29,711.60.  The 
rationale for changing antifungals was not clear especially from posaconazole to 
itraconazole. This was an outpatient decision and may be due long duration of 
posaconazole (120 days!).  However, she still had ongoing issues with recurrent 
CMV reactivations, cytopenias, active extensive GVHD of skin and gut and on 
immunosuppressive therapy.  TDM on 2 occasions (retrospectively) showed that 
her serum posaconazole and itraconazole levels were sub-therapeutic at 0.2 mg/L 
and 0.18 mg/L, respectively.  TDM should form a crucial component of such 
patients in the future but at the time of the study this was not available locally. 
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The difficulty in proving IFD diagnosis is exemplified in this case.  The interval 
between probable and proven IFD was 168 days. She became a proven case at 
post mortem.  The PE, ongoing diarrhea, chest pain, and reduced conscious level 
on her last admission before death were not connected to IFD ante-mortem. Only 
post mortem examination could have proven this case and the extent of the 
disease was colossal. Unfortunately, the post mortem samples were culture 
negative and tissue PCR failed and she remained a proven disseminated mould 
disease NOS. 
 
Case 7: This was another case of disseminated aspergillosis with biopsy proven 
cardiac involvement post allograft.  Her baseline CT chest showed GGO but her 
immediate post- transplant period was relatively straightforward.  Prior to her 
allograft she was treated with alemtuxumab for her p53 deleted CLL.   Her 
allograft was complicated by gut GVHD, CMV and adenovirus reactivations, 
prolonged cytopenia, and recurrent bacteraemias.  In the late post-transplant 
phase she was admitted in her local hospital with recurrent fevers and developed 
new cardiac murmurs and was subsequently diagnosed with A. fumigatus 
endocarditis 8.6 months post allograft.  She also had pulmonary CT signs 
(nodules) and space occupying lesion in the brain suggestive of IA. It is worth 
noting that she had fully sensitive A. fumigatus and despite combination 
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antifungals she succumbed to her disease. The total antifungal cost was 
£117,279.20 (£3,421.96 on prophylaxis and £113,857.20 on treatment). 
 
Prolonged follow-up is necessary to capture this type of long term events. Most of 
this took place in her local hospital and was admitted in ITU in a neighbouring 
trust.  Alemtuzumab is associated with profound and prolonged immune 
suppression and may explain the longer at risk period in this patient.30    
 
Case 8: This was the only case of proven fusariosis in our cohort and indeed the 
only case identified among the King’s haematology patients in the last 20 years.  
She had two primary graft failures from different donors and unsurprisingly was 
persistently pancytopenia for a prolonged period of time.  Fusariosis is associated 
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7 Summary & Conclusions 
 The incidence of IFD by using a comprehensive diagnostic approach is 
higher than reported in most studies in the literature.  This approach bears 
closer resemblance to post mortem data.  In order to demonstrate the true 
incidence of IFD two things are required.  The first is the use of all available 
tools that are recognized for the diagnosis of IFD.  Relying on a single 
mycological test such as GM can lead to misleadingly low rates.  Secondly, 
prolonged follow-up is necessary to truly capture the at-risk period.   
 The cumulative incidence of IFD at 3, 6, 12, and 24 months was 16, 19, 21, 
and 21% respectively (Figure 35). The cumulative incidence of IA at 3, 6, 
12, and 24 months was 14, 16, 17 and 18% respectively.  The proven 
cases were A. fumigatus (2), moulds NOS (5), Fusarium spp. (1), 
Pneumocystis jiroveci (1), non-Candida albicans spp. (5). The median time 
from index treatment to onset of IFD was 142, 17, and 41 days for proven 
mould disease, candidiasis and probable IFD, respectively. 
 The index treatment, identified as the treatment during which IFD occurred, 
was chemotherapy (21: induction 16, consolidation 4, aplasia post 
consolidation 1), allogeneic HSCT (17), IST (4: pre-IST aplasia 2, IST 2) 
and autologous HSCT (2). Allograft/chemotherapy/IST were associated 
with the highest risk of IFD with treatment-specific incidences of 16, 14, 
and 12%, respectively.  Autograft was associated with low risk of IFD (3%). 
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 Bacteraemia was seen in 74 (36%) of this cohort. These organisms were 
Gram positive cocci (27; 36%), Gram negative rods (25; 34%), mixed (20; 
27%) and non-tuberculous mycobacterial spp (2; 3%). Concomitant 
bacteraemia was seen in 18 (9%) of the study patients. 
 Antifungal therapy was given to 101 (50%) patients during the course of the 
study emperically. The median duration of treatment was 32 days 
(interquartile range 8-80 days; range 1-456 days). The percentage of 
patients who were treated for 2 weeks or more (33%) was similar to the 
combined incidence of proven/probable/possible IFD (70/209; 33%) and 
also to autopsy data77. 
 The sensitivity, specificity, PPV, and NPV for IFD detection by GM assay 
was 54, 71, 82, and 39% respectively.  The coresponding values for BDG 
assay were 79, 55, 83, and 49%; whole blood PCR were 15, 97, 75, and 
73%; serum PCR were 35, 96, 94, and 40%; LFD 9, 98, 44, and 88%, 
respectively. The sensitivity of biopsy was 35%. The proportion of caes 
truly  identified by both GM and BDG was 38%, GM and LFD 9%, BDG and 
LFD 22%. Serum and blood PCR were dually positive in 24% of cases of 
proven/proable IFD.  No single test was able to detect all the cases but 
combining the results from BDG and GM assays seemed to offer the best 
biomarker combination. 
 Biopsy is feasible and safe during intensive chemotherapy or HSCT. 
Tissue diagnosis remains the gold standard for the correct diagnosis or 
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exclusion of IFD. Given the safety of the procedure, clinicians should 
perform this more often in patients who are fit for biopsy once their pre-
operative parameters are optimised.  However, better localization 
techniques are required to obtain adequate samples and therefore avoid 
non-specific results.  
 Baseline CT abnormalities were detected in 38% of patients which 
preceded neutropenia and signs and symptoms of sepsis and ahead of 
positive mycological results.  These abnormalities, especially EORTC-signs 
(HR 4.3; 95% CI 1.9-9.8; P<0.001), were associated with significantly 
increased risk of IPA in a multivariate model. This should form part of the 
initial screening before the initiation of chemotherapy or HSCT. 
 Other independent risk factors were baseline MCP-1 >841 pg/ml (HR 2.7; 
95% CI 1.2-6.1; P=0.016), baseline IL-2R >834 pg/ml (HR 2.3; 95% CI 1.1-
5.1; P=0.037), baseline Karnofsky score <90 (HR 2.1; 95% CI 1.1-4.2; 
P=0.034),  monocytopenia (<0.1 x109/L) for >10 days (HR 2.6; 95% CI 1.3-
5.4; P=0.009), and bacteraemia during the treatment period (HR 2.5; 95% 
CI 1.2-5.0; P=0.013). 
 No statistically significant differences in follow-up cytokines were found 
between proven/probable IFD and those with no evidence of IFD.  Baseline 
and follow-up cytokines had no prognostic significance.   
 The overall survival (OS) estimate at 3, 6, 12, and 24 months were 91%, 
81%, 72% and 68%, respectively for the whole cohort and 92%, 83%, 76%, 
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and 70%, respectively for the IA cohort.  The 2-year survival estimates 
(95% CI) were 45 (29-61)%,  66 (56-76)%, and 87 (77-97)%,  for 
proven/probable, possible/not classified and no evidence of IFD 
respectively. The corresponding estimates for the IA cohort (N=195) were 
52 (34-70)%, 66 (56-76)%, and 87 (79-95)% for proven/probable IA, 
possible IA/not classified, and no evidence respectively. 
 Relapse or progression of underlying haematological malignancy was the 
commonest cause of death (59%) while IFD was the second commonest 
cause accounting for 20% of deaths. The IFD-attributable mortality was 
59% for patients who died in remission without GVHD but the overall IFD-
attributable mortality was 82%.  Therefore, proven/probable IFD carries 
considerable mortality. 
 The factors associated with prognosis were ITU admission, 
allograft/chemotherapy/IST, AML/MDS, bacteraemia, hepatic dysfunction, 
renal impairment, and proven/probable IFD.  
 Case 2 high-lights the difficulty of making IFD diagnosis.  As CT scan 
interpretation is observer-dependent it is important to have chest radiologist 
review even though this may be challenging in busy clinical settings and 
where a trained chest radiologist may not be available. The importance of 
autopsy examination was clearly demonstrated here, unifying disparate 
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8 Future directions 
Having demonstrated the incidence and risk factors of IFD in this cohort which 
represents 85% of eligible cases, a number of key diagnostic approaches need 
further development. 
1. Serodiagnostics  
It is clear from the results of this study that a single assay is insufficient and 
the best combination is GM and BDG.  We now need to establish how best 
to use these in combination. In the study GM was done twice a week on all 
patients while BDG was done on a selection of cases.  The cost of BDG is 
an important consideration (current market price/test is GM £8.43, BDG 
£47.38). There are three different options: 
i. GM twice weekly on all during the at-risk period and BDG on 
positive GM and CT abnormalities both with and without EORTC 
signs. 
ii. Surveillance testing using both GM and BDG assays 
iii. BDG twice weekly and GM on positive sera and CT signs. 
Option one is most logical and cost-effective. 
2. Radiology 
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The finding of 38% prevalence of pre-therapy chest CT abnormalities is 
important.  Although it is an independent risk factor for IPA, its role in the 
incidence of IPA is not established.  A clinical trial randomising patients 
with baseline abnormalities to upfront ‘pre-emptive’ antifungal therapy vs. 
continuing antifungal prophylaxis until clinical indication for therapy 
(standard of care) would be an important management strategy.  
 
The main drawback for CT in the diagnosis of IFD is its lack of specificity.  
A novel in vivo imaging method involving the use of 68Ga-labelled 
siderophores internalized by the fungus and the site of infection, which are 
subsequently detected by positron emission tomography scanning, is an 
important advance.374,375  The early in vitro and animal data are promising 
but need to be translated into the clinic.  
 
3. Bronchoscopy 
There is increasing evidence for the diagnostic value of bronchoscopy and 
BAL GM and BDG.303,376-381  The GMI cut-off remains a matter of 
debate303,382 Although a positive BAL culture does not distinguish between 
colonisation and infection, it is highly suggestive of the latter in patients at 




The low bronchoscopy rate in this study reflects the clinical reality within 
the wider haematology patients.  Renewed efforts need to be made to 
enable timely bronchoscopy service to these patients by linking more 
closely with the respiratory physicians and identifying interested individuals. 
 
4. Biopsy 
Although minimally invasive approaches such as VATS provide an 
opportunity for obtaining tissue diagnosis the high rate of inconclusive 
biopsy results is a worry.  Moreover, VATS is not suitable for centrally 
located lesions or large lesions greater than 3 cm.384  The methylene blue 
localisation technique used here was also disappointing as it did not 
improve the diagnostic yield although the numbers were small. The right 
surgical technique is at the discretion of the cardiothoracic surgeons but 
other localisation techniques such as image-guided placement of a hook-
wire281,282 or platinum microcoils283 could be further explored with the 
surgeons. 
 
5. TDM & Changes in antifungal protocol 
Now that local capacity has been developed TDM should be incorporated 
into local protocols to ensure that adequate recommended therapeutic 
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levels are achieved.  Moreover, the incidence of IFD should be 
reinvestigated again to assess the impact of changes in local protocol 
which recommends posaconazole for all high risk patients.  
 
6. Genetic risk profiling  
Genetic susceptibility to IFD based on mutations of key innate immunity 
genes such as Dectin-166,121, TLRs62 and cytokines67,68 hold promise in 
providing some tools for better susceptibility profiling. This should form part 
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Appendix 2 Database variables (summary) 
 
1. Baseline information 
Patient ID age sex ethnic origin weight smoking history alcohol 
history  previous therapy date of admission reason for admission 
Karnofsky score PAM score (allografts)     disease 
status (CR/PR/Stable/progression/new diagnosis) lung function (FEV1, TLCO) 
baseline CT results  GvHD (yes/no)    co-morbidities FBC LFT 
U&E CRP  
2. Clinical assessment (follow-up) 
Treatment (chemotherapy/allograft/IST) fever pleuritic chest pain GvHD 
(acute/chronic and grade) 
3. Antibiotics  
Drug  dose reason for starting reason for stopping 
4. Antifungals 
a) Prophylaxis (drug, dose, reason for starting [primary or secondary unit 
protocol, other], date of starting and stopping) 
b) Treatment (drug, dose, reason for starting [empiric, possible, probable, proven 
IFD] and stopping) 
5. Antivirals  
Drug  dose reason for starting reason for stopping 
6. Other immunosuppressive agents including steroids, dose, duration, reason 
7. Galactomannan (date, GMI, positive/negative) 
8. Β-D glucan (date, results) 
9. PCR (date, type, results) 
10. CT (date, results of baseline/diagnostic/follow-up 1 or 2) 
11.  FBC (Hb, WBC, Neutrophils, platelets, monocytes, lymphocytes; duration of 
neutropenia, monocytopenia, and lymphopenia) 
12.  LFT (bilirubin, AST, ALP, GGT, albumin) 
13. U&E (urea, creatinine, electrolyes) 
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14. CRP 
15. EORTC status (& date) 
16. Outcome (alive/dead, cause of death, overall survival) 
17. Blood culture results 
18. Viral PCR results 
19. Bronchoscopy results 
20. Biopsy results  
 
